e10vk
UNITED STATES SECURITIES AND
EXCHANGE COMMISSION
Washington, D.C.
20549
Form 10-K
|
|
|
(Mark One)
|
|
|
þ
|
|
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the fiscal year ended
December 31, 2009
|
or
|
o
|
|
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
|
|
|
For the transition period
from to
|
Commission File Number
001-33689
athenahealth, Inc.
(Exact name of registrant as
specified in its charter)
|
|
|
Delaware
(State or other jurisdiction
of
incorporation or organization)
|
|
04-3387530
(I.R.S. Employer
Identification No.)
|
|
|
|
311 Arsenal Street,
Watertown, Massachusetts
(Address of principal
executive offices)
|
|
02472
(Zip Code)
|
617-402-1000
Registrants telephone
number, including area code
Securities registered pursuant to Section 12(b) of the
Act:
|
|
|
Title of Each Class
|
|
Name of Each Exchange on Which Registered
|
|
Common Stock, $0.01 par value
|
|
The NASDAQ Stock Market LLC
|
Securities registered pursuant to Section 12(g) of the
Act:
None
Indicate by check mark if the registrant is a well-known
seasoned issuer, as defined in Rule 405 of the Securities
Act. Yes þ No o
Indicate by check mark if the registrant is not required to file
reports pursuant to Section 13 or Section 15(d) of the
Act. Yes o No þ
Indicate by check mark whether the registrant (1) has filed
all reports required to be filed by Section 13 or 15(d) of
the Securities Exchange Act of 1934 during the preceding
12 months (or for such shorter period that the registrant
was required to file such reports), and (2) has been
subject to such filing requirements for the past
90 days. Yes þ No o
Indicate by check mark whether the registrant has submitted
electronically and posted on its corporate Web site, if any,
every Interactive Data File required to be submitted and posted
pursuant to Rule 405 of
Regulation S-T
(§ 232.405 of this chapter) during the preceding
12 months (or for such shorter period that the registrant
was required to submit and post such
files). Yes o No o
Indicate by check mark if disclosure of delinquent filers
pursuant to Item 405 of
Regulation S-K
(§ 229.405 of this chapter) is not contained herein,
and will not be contained, to the best of registrants
knowledge, in definitive proxy or information statements
incorporated by reference in Part III of this
Form 10-K
or any amendment to this
Form 10-K. o
Indicate by check mark whether the registrant is a large
accelerated filer, an accelerated filer, a non-accelerated
filer, or a smaller reporting company. See the definitions of
large accelerated filer, accelerated
filer and smaller reporting company in Rule
12b-2 of the
Exchange Act. (Check one):
|
|
|
|
Large
accelerated
filer þ
|
Accelerated
filer o
|
Non-accelerated
filer o
|
Smaller
reporting
company o
|
(Do not check if a smaller reporting company)
Indicate by check mark whether the registrant is a shell company
(as defined in
Rule 12b-2
of the
Act). Yes o No þ
The aggregate market value of the voting and non-voting common
equity held by non-affiliates computed by reference to the price
at which the common equity was last sold, or the average bid and
asked price of such common equity, as of the last business day
of the registrants most recently completed second fiscal
quarter was $1,169,309,706.
Indicate the number of shares outstanding of each of the
registrants classes of common stock, as of the latest
practicable date. At March 12, 2010, the registrant had
34,034,323 shares of Common Stock, par value $0.01 per
share, outstanding.
DOCUMENTS
INCORPORATED BY REFERENCE
Parts II and III of this
Form 10-K
incorporate information by reference from the registrants
definitive proxy statement to be filed with the Securities and
Exchange Commission within 120 days after the close of the
fiscal year covered by this annual report.
INDEX
|
|
|
|
|
|
|
|
|
|
Business
|
|
|
1
|
|
|
|
Risk Factors
|
|
|
20
|
|
|
|
Unresolved Staff Comments
|
|
|
44
|
|
|
|
Properties
|
|
|
44
|
|
|
|
Legal Proceedings
|
|
|
44
|
|
|
|
(Removed and Reserved)
|
|
|
44
|
|
|
PART II
|
|
|
Market for Registrants Common Equity,
Related Stockholder Matters and Issuer Purchases of Equity
Securities
|
|
|
45
|
|
|
|
Selected Financial Data
|
|
|
48
|
|
|
|
Managements Discussion and Analysis of
Financial Condition and Results of Operations
|
|
|
50
|
|
|
|
Quantitative and Qualitative Disclosures About
Market Risk
|
|
|
68
|
|
|
|
Financial Statements and Supplementary Data
|
|
|
68
|
|
|
|
Changes in and Disagreements With Accountants on
Accounting and Financial Disclosure
|
|
|
68
|
|
|
|
Controls and Procedures
|
|
|
68
|
|
|
|
Other Information
|
|
|
72
|
|
|
PART III
|
|
|
Directors, Executive Officers and Corporate
Governance
|
|
|
72
|
|
|
|
Executive Compensation
|
|
|
72
|
|
|
|
Security Ownership of Certain Beneficial Owners
and Management and Related Stockholder Matters
|
|
|
72
|
|
|
|
Certain Relationships and Related Transactions,
and Director Independence
|
|
|
72
|
|
|
|
Principal Accounting Fees and Services
|
|
|
72
|
|
|
PART IV
|
|
|
Exhibits, Financial Statement Schedules
|
|
|
73
|
|
|
|
|
76
|
|
EX-10.24 MASTER EQUIPMENT LEASE AGREEMENT BY AND BETWEEN CIT TECHNOLOGIES CORPORATION AND THE REGISTRANT, DATED JUNE 1, 2007 |
EX-10.27 PROFESSIONAL SERVICES AGREEMENT BY AND BETWEEN THE REGISTRANT AND INTERNATIONAL BUSINESS MACHINES CORPORATION DATED AS OF OCTOBER 2, 2009 |
EX-10.28 MASTER AGREEMENT FOR U.S. AVAILABILITY SERVICES BETWEEN SUNGARD AVAILABLILITY SERVICES LP AND THE REGISTRANT, DATED DECEMBER 1, 2009, AS AMENDED |
EX-21.1 SUBSIDIARIES OF THE REGISTRANT |
EX-23.1 CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM |
EX-31.1 CERTIFICATION OF CHIEF EXECUTIVE OFFICER |
EX-31.2 CERTIFICATION OF CHIEF FINANCIAL OFFICER |
EX-32.1 CERTIFICATIONS OF CHIEF EXECUTIVE OFFICER AND CHIEF FINANCIAL OFFICER |
i
EXPLANATORY
NOTE REGARDING RESTATEMENT
In this Annual Report on
Form 10-K,
the terms athena, athenahealth,
we, us, and our refer to
athenahealth, Inc. and its subsidiaries, Anodyne Health
Partners, Inc., athenahealth MA, Inc., and athenahealth
Technology Private Limited, and any subsidiary that may be
acquired or formed in the future.
athenahealth, athenaNet, and the athenahealth logo are
registered service marks of athenahealth; Anodyne Analytics,
Anodyne Intelligence Platform, athenaClinicals, athenaCollector,
athenaCommunicator, athenaEnterprise, athenaRules, PayerView,
and ReminderCall are service marks of athenahealth. This Annual
Report on
Form 10-K
also includes the registered and unregistered trademarks and
service marks of other persons.
This Annual Report on
Form 10-K
for the fiscal year ended December 31, 2009, includes
restatement of the following previously filed consolidated
financial statements and data (and related disclosures):
(1) our consolidated balance sheet as of December 31,
2008, and the related consolidated statements of operations,
stockholders equity, and cash flows for each of the fiscal
years ended December 31, 2007 and 2008; (2) our
selected financial data as of and for our fiscal years ended
December 31, 2005, 2006, 2007, and 2008, located in Part
II, Item 6 of this Annual Report on
Form 10-K;
(3) our managements discussion and analysis of
financial condition and results of operations as of and for our
fiscal years ended December 31, 2007 and 2008, contained in
Part II, Item 7 of this Annual Report on
Form 10-K;
and (4) our unaudited quarterly financial information for
each quarter in our fiscal year ended December 31, 2008,
and for the first three quarters in our fiscal year ended
December 31, 2009, in Note 20, Summarized
Quarterly Unaudited Financial Data of the Notes to
Consolidated Financial Statements in Part II, Item 8 of
this Annual Report on
Form 10-K.
We have completed our previously announced internal accounting
review related to the amortization period for deferred
implementation revenue. Implementation revenue consists
primarily of professional services fees related to assisting
customers with the implementation of our services. These
non-refundable fees are generally billed up front and recorded
as deferred revenue until the implementation is complete and
then recognized ratably over the expected performance period.
Previously, the expected performance period was estimated based
upon the initial customer contract terms, the vast majority of
which were one year in duration. Implementation and other
revenue has ranged from four to seven percent of total revenue
on an annual basis since 2007.
As a result of this review, we have concluded that in prior and
future periods, we will amortize deferred implementation revenue
over a longer expected performance period of twelve years in
order to reflect the estimated expected customer life.
Accordingly, we will restate the implementation and
other revenue within our previously filed consolidated
financial statements to reflect the longer amortization period
for deferred implementation revenue. We will continue to record
implementation expenses in the period as incurred. The length of
the amortization period for deferred implementation revenue
recognition does not impact cumulative total implementation
revenue under contract nor does it impact cash flow. The
restatement will result in the deferral to future periods of
$22.3 million of implementation revenue previously
recognized through September 30, 2009.
In addition, in connection with the restatement, certain prior
year amounts have been reclassified to conform to revised
accounting policies. These reclassifications had no effect on
net income or shareholders equity for any period and
pertain to: (1) reimbursements of
out-of-pocket
expenses that were previously netted against corresponding
expense and have now been grossed up and included in
implementation and other revenue; (2) certain
deferred tax liabilities that have been reclassified from
non-current to current; (3) draw downs of capital leased
lines that were previously presented as sources of cash within
the financing activities section of the cash flow statements and
have now been reclassified as investing activities; and (4) the
excess tax benefit from
stock-based
awards that were previously presented as sources of cash within
the operating activities section of the consolidated
statements of cash flows in the accrued expense line have been
reclassified as operating activities in the excess
tax benefit from stock-based awards line item.
Financial information included in the Annual Reports on
Form 10-K,
Quarterly Reports on
Form 10-Q,
and Current Reports on
Form 8-K
filed by us prior to March 15, 2010, and all earnings,
press releases, and similar communications issued by us prior to
March 15, 2010, should not be relied upon and are
superseded in their entirety by this Annual Report on
Form 10-K.
ii
For more information regarding the restatement, please refer to
Part II, Item 6, Selected Financial Data;
Part II, Item 7, Managements Discussion
and Analysis of Financial Condition and Results of
Operations; Note 2, Restatement and
Reclassification of Previously Issued Consolidated Financial
Statements, and Note 20, Summarized Quarterly
Unaudited Financial Data, of the Notes to Consolidated
Financial Statements in Part II, Item 8; and
Part II, Item 9A, Controls and Procedures.
iii
PART I
SPECIAL
NOTE REGARDING
FORWARD-LOOKING
STATEMENTS AND INDUSTRY DATA
This Annual Report on
Form 10-K
contains forward-looking statements. All statements other than
statements of historical fact contained in this Annual Report on
Form 10-K
are forward-looking statements, including those regarding our
patient cycle management service; the combination or integration
of newly acquired services with athenaCollector and athenaNet;
expanded sales and marketing efforts; changes in expenses
related to operations, selling, marketing, research and
development, general and administrative matters, and
depreciation and amortization; liquidity issues; additional
fundraising; and the expected performance period and estimated
term of our client relationships, as well as more general
statements regarding our expectations for future financial or
operational performance, product and service offerings,
regulatory environment, and market trends. In some cases, you
can identify forward-looking statements by terminology such as
may, will, should,
expects, plans, anticipates,
believes, estimates,
predicts, potential, or
continue; the negative of these terms; or other
comparable terminology.
Forward-looking statements are only current predictions and are
subject to known and unknown risks, uncertainties, and other
factors that may cause our or our industrys actual
results, levels of activity, performance, or achievements to be
materially different from those anticipated by such statements.
These factors include, among other things, those listed under
Risk Factors and elsewhere in this Annual Report on
Form 10-K.
Although we believe that the expectations reflected in the
forward-looking statements contained in this Annual Report on
Form 10-K
are reasonable, we cannot guarantee future results, levels of
activity, performance, or achievements. Except as required by
law, we are under no duty to update or revise any of such
forward-looking statements, whether as a result of new
information, future events, or otherwise, after the date of this
Annual Report on
Form 10-K.
Unless otherwise indicated, information contained in this Annual
Report on
Form 10-K
concerning our industry and the markets in which we operate,
including our general expectations and market position, market
opportunity, and market share, is based on information from
independent industry analysts and third-party sources (including
industry publications, surveys, and forecasts), our internal
research, and management estimates. Management estimates are
derived from publicly available information released by
independent industry analysts and third-party sources, as well
as data from our internal research, and are based on assumptions
made by us based on such data and our knowledge of such industry
and markets, which we believe to be reasonable. None of the
sources cited in this Annual Report on
Form 10-K
has consented to the inclusion of any data from its reports, nor
have we sought their consent. Our internal research has not been
verified by any independent source, and we have not
independently verified any third-party information. While we
believe the market position, market opportunity, and market
share information included in this Annual Report on
Form 10-K
is generally reliable, such information is inherently imprecise.
In addition, projections, assumptions, and estimates of our
future performance and the future performance of the industries
in which we operate are necessarily subject to a high degree of
uncertainty and risk due to a variety of factors, including
those described in Risk Factors in Item 1A of
Part 1 of this Annual Report on
Form 10-K
and elsewhere in this Annual Report on
Form 10-K.
These and other factors could cause results to differ materially
from those expressed in the estimates made by the independent
parties and by us.
Overview
athenahealth is a leading provider of Internet-based business
services for physician practices. Our service offerings are
based on four integrated components: our proprietary
Internet-based software, our continually updated database of
payer reimbursement process rules, our back-office service
operations that perform administrative aspects of billing and
clinical data management for physician practices, and our
automated and live patient communication services. Our principal
offering, athenaCollector, automates and manages billing-
1
related functions for physician practices and includes a medical
practice management platform. We have also developed a service
offering, athenaClinicals, that automates and manages
medical-record-related functions for physician practices and
includes an electronic health record, or EHR, platform.
ReminderCall, which we added to our service suite in September
2008, is our automated appointment reminder system that allows
patients to either confirm the appointment or request
rescheduling. We have now combined ReminderCall with other
automated patient messaging services, live operator services,
and a patient web portal in the first edition of our
athenaCommunicator services suite that we beta launched in 2009
and expect to offer commercially in the first half of 2010. We
refer to athenaCollector as our revenue cycle management
service, athenaClinicals as our clinical cycle management
service, and athenaCommunicator as our patient cycle management
service. As a complement to these services, our newest offering,
Anodyne Analytics, is a web-based, Software-as-a-Service
business intelligence platform that organizes and displays
detailed and insightful practice performance data for decision
makers at our client practices. Our services are designed to
help our clients achieve faster reimbursement from payers,
reduce error rates, increase collections, lower operating costs,
improve operational workflow controls, improve patient
satisfaction and compliance, and more efficiently manage
clinical and billing information.
In the last six years, we have primarily focused on developing
our proprietary Internet-based software application and
integrated service operations to expand our client base. In
2005, we formed a subsidiary in India to complement our
U.S.-based
software development activities and to work closely with our
business partners in India. In September 2008, we completed our
first acquisition, purchasing the assets of Crest Line
Technologies, LLC (d.b.a. MedicalMessaging.net), a privately
held company that developed ReminderCall and associated
services. We continued this expansion of our offerings in
October 2009 with our acquisition of our new operating
subsidiary, Anodyne Health Partners, Inc. (Anodyne),
a privately held company that developed the Anodyne Analytics
service. In 2009, we generated revenue of $188.5 million
from the sale of our services, compared to $136.3 million
in 2008. As of December 31, 2009, there were more than
23,350 medical providers, including more than 15,700 physicians,
using our services across 43 states and the District of
Columbia and 60 medical specialties.
Market
Opportunity
We believe that the market opportunity for our services is, in
large part, currently driven by physician practice collections
in the United States. According to the U.S. Centers for
Medicare and Medicaid Services, physician and clinical services
spending increased since 2000 by an average of 7.0% per year to
$496 billion in 2008.
Growth in managed care has increased the complexity of physician
practice reimbursement. Managed care plans typically create
reimbursement structures with greater complexity than previous
methods, placing greater responsibility on the physician
practice to capture and provide appropriate data to obtain
payments. Also, despite substantial consolidation in the number
of managed care organizations over the last decade, many of the
legacy information technology platforms used to manage the plans
operated by these companies have remained in place. As a result
of this increasing complexity, physician practices must keep
track of multiple plan designs and processing requirements to
ensure appropriate payment for services rendered.
Physician practice-based billing activities that are required to
ensure appropriate payment for services rendered have increased
in number and complexity for the following reasons:
|
|
|
|
|
Diversity of health benefit plan
design. Health insurers have introduced a wide
range of benefit structures, many of which are customized to
unique goals of particular employer groups. This has resulted in
an increase in rules regarding who is eligible for healthcare
services, what healthcare services are eligible for
reimbursement, and who is responsible for payment for healthcare
services delivered.
|
|
|
|
Dynamic nature of health benefit plan
design. Health insurers continuously update their
reimbursement rules based on ongoing monitoring of consumption
patterns, in response to new medical products and procedures,
and to address changing employer demands. As these changes are
made frequently throughout the year and are frequently specific
to each individual health plan, physician practices need
|
2
|
|
|
|
|
to be continually aware of this dynamic element of the
reimbursement cycle as it could impact overall reimbursement and
specific workflows.
|
|
|
|
|
|
Proliferation of new payment models. New
health benefit plans and reimbursement structures have
considerably modified the ways in which physician practices are
paid. For example, there is an increasing trend toward
consumer-driven health plans, or CDHPs, that require a far
greater portion of fees to be paid by the consumer, typically
until a pre-specified threshold is achieved. Care-based
initiatives, including
pay-for-performance,
or P4P programs, which provide reimbursement incentives centered
around capture and submission of specified clinical information,
have dramatically increased the administrative and clinical
documentation burden of the physician practice.
|
|
|
|
Changes in the regulatory environment. The
Health Insurance Portability and Accountability Act of 1996, or
HIPAA, required changes in the way private health information is
handled, mandated new data formats for the health insurance
industry, and created new security standards. Among the changes
introduced by HIPAA, physicians have been required to adopt
National Provider Identifiers, and this has affected physician
practice billing and collection workflow requirements.
|
In addition to administering typical business functions,
physician practices must invest significant time and resources
in activities that are required to secure reimbursement from
patients or third-party payers and process inbound and outbound
communications related to physician orders to laboratories and
pharmacies. In order to process these communications, physician
practices often manipulate locally or remotely installed
software, execute paper-based and fax-based communications to
and from payers, and conduct telephone-based discussions with
payers and intermediaries to resolve unpaid claims or to inquire
about the status of transactions.
The
Established Model
Currently, the majority of physician practices bill for their
services in one of three ways: purchasing, installing, and
operating locally installed practice management software; paying
for use of remotely installed on-demand practice
management software; or hiring a third-party billing service to
collect billing-related information and input the information
into a software system maintained by the service. In terms of
medical-record-management, the majority of physician practices
rely on paper-based systems or use locally or remotely installed
EHR software to generate electronic medical record information.
However, these software systems do not eliminate paper-based
transactions and information exchanges with intermediaries such
as labs, pharmacies, and hospitals. Physician practices are
still responsible for inputting all medical record information
into the software, as these systems are not automatically linked
to those of the intermediaries. In many instances, the solutions
that are installed at a physician practice or a remote location
are operated by that practices administrative staff. As
the complexity and number of health benefit plan payer rules has
increased, the ability of locally or remotely installed software
solutions to keep up with new and revised payer rules has lagged
behind this trend, leading to higher levels of unpaid claims,
prolonged billing cycles, increased clinical inefficiencies, and
missed opportunities for reimbursements for participation in P4P
programs. While locally or remotely installed software has been
shown to provide improvement in physician practice efficiency
and collections relative to paper-based systems, we believe that
such standalone software is not suited for todays dynamic
and increasingly complex healthcare system.
Despite advances in practice management and EHR software to
address the administrative needs of physician practices, the
billing, collections, and medical record management functions
remain expensive, inefficient, and challenging for many
physician practice groups. We believe that established locally
or remotely installed physician practice management and EHR
software has generally suffered from the following challenges:
|
|
|
|
|
Software is static and isolated. Payer rules
change continuously, and the systems used to seek reimbursement
require constant updating to remain accurate. If it is not
linked to a centrally hosted, continuously updated knowledge
base of payer rules, software typically cannot reflect real-time
changes based upon health-benefit-plan-specific requirements.
Additionally, since most software vendors are not in the
business of processing claims, they are often unaware of the
creation of new payer rules and
|
3
|
|
|
|
|
changes to existing payer rules. As a result, physician
practices typically have the responsibility to navigate this
complex and dynamic reimbursement system in order to submit
accurate and complete claims. We believe that their inability to
keep current on these rule changes is the single largest factor
leading to claims denials and diverting time and resources away
from revenue and clinical cycle workflow.
|
|
|
|
|
|
Software requires reliance on physician practice
personnel. Physician practices have difficulty
managing the increased complexity of billing, collections, and
medical record management because they lack the necessary
infrastructure and suffer from significant staff turnover rates.
Despite attempts to automate workflow, many software solutions
still require that a number of healthcare supply chain
interactions be executed manually via paper, fax, or phone.
These manual interactions include insurance product monitoring,
insurance eligibility, claims submission, claims tracking,
remittance posting, denials management, payment processing,
formatting of lab requisitions, submitting of lab requisitions,
and monitoring and classification of all inbound faxes. These
tasks are prone to human error, are inefficient, and generally
require the accumulation of rules and claims processing
knowledge by the individuals involved. High employee turnover in
physician practices leads to critical reimbursement and
transaction processing knowledge being lost.
|
|
|
|
Software vendors are not paid on results. Most
established practice management and EHR software companies
operate under a business model that does not directly
incentivize them to improve their clients financial and
operational results. The established software business model
involves a substantial upfront license payment in addition to
ongoing maintenance fees. While the goal of practice management
and EHR software is to improve reimbursement and clinical
efficiency, the responsibility for realizing these efficiencies
still largely rests on physician practices administrative
and clinical staff.
|
We believe that the use of traditional outsourced back-office
service providers does not adequately compensate for the
deficiencies of the locally or remotely installed software
model. Such service providers generally rely on third-party
software that suffers from the same deficiencies that physicians
experience when they perform their own back-office processing
operations. The software often is not connected to payer rules
that can be enforced in real time by office staff throughout the
patient workflow. In addition, these service providers typically
operate discrete databases and sometimes utilize separate
processes for each client they serve, which affords limited
advantages of scale, thereby conferring limited cost advantages
to physician practices. Without either control over the software
application or an integrated rules database, outsourced service
providers cannot offer physicians the benefits of our
Internet-based business service model.
The payer universe is dynamic and continuously growing in
complexity as rules are changed and new rules are added, making
it extremely difficult for physician practices, and even payers,
to effectively manage the reimbursement rules landscape. In
addition, clinical data management and reporting is also
beginning to impact reimbursement for physician practices. While
locally or remotely installed software has struggled to meet
these challenges, the Internet has developed in the broader
economy into a reliable and efficient medium that opens the door
to entirely new ways of performing business functions. The
Internet is ideally suited to centralization of the large-scale
research needed to stay current with payer rules and to the
instantaneous dissemination of this information. The Internet
also allows real-time consolidation and centralized execution of
administrative work across many medical practice locations. As a
result, the health care industry is well suited to benefit from
the efficiency and effectiveness of the Internet as a delivery
platform.
Our
Solution
The dynamic and increasingly complex healthcare market requires
an integrated solution to manage the reimbursement and clinical
landscape effectively. We believe that we are the first company
to integrate web-based software, a continually updated database
of payer rules, back-office service operations, and automated
and live patient communication services into a single
Internet-based business service for physician practices.
4
We seek to deliver these services at each critical step in the
revenue and clinical cycle workflow through a combination of
software, knowledge, and work:
|
|
|
|
|
Software. athenaNet, our proprietary web-based
practice management and EHR application, is a workflow
management tool used to properly handle billing, collections,
patient communications, and medical-record-management-related
functions. All users across our client-base simultaneously use
the same version of our software application, which connects
them to our continually updated database of payer rules and to
our services team.
|
|
|
|
Knowledge. athenaRules, our proprietary
database of payer reimbursement process rules, enforces
physician practice workflow requirements and is continually
updated with payer-specific coding and documentation
information. This knowledge continues to grow as a result of our
years of experience managing back-office service operations for
hundreds of physician practices, including processing medical
claims with tens of thousands of health benefit packages.
athenaRules is also designed to access medication formularies,
identify potential medication errors such as
drug-to-drug
interactions or allergy reactions, and identify the specific
clinical activities that are required to comply with P4P
programs.
|
|
|
|
Work. The athenahealth service operations,
consisting of approximately 582 people, interact with
clients at all key steps of the revenue and clinical cycle
workflow. These operations include setting up medical providers
for billing, checking the eligibility of scheduled patients
electronically, submitting electronic and paper-based claims to
payers directly or through intermediaries, processing clinical
orders, receiving and processing checks and remittance
information from payers, documenting the result of payers
responses, and evaluating and resubmitting claims denials.
|
We are economically aligned with our physician practice clients
because payment for our services in most cases is dependent on
the results our services achieve for our clients. The positive
results of our approach are seen in the significant growth in
the number of clients serviced, collections under management,
and overall revenue in each of the preceding nine years.
Key advantages of our solution include:
|
|
|
|
|
Low total cost of the athenahealth
solutions. The cost of our services includes a
modest upfront expenditure for implementation and training, with
ongoing monthly service fees typically based on a percentage of
client collections. This approach differs from the established
model that requires upfront investments in software, hardware,
implementation service and support, and additional information
technology staff. We continually update our web-based software
and add or revise over 100 rules on average each month in our
shared payer knowledge base, which enables our clients to use
these new features with minimal disruption and no incremental
cost. Once implemented, our clients access our services by using
an Internet connection and a web browser. We believe that our
services-based model provides advantages to our clients based on
the elimination of future upgrade, training, and extra
follow-up
costs associated with the established model.
|
|
|
|
Comprehensive payer rules engine that is continuously
expanded and updated. We believe that we have the
largest and most comprehensive continually updated database of
payer reimbursement process rules in the United States. We
collect health-benefit-plan-specific processing information so
that the medical office workflow and the work of our service
operations can be tailored to the requirements of each health
benefit plan. Real-time error alerts automatically triggered by
our rules engine enable our clients in many cases to catch
billing-related errors immediately at the beginning of the
reimbursement cycle, fix these errors quickly, and generate
medical claims that achieve high first-pass success rates. Payer
rules change frequently and are not commonly published by
payers; therefore most rules must be learned from experience. We
have full-time staff focused on finding, researching,
documenting, and implementing new rules, enabling our solution
to consistently deliver quantifiably improved financial results
for our clients. Additionally, we discover and implement even
more new rules as new clients connect to our rules engine and
expose our staff to new reimbursement scenarios. Our other
clients
|
5
|
|
|
|
|
benefit from the addition of these new rules, and this
continuous updating increases our value proposition benefiting
both current and future clients.
|
|
|
|
|
|
Real-time workflow and process optimization result in
improved financial and operational outcomes. Our
solution enables real-time communications between the physician
practices staff and our service operations staff
throughout the patient encounter and billing processes. We
believe that this online interaction is vital for delivering the
financial and operational performance our clients enjoy. The
monitoring and managing of physician practice workflows allows
us to stay close to client needs and constantly upgrade our
offerings in order to improve the effectiveness of our overall
service. These elements allow us to identify and influence
critical practice workflow steps to maximize billing performance
and deliver improved financial and operational outcomes for our
clients.
|
|
|
|
Critical mass and access to superior scale and
capabilities. We have taken physician back-office
tasks that would otherwise be performed on a local or regional
basis and have brought them together on a single national
platform. Our platform was designed and constructed to enable us
to assume responsibility for the completion of automated and
manual tasks in the revenue and clinical workflow cycles, while
providing critical tools and knowledge to effectively assist
clients in completing those tasks that must be done
on-site in
the physician practice. As a result of our centralized
infrastructure, we can apply a broad array of resources (from
athenahealth, our clients, and our off-shore partners) to
address the myriad of discrete tasks within the revenue and
clinical workflow cycles in a cost-effective manner. This
approach allows us to deliver services and performance superior
to what any particular physician practice could achieve on its
own.
|
Our
Strategy
Our mission is to be the most trusted business service to
medical groups. Key elements of our strategy include:
|
|
|
|
|
Remaining intensely focused on our clients
success. Our business model aligns our goals with
our clients goals and provides an incentive for us to
improve the performance of our clients continually. We believe
that this approach enables us to maintain client loyalty,
enhance our reputation, and improve the quality of our solutions.
|
|
|
|
Maintaining and growing our payer rules
database. Our rules engine development work is
designed to increase the percentage of transactions that are
successfully executed on the first attempt and to reduce the
time to resolution after claims or other transactions are
submitted. We continue to develop our centralized payer
reimbursement process rules database, athenaRules, by learning
from experience gained across our national network of clients.
|
|
|
|
Attracting new clients. We expect to continue
with current and expanded sales and marketing efforts to address
our market opportunity by aggressively seeking new clients. We
believe that our Internet-based business services provide
significant value for physician practices of any size. With more
than 600,000 practicing physicians in the United States, we
estimate that our client base currently represents less than
three percent of the U.S. addressable market for revenue
cycle management and clinical cycle management services.
|
|
|
|
Increasing revenue per client by adding new service
offerings. We expanded our offerings in September
2008 by acquiring the assets of Crest Line Technologies, LLC,
which provided our ReminderCall service, and in October 2009 by
acquiring Anodyne, which developed our Anodyne Analytics
service. In 2009, we beta launched our athenaCommunicator
services suite that combined ReminderCall with other automated
patient messaging services, live operator services, and a
patient web portal, and we expect to offer athenaCommunicator
commercially in the first half of 2010. We continue to explore
additional services to address other administrative tasks within
physician practices.
|
|
|
|
Expanding operating margins by reducing the costs of
providing our services. We believe that we can
increase our operating margins as we increase the scalability of
our service operations. Our integrated operations enable us to
deploy efficient and effective resources in providing our
services.
|
6
Our
Services
athenahealth is a leading provider of Internet-based business
services for physician practices. Our service offerings are
based on our proprietary web-based software, a continually
updated database of payer rules, integrated back-office service
operations, and our automated and live patient communication
services. Our services are designed to help our clients achieve
faster reimbursement from payers, reduce error rates, increase
collections, lower operating costs, improve operational workflow
controls, and more efficiently manage clinical and billing
information.
athenaCollector
Our principal offering, athenaCollector, is our revenue cycle
management service that automates and manages billing-related
functions for physician practices and includes a practice
management platform. athenaCollector assists our physician
clients with the proper handling of claims and billing processes
to help manage reimbursement quickly and efficiently.
Software
(athenaNet)
Through athenaNet, athenaCollector utilizes the Internet to
connect physician practices to our rules engine and service
operations team. In its 2009 year-end Best in
KLAS survey, KLAS Enterprises, LLC, a healthcare
information technology industry research firm, reported
athenaNet No. 1 in the Other Revenue Cycle Solutions
category for practices with a single physician, No. 1 in
the Practice Management category for practice groups with two to
five physicians, No. 2 in the Practice Management category
for practice groups with six to 25 physicians, and No. 2 in
the Practice Management category for practice groups with 25 to
100 physicians. Apart from the single-physician practice
category, which was first instituted in 2008, athenaNet has been
ranked in the top 5 in each of these categories in each annual
Best in KLAS ranking since 2004.
7
athenaNet includes a workflow dashboard used by our clients and
our services team to track claims requiring edits in real-time
before they are sent to the payer, claims requiring work that
have come back from the payer unpaid, and claims that are being
held up due to administrative steps required by the individual
client. This Internet-native functionality provides our clients
with the benefits of our database of payer rules as it is
updated and enables them to interact with our services team to
efficiently monitor workflows. The Internet-based architecture
of athenaNet allows each transaction to run through our
centralized rules engine so that mistakes can be corrected
quickly across all of our clients. In the future, we plan to
further leverage the efficiencies currently provided by
athenaNet with the additional detail and analysis offered by our
Anodyne Analytics service.
Knowledge
(athenaRules)
Physician practices route all of their
day-to-day
electronic and paper-based payer communications to us, which we
then process using athenaRules and our service operations to
avoid reimbursement delays and improve practice performance. Our
proprietary database of payer knowledge has been constructed
based on over nine years of experience in dealing with physician
workflow in hundreds of physician practices with medical claims
from tens of thousands of health benefit packages. The core
focus of the database is on the payer rules, which are the key
drivers of claim payment and denials. Understanding denials
allows us to construct rules to avoid future denials across our
entire client base, resulting in increased automation of our
workflow processes. On average, over 100 rules are added or
revised in our rules engine each month. athenaRules has been
designed to interact seamlessly with athenaNet in the medical
office workflow and in our service operations.
Work
(athenahealth Service Operations)
athenahealth Service Operations enables the service teams that
collaborate with client staff to achieve successful
transactions. Our Service Operations consists of both
knowledgeable staff and technological infrastructure used to
execute the key steps associated with proper handling of
physician claims and clinical data management. The service team
is comprised of approximately 582 people on our service
teams who interact with physicians, providers, and clinicians at
all of the key steps in the revenue cycle, including:
|
|
|
|
|
coordinating with payers to ensure that client providers are
properly set up for billing;
|
|
|
|
checking the eligibility of scheduled patients electronically;
|
|
|
|
submitting claims to payers directly or through intermediaries,
whether electronically or via printed claim forms;
|
|
|
|
obtaining confirmation of claim receipt from payers, either
electronically or through phone calls;
|
|
|
|
receiving and processing checks and remittance information from
payers and documenting the result of payers responses;
|
|
|
|
evaluating denied claims and determining the best approach to
appealing
and/or
resubmitting claims to obtain payment;
|
|
|
|
billing patients for balances that are due;
|
|
|
|
compiling and delivering management reporting about the
performance of clients at both the account level and the
provider level;
|
|
|
|
transmitting key clinical data to the revenue cycle workflow to
eliminate the need for code re-entry and to permit assembling
all key data elements required to achieve maximum appropriate
reimbursement; and
|
|
|
|
providing proactive and responsive client support to manage
issues, address questions, identify training needs, and
communicate trends.
|
8
athenaClinicals
athenaClinicals is our clinical cycle management service that
automates and manages medical-record-management-related
functions for physician practices and includes an EHR platform.
It assists medical groups with the proper handling of physician
orders and related inbound and outbound communications to ensure
that orders are carried out quickly and accurately and to
provide an
up-to-date
and accurate online patient clinical record. athenaClinicals is
designed to improve clinical administrative workflow, and its
software component has received certification from the
Certification Commission for Healthcare Information Technology,
or CCHIT, under that bodys 2008 standards.
Software
(athenaNet)
Through athenaNet, athenaClinicals displays key clinical
measures by office location related to the drivers of high
quality and efficient care delivery on a workflow dashboard,
including lab results requiring review, patient referral
requests, prescription requests, and family history of previous
exams. According to the 2009 year-end Best in
KLAS survey, athenaClinicals achieved 100% client
confidence in its ability to enable clients to meet the 2011
Meaningful Use standards under the Health Information Technology
for Economic and Clinical Health Act (the HITECH
Act). Similar to its functionality within athenaCollector,
athenaNet provides comprehensive reporting on a range of
clinical results, including distribution of different procedure
codes (leveling), incidence of different diagnoses, timeliness
of turnaround by lab companies and other intermediaries, and
other key performance indicators.
Knowledge
(athenaRules)
Clinical data must be captured according to the requirements and
incentives of different payers and plans. Clinical
intermediaries such as laboratories and pharmacy networks
require specific formats and data elements as well. athenaRules
is designed to access medication formularies, identify potential
medication errors such as
drug-to-drug
interactions or allergy reactions, and identify the specific
clinical activities that are required to adhere to P4P programs
including Medicare incentive payments under the HITECH Act,
which can add incremental revenue to the physician practice.
Work
(athenahealth Service Operations)
athenaClinicals provides the additional functionality that we
believe medical groups expect from an EHR to help them complete
the key processes that affect the clinical care record related
to patient care, including:
|
|
|
|
|
identifying available P4P programs, incentives, and enrollment
requirements and assisting with the enrollment and data
submission for those programs;
|
|
|
|
entering data about patient encounters as they happen;
|
|
|
|
delivering outbound physician orders such as prescriptions and
lab requisitions; and
|
|
|
|
capturing, classifying, and presenting inbound documentation,
such as lab results, electronically or via fax.
|
athenaCommunicator
As a result of our acquisition of the assets of Crest Line
Technologies, LLC (d.b.a. MedicalMessaging.net) in September
2008, we offer automated messaging services that remind patients
of appointment details and allow them to use that automated
system to confirm or reschedule the appointment or to speak with
a live operator. These services help to reduce no-shows and
thereby increase the number of revenue-generating appointments.
We have renamed these services ReminderCall and expanded their
marketing to our existing clients and prospective clients while
also offering our other services to existing MedicalMessaging
clients. We have developed an expanded set of services, called
athenaCommunicator, which includes ReminderCall and other
automated patient messaging services, live operator services,
and a patient web portal. A beta version of athenaCommunicator
was first offered to clients in July 2009, and, although the
specific packaging, pricing,
9
and marketing plans for this new service line have not been
completed, we expect to offer an initial commercial version of
these services in the first half of 2010, with expanded versions
likely to follow in subsequent years.
Anodyne
Analytics
With the acquisition of our newest operating subsidiary,
Anodyne, in October 2009, we expanded the business intelligence
function of our existing services through the addition of
Anodyne Analytics. This web-based Software-as-a-Service platform
organizes and analyzes billing and claims-based data, allowing
physician practices to quickly and easily visualize that data
through a wide array of business performance metrics. These
metrics can be provided either as broad, practice-wide summaries
or as discrete, highly specific analyses based on complex
user-defined requests. In the future, we plan to further
leverage the efficiencies currently provided by athenaNet with
the additional detail and analysis offered by Anodyne Analytics
and the Anodyne Intelligence Platform.
Sales and
Marketing
We have developed a sales and marketing capability aimed at
expanding our network of physician clients and expect to expand
these efforts in the future. We have a significant direct sales
effort, which we augment through our indirect channel
relationships.
Direct
Sales
As of December 31, 2009, we employed a direct sales and
sales support force of 124 employees. Of these employees,
94 were sales professionals. Due to of our ongoing service
relationship with clients, we conduct a consultative sales
process. This process includes understanding the needs of
prospective clients, developing service proposals, and
negotiating contracts to enable the commencement of services.
Our sales team can be divided into three groups: the enterprise
team who are dedicated to physician practices with 150 or more
physicians; the group team who are dedicated to physician
practices with four to 149 physicians; and the small group team
who are dedicated to physician practices with one to three
physicians. This sales force includes 45 quota-carrying sales
representatives, five members of the enterprise team, 18 members
of the group team, and 22 members of the small group team. Our
sales force is supported by 30 personnel in our marketing
organization who provide specialized support for promotional and
selling efforts.
Channel
Partners
In addition to our employed sales force, we maintain business
relationships with individuals and organizations that promote or
support our sales or services within specific industries or
geographic regions, which we refer to as channels. We refer to
these individuals and organizations as our channel partners. In
most cases, these relationships are generally agreements that
compensate channel partners for providing us sales lead
information that results in sales. These channel partners
generally do not make sales but instead provide us with leads
that we use to develop new business through our direct sales
force. Other channel relationships permit third parties to act
as value-added resellers or as independent sales
representatives. In some instances, the channel relationship
involves endorsement or promotion of our services by these third
parties. In 2009, channel-based leads were associated with
approximately half of our new business. Our channel
relationships include state medical societies, healthcare
information technology product companies, healthcare product
distribution companies, and consulting firms. Examples of these
types of channel relationships include:
|
|
|
|
|
the Ohio State Medical Society;
|
|
|
|
Eclipsys Corporation; and
|
|
|
|
WorldMed Shared Services, Inc. (d/b/a PSS World Medical
Shares Services, Inc.), or PSS.
|
In May 2007, we entered into a marketing and sales agreement
with PSS for the marketing and sale of athenaClinicals and
athenaCollector. The agreement has an initial term of three
years and may be terminated by either party for cause or
convenience. The agreement shall automatically renew after the
initial term for
10
successive one year periods unless athenahealth or PSS gives
notice of termination no later than sixty days prior to
expiration of the then-current term. Under the terms of the
agreement, we will pay PSS sales commissions based upon the
estimated contract value of orders placed with PSS, which will
be adjusted 15 months after the date the service begins for
each client, in order to reflect actual revenue received by us
from clients. Subsequent commissions will be based upon a
specified percentage of actual revenue generated from orders
placed with PSS. We funded $0.3 million toward the
establishment of an incentive plan for the PSS sales
representatives during the first twelve months of the agreement
and are responsible for co-sponsoring training sessions and
conducting on-line education for PSS sales representatives.
Under the terms of the agreement, athenahealths revenue
cycle services and clinical cycle services are now the exclusive
revenue and clinical cycle solutions sold by PSS, except that
PSS may sell clinical cycle services not based on an application
service provider model. Additionally, the terms of the agreement
prohibit us from entering into a similar agreement with any
business that has, as its primary source of revenue, revenue
from the business of distributing medical and surgical supplies
to the physician ambulatory care market in the United States.
None of our existing channel relationships are affected by our
exclusive arrangement with PSS, and while our agreement with PSS
precludes us from entering into similar arrangements with other
distributors of medical and surgical supplies to the physician
ambulatory care market in the United States, we believe that PSS
is of sufficient size so as to offer us a compelling opportunity
to market our services to prospective clients that would
otherwise be difficult for us to reach. According to PSS, they
are the largest provider of medical and surgical supplies to the
physician market in the United States, with a sales force
consisting of more than 750 sales consultants who distribute
medical supplies and equipment to more than 100,000 offices in
all 50 states.
Marketing
Initiatives
Since our service model is new to most physicians, our marketing
and sales objectives are designed to increase awareness of our
company, establish the benefits of our service model, and build
credibility with prospective clients so that they will view our
company as a trustworthy long-term service provider. To execute
on this strategy, we have designed and implemented specific
activities and programs aimed at converting leads to new clients.
Our marketing initiatives are generally targeted towards
specific segments of the physician practice market. These
marketing programs primarily consist of:
|
|
|
|
|
traditional print advertising;
|
|
|
|
sponsoring
pay-per-click
search advertising and other Internet-focused awareness building
efforts (such as social media, online videos, webinars, and
destination websites covering compliance and other issues of
interest to physician practices);
|
|
|
|
engaging in public relations activities aimed at generating
media coverage;
|
|
|
|
participating in industry-focused trade shows;
|
|
|
|
disseminating targeted mail,
e-mail, and
phone calls to physician practices;
|
|
|
|
conducting informational meetings (such as strategic retreats
with targeted potential clients); and
|
|
|
|
dinner seminar series.
|
In June 2006, we introduced our annual PayerView rankings in
order to provide an industry-unique framework to systematically
address what we believe is administrative complexity existing
between payers and providers. PayerView is designed to look at
payers performance based on a number of categories, which
combine to provide an overall ranking aimed at quantifying the
ease of doing business with the payer. All data used
for the rankings come from actual claims performance data of our
clients and depict our experience in dealing with individual
payers across the nation. The rankings include national payers
that meet a minimum yearly threshold of 120,000 charge lines of
data and regional payers that meet a minimum yearly threshold of
20,000 charge lines.
11
Technology,
Development, and Operations
Our primary data center is in Bedford, Massachusetts with
Digital 55 Middlesex, LLC (as successor to Sentinel
Properties Bedford, LLC) and our production
data is housed in systems at our Watertown, Massachusetts and
Belfast, Maine offices. As backup to the primary data center, we
have a backup data center at our Belfast, Maine offices. In
addition, in December 2009 we signed a contract with a major
provider of disaster recovery services, SunGard Availability
Services, LP, to store our disaster recovery plans, deepen the
resiliency of our technology recovery infrastructure, and
provide disaster recovery testing services. In the case of a
significant event at our primary data center, we could become
operational in a reasonable timeframe at our backup data center.
The services provided by our data centers and disaster recovery
service providers are generally commercially available at
comparable rates from other service providers.
Our mission-critical business application is hosted by us and
accessed by clients using Internet connections or private
network connections. We have devoted significant resources to
producing software and related application and data center
services that meet the functionality and performance
expectations of clients. We use commercially available hardware
and a combination of proprietary and commercially available
software to provide our services. Software licenses for the
commercially sourced software are generally available on
commercially reasonable terms. The design of our application and
database servers is modular and scalable in that, as new clients
are added, we are able to add additional capacity as necessary.
We refer to this as a horizontal scaling
architecture, which means that hardware to support new
clients is added alongside existing clients hardware and
does not directly affect existing clients.
We devote significant resources to innovation. We execute
monthly releases of new software functionality to our clients
each year. Our software development life cycle methodology
ensures that each software release is properly designed, built,
tested, and rolled out. Our clients all operate on the same
version of our software, although some rules are designed to
take effect only locally for particular clients. Our software
development activities involve approximately 78 technologists
employed by us in the United States as of December 31,
2009. We complement this teams work with software
development services from third-party technology development
providers in Huntsville, Alabama and Pune, India, and with our
own direct employees at our development centers operated through
our subsidiaries located in Alpharetta, Georgia, and Chennai,
India. In addition to our core software development activities,
we dedicate full-time staff to our ongoing development and
maintenance of the athenaRules database. On average, over 100
rules are added or revised in our rules engine each month. We
also employ process program management and product management
personnel, who work continually on improvements to our service
operations processes and our service design, respectively.
Once our clients are live on our service, we collaborate with
them to generate business results. We employed approximately
582 people in our service operations dedicated to providing
these services to our clients as of December 31, 2009.
These employees assist our clients at each critical step in the
revenue cycle and clinical cycle workflow process and provide
services that include insurance benefits packaging, insurance
eligibility confirmation, claims submission, claims tracking,
remittance posting, denials management, payment processing,
formatting of lab requisitions, submission of lab requisitions,
and monitoring and classification of all inbound faxes.
Additionally, we use third parties for data entry, data
matching, data characterization, and outbound telephone
services. Currently, we have contracted for these services with
International Business Machines Corporation and Vision Business
Process Solutions Inc., a subsidiary of Dell, Inc. (formerly
Perot Systems Corporation), to provide data entry and other
services from facilities located in India and the Philippines to
support our client service operations. These services are
generally commercially available at comparable rates from other
service providers.
During 2009, athenahealth:
|
|
|
|
|
posted approximately $4.9 billion in physician collections;
|
|
|
|
processed over 40 million medical claims;
|
|
|
|
handled approximately 96.5 million charge postings; and
|
|
|
|
sorted over 30 million pages of paper, which amounted to
approximately 300,000 pounds of mail.
|
12
We depend on satisfied clients to succeed. Our client contracts
require minimum commitments by us on a range of tasks, including
claims submission, payment posting, claims tracking, and claims
denial management. We also commit to our clients that athenaNet
is accessible 99.7% of the time, excluding scheduled maintenance
windows. Each quarter, our management conducts a survey of
clients to identify client concerns and track progress against
client satisfaction objectives. In our most recent survey for
athenaCollector, 88.7% of the respondents reported that they
would recommend our services to a trusted friend or colleague.
In addition to the services described above, we also provide
client support services. There are several client service
support activities that take place on a regular basis, including
the following:
|
|
|
|
|
client support by our client services center that is designed to
address client questions and concerns rapidly, whether those
questions and concerns are registered via a phone call or via an
online support case through our customized use of customer
relationship management technology;
|
|
|
|
account performance and issue resolution activities performed by
the account management organization that are designed to address
open issues and focus clients on the financial results of the
co-sourcing relationship; these activities are intended to aid
in client retention, determine appropriate adjustments to
service pricing at renewal dates, and provide incremental
services when appropriate; and
|
|
|
|
relationship management by regional leaders of the client
services organization to ensure that decision-makers at client
practices are satisfied and that regional performance is managed
proactively with regard to client satisfaction, client margins,
client retention, renewal pricing, and added services.
|
The increased burden on patients to pay for a larger percentage
of their healthcare services, together with the need for
providers to have the ability to determine this patient payment
responsibility at the time of service, has led some payers to
develop the capability to accept and process claims in real
time. Under such a real-time adjudication, or RTA, system,
payers notify physicians immediately upon receipt of billing
information if third-party claims are accepted or rejected, the
amount that will be paid by the payer, and the amount that the
patient may owe under the particular health plan involved. This
capability is frequently referred to within the industry as
real time adjudication because it avoids the
processing time that adjudication of claims by payers has
historically involved. Taking advantage of this payer
capability, we have designed a platform for transacting with
payer RTA systems that is payer-neutral and designed to
integrate the various payer RTA processes so that our clients
experience the same workflow regardless of payer. Using this
platform, we have collaborated with two major payers, Humana and
United Healthcare, to process RTA transactions with their
systems.
Competition
We have experienced, and expect to continue to experience,
intense competition from a number of companies. Our primary
competition is the use of locally installed software to manage
revenue and clinical cycle workflow within the physicians
office. Other nationwide competitors have begun introducing
services that they refer to as on-demand or
software-as-a-service models, under which software
is centrally hosted and services are provided from central
locations. Software and service companies that sell practice
management and EHR software and medical billing and collection
services include GE Healthcare, Sage Software Healthcare, Inc.,
Allscripts-Misys Healthcare Solutions, Inc., Siemens Medical
Solutions USA, Inc., eClinical Works, LLC, and Quality Systems,
Inc. As a service company that provides revenue cycle services,
we also compete against large billing companies such as McKesson
Corp.; Ingenix, a division of United Healthcare, Inc.; and
regional billing companies.
The principal competitive factors in our industry include:
|
|
|
|
|
ability to quickly adapt to increasing complexity of the
healthcare reimbursement system;
|
|
|
|
size and scope of payer rules knowledge;
|
|
|
|
ease of use and rates of user adoption;
|
|
|
|
product functionality and scope of services;
|
13
|
|
|
|
|
scope of network connections to support electronic data
interactions;
|
|
|
|
performance, security, scalability, and reliability of service;
|
|
|
|
sale and marketing capabilities of the vendor; and
|
|
|
|
financial stability of the vendor.
|
We believe that we compete favorably with our competitors on the
basis of these factors. However, many of our competitors and
potential competitors have significantly greater financial,
technological, and other resources and name recognition than we
do, as well as more established distribution networks and
relationships with healthcare providers. As a result, many of
these companies may respond more quickly to new or emerging
technologies and standards and changes in customer requirements.
These companies may be able to invest more resources than we can
in research and development, strategic acquisitions, sales and
marketing, and patent prosecution and litigation and to finance
capital equipment acquisitions for their customers.
Government
Regulation
Although we generally do not contract with U.S. state or
local government entities, the services that we provide are
subject to a complex array of federal and state laws and
regulations, including regulation by the Centers for Medicare
and Medicaid Services, or CMS, of the U.S. Department of
Health and Human Services, as well as additional regulation.
Government
Regulation of Health Information
HIPAA Privacy and Security Rules. The Health
Insurance Portability and Accountability Act of 1996, as
amended, and the regulations that have been issued under it
(collectively, HIPAA) contain substantial
restrictions and requirements with respect to the use and
disclosure of individuals protected health information.
These are embodied in the Privacy Rule and Security Rule
portions of HIPAA. The HIPAA Privacy Rule prohibits a covered
entity from using or disclosing an individuals protected
health information unless the use or disclosure is authorized by
the individual or is specifically required or permitted under
the Privacy Rule. The Privacy Rule imposes a complex system of
requirements on covered entities for complying with this basic
standard. Under the HIPAA Security Rule, covered entities must
establish administrative, physical, and technical safeguards to
protect the confidentiality, integrity, and availability of
electronic protected health information maintained or
transmitted by them or by others on their behalf.
The HIPAA Privacy and Security Rules apply directly to covered
entities, such as healthcare providers who engage in
HIPAA-defined standard electronic transactions, health plans,
and healthcare clearinghouses. Because we translate electronic
transactions to and from the HIPAA-prescribed electronic forms
and other forms, we are considered a clearinghouse, and as such
are a covered entity. In addition, our clients are also covered
entities. In order to provide clients with services that involve
the use or disclosure of protected health information, the HIPAA
Privacy and Security Rules require us to enter into business
associate agreements with our clients. Such agreements must,
among other things, provide adequate written assurances:
|
|
|
|
|
as to how we will use and disclose the protected health
information;
|
|
|
|
that we will implement reasonable administrative, physical, and
technical safeguards to protect such information from misuse;
|
|
|
|
that we will enter into similar agreements with our agents and
subcontractors that have access to the information;
|
|
|
|
that we will report security incidents and other inappropriate
uses or disclosures of the information; and
|
|
|
|
that we will assist the client in question with certain of its
duties under the Privacy Rule.
|
HIPAA Transaction Requirements. In addition to
the Privacy and Security Rules, HIPAA also requires that certain
electronic transactions related to health care billing be
conducted using prescribed electronic formats. For example,
claims for reimbursement that are transmitted electronically to
payers must comply with
14
specific formatting standards, and these standards apply whether
the payer is a government or a private entity. As a covered
entity subject to HIPAA, we must meet these requirements, and
moreover, we must structure and provide our services in a way
that supports our clients HIPAA compliance obligations.
HITECH Act. The HITECH Act, which became law
in February 2009, and the regulations issued and to be issued
under it have provided and are expected to provide, among other
things, clarification of certain aspects of both the Privacy and
Security Rules, expansion of the disclosure requirements for a
breach of the Security Rule, and strengthening of the civil and
criminal penalties for failure to comply with HIPAA. As these
additional requirements are adopted, we will be required to
comply with them.
State Laws. In addition to the HIPAA Privacy
and Security Rules and the requirements imposed by the HITECH
Act, most states have enacted patient confidentiality laws that
protect against the disclosure of confidential medical
information, and many states have adopted or are considering
further legislation in this area, including privacy safeguards,
security standards, and data security breach notification
requirements. Such state laws, if more stringent than HIPAA and
HITECH Act requirements, are not preempted by the federal
requirements, and we must comply with them. For example, the
Massachusetts Office of Consumer Affairs and Business
Regulations issued final data security regulations, which became
effective in March 2010 and establish minimum standards for
protecting and storing personal information about Massachusetts
residents contained in paper or electronic format.
Red Flag Rules. Starting June 1, 2010,
medical practices that act as creditors to their
patients will need to comply with new Federal Trade Commission
rules promulgated under the Fair and Accurate Credit
Transactions Act of 2003 that are aimed at reducing the risk of
identity theft. These rules require creditors to adopt policies
and procedures that identify patterns, practices, or activities
that indicate possible identity theft (called red
flags); detect those red flags; and respond appropriately
to those red flags to prevent or mitigate any theft. The rules
also require creditors to update their policies and procedures
on a regular basis. Because most practices treat their patients
without receiving full payment at the time of service, our
clients are generally considered creditors for
purposes of these rules and are required to comply with them.
Although we are not directly subject to these rules
since we do not extend credit to customers we do
handle patient data that, if improperly disclosed, could be used
in identity theft. Because the red flag rules were originally
slated to take effect in November 2008, we have been assisting
in our clients efforts to the extent necessary to
implement appropriate procedures for some time and plan on
continuing to do so.
Government
Regulation of Reimbursement
Our clients are subject to regulation by a number of
governmental agencies, including those that administer the
Medicare and Medicaid programs. Accordingly, our clients are
sensitive to legislative and regulatory changes in, and
limitations on, the government healthcare programs and changes
in reimbursement policies, processes, and payment rates. During
recent years, there have been numerous federal legislative and
administrative actions that have affected government programs,
including adjustments that have reduced or increased payments to
physicians and other healthcare providers and adjustments that
have affected the complexity of our work. For example, Medicare
reimbursement was, for a period of time in 2006, reduced with
respect to portions of the physician payment fee schedule. The
federal government subsequently rescinded reduction and decided
to pay physicians the amount of the reduction that had been
applied to claims already processed under the reduced payment
fee schedule. To collect these payments for our clients, we
re-submitted claims that had previously been processed. This
process required substantial unanticipated processing work by
us, and the additional payments for re-submitted claims were
sometimes very small. It is possible that the federal or state
governments will implement future reductions, increases, or
changes in reimbursement under government programs that
adversely affect our client base or our cost of providing our
services. Any such changes could adversely affect our own
financial condition by reducing the reimbursement rates of our
clients or by increasing our cost of serving clients.
15
Fraud
and Abuse
A number of federal and state laws, loosely referred to as
fraud and abuse laws, are used to prosecute
healthcare providers, physicians, and others that make, offer,
seek, or receive referrals or payments for products or services
that may be paid for through any federal or state healthcare
program and, in some instances, any private program. Given the
breadth of these laws and regulations, they are potentially
applicable to our business; the transactions that we undertake
on behalf of our clients; and the financial arrangements through
which we market, sell, and distribute our services. These laws
and regulations include:
Anti-Kickback Laws. There are numerous federal
and state laws that govern patient referrals, physician
financial relationships, and inducements to healthcare providers
and patients. The federal healthcare programs
anti-kickback law prohibits any person or entity from offering,
paying, soliciting, or receiving anything of value, directly or
indirectly, for the referral of patients covered by Medicare,
Medicaid, and other federal healthcare programs or the leasing,
purchasing, ordering, or arranging for or recommending the
lease, purchase, or order of any item, good, facility, or
service covered by these programs. Courts have construed this
anti-kickback law to mean that a financial arrangement may
violate this law if any one of the purposes of one of the
arrangements is to encourage patient referrals or other federal
healthcare program business, regardless of whether there are
other legitimate purposes for the arrangement. There are several
limited exclusions known as safe harbors that may protect some
arrangements from enforcement penalties. These safe harbors have
very limited application. Penalties for federal anti-kickback
violations are severe, and include imprisonment, criminal fines,
civil money penalties with triple damages, and exclusion from
participation in federal healthcare programs. Many states have
similar anti-kickback laws, some of which are not limited to
items or services for which payment is made by a government
healthcare program.
False or Fraudulent Claim Laws. There are
numerous federal and state laws that forbid submission of false
information or the failure to disclose information in connection
with the submission and payment of physician claims for
reimbursement. In some cases, these laws also forbid abuse of
existing systems for such submission and payment, for example,
by systematic over treatment or duplicate billing for the same
services to collect increased or duplicate payments. These laws
and regulations may change rapidly, and it is frequently unclear
how they apply to our business. For example, one federal false
claim law forbids knowing submission to government programs of
false claims for reimbursement for medical items or services.
Under this law, knowledge may consist of willful ignorance or
reckless disregard of falsity. How these concepts apply to
services such as ours that rely substantially on automated
processes has not been well defined in the regulations or
relevant case law. As a result, our errors with respect to the
formatting, preparation, or transmission of such claims and any
mishandling by us of claims information that is supplied by our
clients or other third parties may be determined to, or may be
alleged to, involve willful ignorance or reckless disregard of
any falsity that is later determined to exist.
In most cases where we are permitted to do so, we charge our
clients a percentage of the collections that they receive as a
result of our services. To the extent that liability under fraud
and abuse laws and regulations requires intent, it may be
alleged that this percentage calculation provides us or our
employees with incentive to commit or overlook fraud or abuse in
connection with submission and payment of reimbursement claims.
The Centers for Medicare and Medicaid Services has stated that
it is concerned that percentage-based billing services may
encourage billing companies to commit or to overlook fraudulent
or abusive practices.
Stark Law and Similar State Laws. The Ethics
in Patient Referrals Act, known as the Stark Law, prohibits
certain types of referral arrangements between physicians and
healthcare entities. Physicians are prohibited from referring
patients for certain designated health services reimbursed under
federally funded programs to entities with which they or their
immediate family members have a financial relationship or an
ownership interest, unless such referrals fall within a specific
exception. Violations of the statute can result in civil
monetary penalties
and/or
exclusion from the Medicare and Medicaid programs. Furthermore,
reimbursement claims for care rendered under forbidden referrals
may be deemed false or fraudulent, resulting in liability under
other fraud and abuse laws.
Laws in many states similarly forbid billing based on referrals
between individuals
and/or
entities that have various financial, ownership, or other
business relationships. These laws vary widely from state to
state.
16
Corporate
Practice of Medicine Laws, Fee-Splitting Laws, and
Anti-Assignment Laws
In many states, there are laws that forbid non-licensed
practitioners from practicing medicine, prevent corporations
from being licensed as practitioners, and forbid licensed
medical practitioners from practicing medicine in partnership
with non-physicians, such as business corporations. In some
states, these prohibitions take the form of laws or regulations
forbidding the splitting of physician fees with non-physicians
or others. In some cases, these laws have been interpreted to
prevent business service providers from charging their physician
clients on the basis of a percentage of collections or charges.
There are also federal and state laws that forbid or limit
assignment of claims for reimbursement from government-funded
programs. Some of these laws limit the manner in which business
service companies may handle payments for such claims and
prevent such companies from charging their physician clients on
the basis of a percentage of collections or charges. In
particular, the Medicare program specifically requires that
billing agents who receive Medicare payments on behalf of
medical care providers must meet the following requirements:
|
|
|
|
|
the agent must receive the payment under an agreement between
the provider and the agent;
|
|
|
|
the agents compensation may not be related in any way to
the dollar amount billed or collected;
|
|
|
|
the agents compensation may not depend upon the actual
collection of payment;
|
|
|
|
the agent must act under payment disposition instructions, which
the provider may modify or revoke at any time; and
|
|
|
|
in receiving the payment, the agent must act only on behalf of
the provider, except insofar as the agent uses part of that
payment to compensate the agent for the agents billing and
collection services.
|
Medicaid regulations similarly provide that payments may be
received by billing agents in the name of their clients without
violating anti-assignment requirements if payment to the agent
is related to the cost of the billing service, not related on a
percentage basis to the amount billed or collected, and not
dependent on collection of payment.
Electronic
Prescribing Laws
States have differing prescription format and signature
requirements. Many existing laws and regulations, when enacted,
did not anticipate the methods of
e-commerce
now being developed. However, due in part to recent industry
initiatives, federal law and the laws of all 50 states now
permit the electronic transmission of prescription orders. In
addition, on November 7, 2005, the Department of Health and
Human Services published its final
E-Prescribing
and the Prescription Drug Program regulations, referred to below
as the
E-Prescribing
Regulations. These regulations are required by the Medicare
Prescription Drug Improvement and Modernization Act of 2003
(MMA) and became effective beginning on
January 1, 2006. The
E-Prescribing
Regulations consist of detailed standards and requirements, in
addition to the HIPAA standards discussed previously, for
prescription and other information transmitted electronically in
connection with a drug benefit covered by the MMAs
Prescription Drug Benefit. These standards cover not only
transactions between prescribers and dispensers for
prescriptions but also electronic eligibility and benefits
inquiries and drug formulary and benefit coverage information.
The standards apply to prescription drug plans participating in
the MMAs Prescription Drug Benefit. Aspects of our
services are affected by such regulation, as our clients need to
comply with these requirements.
Anti-Tampering
Laws
For certain prescriptions that cannot or may not be transmitted
electronically from physician to pharmacy, both federal and
state laws require that the written forms used exhibit
anti-tampering features. For example, the U.S. Troop
Readiness, Veterans Care, Katrina Recovery, and Iraq
Accountability Appropriations Act of 2007 has since April 2008
required that most prescriptions covered by Medicaid must
demonstrate security features that prevent copying, erasing, or
counterfeiting of the written form. Because our clients will, on
17
occasion, need to use printed forms, we must take these laws
into consideration for purposes of the prescription functions of
our athenaClinicals service.
Electronic
Health Records Certification Requirements
The federal Office of the National Coordinator for Health
Information Technology, or ONCHIT, is responsible for promoting
the use of interoperable electronic health records and systems.
ONCHIT has introduced a strategic framework and has awarded
contracts to advance a national health information network and
interoperable EHRs. One project within this framework is a
voluntary private sector based certification
commission, CCHIT, that certifies electronic health record
systems as meeting minimum functional and interoperability
requirements. Our clinical application functionality is
certified by CCHIT under its 2008 criteria. Due to the possible
incorporation of CCHITs criteria into the meaningful use
standards under the HITECH Act, such certification may become a
de facto requirement for selling clinical systems in the
future; however, CCHITs certification requirement may
change substantially. While we believe our system is well
designed in terms of function and interoperability, we cannot be
certain that it will meet future requirements.
United
States Food and Drug Administration
The FDA has promulgated a draft policy for the regulation of
computer software products as medical devices and a proposed
rule for reclassification of medical device data systems under
the Federal Food, Drug and Cosmetic Act, as amended, or FDCA. If
our computer software functionality is a medical device under
the policy or a medical device data system under the rule, we
could be subject to the FDA requirements discussed below.
Although it is not possible to anticipate the final form of the
FDAs policy or final rule with regard to computer
software, we expect that the FDA is likely to become
increasingly active in regulating computer software intended for
use in healthcare settings regardless of whether the draft
policy or proposed rule is finalized or changed.
Medical devices are subject to extensive regulation by the FDA
under the FDCA. Under the FDCA, medical devices include any
instrument, apparatus, machine, contrivance, or other similar or
related article that is intended for use in the diagnosis of
disease or other conditions or in the cure, mitigation,
treatment, or prevention of disease. FDA regulations govern,
among other things, product development, testing, manufacture,
packaging, labeling, storage, clearance or approval, advertising
and promotion, sales and distribution, and import and export.
FDA requirements with respect to devices that are determined to
pose lesser risk to the public include:
|
|
|
|
|
establishment registration and device listing with the FDA;
|
|
|
|
the Quality System Regulation, or QSR, which requires
manufacturers, including third-party or contract manufacturers,
to follow stringent design, testing, control, documentation, and
other quality assurance procedures during all aspects of
manufacturing;
|
|
|
|
labeling regulations and FDA prohibitions against the
advertising and promotion of products for uncleared, unapproved
off-label uses and other requirements related to advertising and
promotional activities;
|
|
|
|
medical device reporting regulations, which require that
manufacturers report to the FDA if their device may have caused
or contributed to a death or serious injury or malfunctioned in
a way that would likely cause or contribute to a death or
serious injury if the malfunction were to recur;
|
|
|
|
corrections and removal reporting regulations, which require
that manufacturers report to the FDA any field corrections and
product recalls or removals if undertaken to reduce a risk to
health posed by the device or to remedy a violation of the FDCA
that may present a risk to health; and
|
|
|
|
post-market surveillance regulations, which apply when necessary
to protect the public health or to provide additional safety and
effectiveness data for the device.
|
Non-compliance with applicable FDA requirements can result in,
among other things, public warning letters, fines, injunctions,
civil penalties, recall or seizure of products, total or partial
suspension of production,
18
failure of the FDA to grant marketing approvals, withdrawal of
marketing approvals, a recommendation by the FDA to disallow us
from entering into government contracts, and criminal
prosecutions. The FDA also has the authority to request repair,
replacement, or refund of the cost of any device.
Foreign
Regulations
Our subsidiary in Chennai, India, is subject to additional
regulations by the Government of India, as well as its regional
subdivisions. These regulations include Indian federal and local
corporation requirements, restrictions on exchange of funds,
employment-related laws, and qualification for tax status and
tax incentives.
Intellectual
Property
We rely on a combination of patent, trademark, copyright, and
trade secret laws in the United States as well as
confidentiality procedures and contractual provisions to protect
our proprietary technology, databases, and our brand. Despite
these reliances, we believe the following factors are more
essential to establishing and maintaining a competitive
advantage:
|
|
|
|
|
the statistical and technological skills of our service
operations and research and development teams;
|
|
|
|
the healthcare domain expertise and payer rules knowledge of our
service operations and research and development teams;
|
|
|
|
the real-time connectivity of our solutions;
|
|
|
|
the continued expansion of our proprietary rules engine; and
|
|
|
|
a continued focus on the improved financial results of our
clients.
|
Our first patent application described and documented our unique
patient workflow process, including the athenaNet
Rules Engine, which applies proprietary rules to practice
and payer inputs on a live, ongoing basis to produce cleaner
healthcare claims, which can be adjudicated more quickly and
efficiently. This patent application was granted in November
2009 and expires in December 2023. We have filed seven
subsequent patent applications and two provisional patent
applications that describe and document other unique aspects of
our functionality and workflow processes during calendar years
2006 through 2009 and are currently pending before the United
States Patent and Trademark Office. We also acquired one patent
application each in connection with the acquisitions of
MedicalMessaging.net in September 2008 and Anodyne in October
2009.
We also rely on a combination of registered and unregistered
service marks to protect our brands. athenahealth,
athenaNet, and the athenahealth logo are registered
service marks of athenahealth. In 2009, we applied for the
registration of athenaClinicals, athenaCollector,
athenaCommunicator, and PayerView as service marks of
athenahealth, and we are currently corresponding with the
examiner to resolve some technical issues. Additionally,
athenaEnterprise, athenaRules, and ReminderCall are service
marks of athenahealth, and in connection with the acquisition of
Anodyne we acquired Anodyne Analytics and Anodyne Intelligence
Platform as service marks.
We have a policy of requiring key employees and consultants to
execute confidentiality agreements upon the commencement of an
employment or consulting relationship with us. Our employee
agreements also require relevant employees to assign to us all
rights to any inventions made or conceived during their
employment with us. In addition, we have a policy of requiring
individuals and entities with which we discuss potential
business relationships to sign non-disclosure agreements. Our
agreements with clients include confidentiality and
non-disclosure provisions.
Employees
As of December 31, 2009, we had 1,035 employees. Of
these employees, 966 were employed in the U.S., including 582 in
service operations, 124 in sales and marketing, 139 in research
and development, and 121 in general and administrative
functions. In addition, as of that date, we had
68 employees located in Chennai, India, who were employed
by our foreign subsidiary, athenahealth Technology Private
Limited, including
19
thirteen in service operations, 42 in research and development,
and thirteen in general and administrative functions. As of the
same date, our domestic operating subsidiary, Anodyne had 37
U.S. employees, of whom seventeen were in service
operations, ten were in sales and marketing, three were in
research and development, and seven provided general and
administrative services. We believe that we have good
relationships with our employees. None of our employees are
subject to collective bargaining agreements or are represented
by a union.
Organization
and Trademarks
We were incorporated in Delaware on August 21, 1997, as
Athena Healthcare Incorporated. We changed our name to
athenahealth.com, Inc. on March 31, 2000, and to
athenahealth, Inc. on November 17, 2000. Our corporate
headquarters are located at 311 Arsenal Street, Watertown,
Massachusetts, 02472, and our telephone number is
(617) 402-1000.
In this Annual Report on
Form 10-K,
the terms athena, athenahealth,
we, us, and our refer to
athenahealth, Inc. and its subsidiaries, Anodyne Health
Partners, Inc., athenahealth MA, Inc., and athenahealth
Technology Private Limited, and any subsidiary that may be
acquired or formed in the future.
Our marks include athenahealth, athenaNet, and the athenahealth
logo as registered service marks; Anodyne Analytics, Anodyne
Intelligence, athenaClinicals, athenaCollector,
athenaCommunicator, athenaEnterprise, athenaRules, PayerView,
and ReminderCall, as unregistered service marks. This Annual
Report on
Form 10-K
also includes the registered and unregistered trademarks and
service marks of other persons.
Financial
Information
The financial information required under this Item 1 is
incorporated herein by reference to Part II, Item 8 of
this Annual Report on
Form 10-K.
Where You
Can Find More Information
Our Annual Reports on
Form 10-K,
Quarterly Reports on
Form 10-Q,
Current Reports on
Form 8-K,
and amendments to those reports filed or furnished pursuant to
Section 13(a) or 15(d) of the Securities Exchange Act of
1934 are available through the investor relations portion of our
website ( www.athenahealth.com ) free of charge as soon
as reasonably practicable after we electronically file such
material with, or furnish it to, the Securities and Exchange
Commission, or SEC. As discussed in Explanatory Note
Regarding Restatement, financial information included in
the reports on
Form 10-K,
Form 10-Q,
and
Form 8-K
filed by us prior to March 15. 2010, and all earnings press
releases and similar communications issued by us prior to
March 15, 2010, should not be relied upon and are
superseded in their entirety by this Annual Report on
Form 10-K.
Information on our investor relations page and on our website is
not part of this Annual Report on
Form 10-K
or any of our other securities filings unless specifically
incorporated herein by reference. In addition, our filings with
the Securities and Exchange Commission may be accessed through
the Securities and Exchange Commissions Interactive Data
Electronic Applications (IDEA) system at www.sec.gov. All
statements made in any of our securities filings, including all
forward-looking statements or information, are made as of the
date of the document in which the statement is included, and we
do not assume or undertake any obligation to update any of those
statements or documents unless we are required to do so by law.
Our operating results and financial condition have varied in
the past and may in the future vary significantly depending on a
number of factors. Except for the historical information in this
report, the matters contained in this report include
forward-looking statements that involve risks and uncertainties.
The following factors, among others, could cause actual results
to differ materially from those contained in forward-looking
statements made in this report and presented elsewhere by
management from time to time. Such factors, among others, may
have a material adverse effect upon our business, results of
operations, and financial condition.
20
RISKS
RELATED TO OUR BUSINESS
Our
operating results have in the past and may continue to fluctuate
significantly, and if we fail to meet the expectations of
analysts or investors, our stock price and the value of your
investment could decline substantially.
Our operating results are likely to fluctuate, and if we fail to
meet or exceed the expectations of securities analysts or
investors, the trading price of our common stock could decline.
Moreover, our stock price may be based on expectations of our
future performance that may be unrealistic or that may not be
met. Some of the important factors that could cause our revenues
and operating results to fluctuate from quarter to quarter
include:
|
|
|
|
|
the extent to which our services achieve or maintain market
acceptance;
|
|
|
|
our ability to introduce new services and enhancements to our
existing services on a timely basis;
|
|
|
|
new competitors and the introduction of enhanced products and
services from new or existing competitors;
|
|
|
|
the length of our contracting and implementation cycles;
|
|
|
|
the financial condition of our current and potential clients;
|
|
|
|
changes in client budgets and procurement policies;
|
|
|
|
the amount and timing of our investment in research and
development activities;
|
|
|
|
technical difficulties or interruptions in our services;
|
|
|
|
our ability to hire and retain qualified personnel and maintain
an adequate rate of expansion of our sales force;
|
|
|
|
changes in the regulatory environment related to healthcare;
|
|
|
|
regulatory compliance costs;
|
|
|
|
the timing, size, and integration success of potential future
acquisitions; and
|
|
|
|
unforeseen legal expenses, including litigation and settlement
costs.
|
Many of these factors are not within our control, and the
occurrence of one or more of them might cause our operating
results to vary widely. As such, we believe that
quarter-to-quarter
comparisons of our revenues and operating results may not be
meaningful and should not be relied upon as an indication of
future performance.
A significant portion of our operating expense is relatively
fixed in nature, and planned expenditures are based in part on
expectations regarding future revenue. Accordingly, unexpected
revenue shortfalls may decrease our gross margins and could
cause significant changes in our operating results from quarter
to quarter. In addition, our future quarterly operating results
may fluctuate and may not meet the expectations of securities
analysts or investors. If this occurs, the trading price of our
common stock could fall substantially either suddenly or over
time.
We
operate in a highly competitive industry, and if we are not able
to compete effectively, our business and operating results will
be harmed.
The provision by third parties of revenue cycle services to
physician practices has historically been dominated by small
service providers who offer highly individualized services and a
high degree of specialized knowledge applicable in many cases to
a limited medical specialty, a limited set of payers, or a
limited geographical area. We anticipate that the software,
statistical, and database tools that are available to such
service providers will continue to become more sophisticated and
effective and that demand for our services could be adversely
affected.
21
Revenue cycle software for physician practices has historically
been dominated by large, well-financed and technologically
sophisticated entities that have focused on software solutions.
Some of these entities are now offering on-demand
services or a software-as-a-service model under
which software is centrally administered, and administrative
services may be provided on a vendor basis. The size, financial
strength, and breadth of offerings of these entities is
increasing as a result of continued consolidation in both the
information technology and healthcare industries. We expect
large integrated technology companies to become more active in
our markets, both through acquisition and internal investment.
As costs fall and technology improves, increased market
saturation may change the competitive landscape in favor of
competitors with greater scale than we possess.
Some of our current large competitors, such as GE Healthcare,
Sage Software Healthcare, Inc., Allscripts-Misys Healthcare
Solutions, Inc., Quality Systems, Inc., Siemens Medical
Solutions USA, Inc., and McKesson Corp. have greater name
recognition, longer operating histories, and significantly
greater resources than we do. As a result, our competitors may
be able to respond more quickly and effectively than we can to
new or changing opportunities, technologies, standards, or
client requirements. In addition, current and potential
competitors have established, and may in the future establish,
cooperative relationships with vendors of complementary
products, technologies, or services to increase the availability
of their products to the marketplace. Current or future
competitors may consolidate to improve the breadth of their
products, directly competing with our integrated offerings.
Accordingly, new competitors or alliances may emerge that have
greater market share, larger client bases, more widely adopted
proprietary technologies, broader offerings, greater marketing
expertise, greater financial resources, and larger sales forces
than we have, which could put us at a competitive disadvantage.
Further, in light of these advantages, even if our services are
more effective than the product or service offerings of our
competitors, current or potential clients might accept
competitive products and services in lieu of purchasing our
services. Increased competition is likely to result in pricing
pressures, which could negatively impact our sales,
profitability, or market share. In addition to new niche
vendors, who offer stand-alone products and services, we face
competition from existing enterprise vendors, including those
currently focused on software solutions, which have information
systems in place with clients in our target market. These
existing enterprise vendors may now, or in the future, offer or
promise products or services with less functionality than our
services, but that offer ease of integration with existing
systems and that leverage existing vendor relationships.
The
market for our services is relatively immature and volatile, and
if it does not develop further or if it develops more slowly
than we expect, the growth of our business will be
harmed.
The market for Internet-based business services is still
relatively new and narrowly based, and it is uncertain whether
these services will achieve and sustain high levels of demand
and market acceptance. Our success will depend to a substantial
extent on the willingness of enterprises, large and small, to
increase their use of on-demand business services in general,
and for their revenue and clinical cycles in particular. Many
enterprises have invested substantial personnel and financial
resources to integrate established enterprise software into
their businesses, and therefore may be reluctant or unwilling to
switch to an on-demand application service. Furthermore, some
enterprises may be reluctant or unwilling to use on-demand
application services, because they have concerns regarding the
risks associated with security capabilities, among other things,
of the technology delivery model associated with these services.
If enterprises do not perceive the benefits of our services,
then the market for these services may not expand as much or
develop as quickly as we expect, either of which would
significantly adversely affect our operating results. In
addition, as a relatively new company in the healthcare business
services market, we have limited insight into trends that may
develop and affect our business. We may make errors in
predicting and reacting to relevant business trends, which could
harm our business. If any of these risks occur, it could
materially adversely affect our business, financial condition,
or results of operations.
If we
do not continue to innovate and provide services that are useful
to users, we may not remain competitive, and our revenues and
operating results could suffer.
Our success depends on providing services that the medical
community uses to improve business performance and quality of
service to patients. Our competitors are constantly developing
products and services that may become more efficient or
appealing to our clients. As a result, we must continue to
invest significant resources in research and development in
order to enhance our existing services and introduce new
22
high-quality services that clients will want. If we are unable
to predict user preferences or industry changes, or if we are
unable to modify our services on a timely basis, we may lose
clients. Our operating results would also suffer if our
innovations are not responsive to the needs of our clients, are
not appropriately timed with market opportunity, or are not
effectively brought to market. As technology continues to
develop, our competitors may be able to offer results that are,
or that are perceived to be, substantially similar to or better
than those generated by our services. This may force us to
compete on additional service attributes and to expend
significant resources in order to remain competitive.
As a
result of our variable sales and implementation cycles, we may
be unable to recognize revenue to offset expenditures, which
could result in fluctuations in our quarterly results of
operations or otherwise harm our future operating
results.
The sales cycle for our services can be variable, typically
ranging from three to five months from initial contact to
contract execution. During the sales cycle, we expend time and
resources, and we do not recognize any revenue to offset such
expenditures. Our implementation cycle is also variable,
typically ranging from three to five months from contract
execution to completion of implementation. Some of our
new-client
set-up
projects are complex and require a lengthy delay and significant
implementation work. Each clients situation is different,
and unanticipated difficulties and delays may arise as a result
of failure by us or by the client to meet our respective
implementation responsibilities. In some cases, especially those
involving larger clients, the sales cycle and the implementation
cycle may exceed the typical ranges by substantial margins.
During the implementation cycle, we expend substantial time,
effort, and financial resources implementing our services, but
accounting principles do not allow us to recognize the resulting
revenue until the service has been implemented, at which time we
begin recognition of implementation revenue over an expected
attribution period of the longer of the estimated expected
customer life, currently twelve years, or the contract term.
This could harm our future operating results.
After a client contract is signed, we provide an implementation
process for the client during which appropriate connections and
registrations are established and checked, data is loaded into
our athenaNet system, data tables are set up, and practice
personnel are given initial training. The length and details of
this implementation process vary widely from client to client.
Typically, implementation of larger clients takes longer than
implementation for smaller clients. Implementation for a given
client may be cancelled. Our contracts typically provide that
they can be terminated for any reason or for no reason in
90 days. Despite the fact that we typically require a
deposit in advance of implementation, some clients have
cancelled before our services have been started. In addition,
implementation may be delayed or the target dates for completion
may be extended into the future for a variety of reasons,
including the needs and requirements of the client, delays with
payer processing, and the volume and complexity of the
implementations awaiting our work. If implementation periods are
extended, our provision of the revenue cycle or clinical cycle
services upon which we realize most of our revenues will be
delayed, and our financial condition may be adversely affected.
In addition, cancellation of any implementation after it has
begun may involve loss to us of time, effort, and expenses
invested in the cancelled implementation process and lost
opportunity for implementing paying clients in that same period
of time.
These factors may contribute to substantial fluctuations in our
quarterly operating results, particularly in the near term and
during any period in which our sales volume is relatively low.
As a result, in future quarters our operating results could fall
below the expectations of securities analysts or investors, in
which event our stock price would likely decrease.
If the
revenue of our clients decreases, or if our clients cancel or
elect not to renew their contracts, our revenue will
decrease.
Under most of our client contracts, we base our charges on a
percentage of the revenue that the client realizes while using
our services. Many factors may lead to decrease in client
revenue, including:
|
|
|
|
|
interruption of client access to our system for any reason;
|
|
|
|
our failure to provide services in a timely or high-quality
manner;
|
23
|
|
|
|
|
failure of our clients to adopt or maintain effective business
practices;
|
|
|
|
actions by third-party payers of medical claims to reduce
reimbursement;
|
|
|
|
government regulations and government or other payer actions
reducing or delaying reimbursement; and
|
|
|
|
reduction of client revenue resulting from increased competition
or other changes in the marketplace for physician services.
|
The current economic situation may give rise to several of these
factors. For example, patients who have lost health insurance
coverage due to unemployment or who face increased deductibles
imposed by financially struggling employers or insurers could
reduce the number of visits those patients make to our physician
clients. Patients without health insurance or with reduced
coverage may also default on their payment obligations at a
higher rate than patients with coverage. Added financial stress
on our clients could lead to their acquisition or bankruptcy,
which could cause the termination of some of our service
relationships. Further, despite the cost benefits that we
believe our services provide, prospective clients may wish to
delay contract decisions due to implementation costs or be
reluctant to make any material changes in their established
business methods in the current economic climate. With a
reduction in tax revenue, state and federal government health
care programs, including reimbursement programs such as
Medicaid, may be reduced or eliminated, which could negatively
impact the payments that our clients receive. Also, although we
currently estimate our expected customer life to be twelve
years, this is only an estimate and there can be no assurance
that our clients will elect to renew their contracts for this
period of time. Our clients typically purchase one-year
contracts that, in most cases, may be terminated on 90 days
notice without cause. If our clients revenue decreases for
any of the above or other reasons, or if our clients cancel or
elect not to renew their contracts, our revenue will decrease.
We may
not see the benefits of, or have our services approved under,
government programs initiated to counter the effects of the
current economic situation or foster the adoption of certain
health information technologies, which could reduce client
demand, trigger certain guarantee obligations, and affect our
access to the market.
Although government programs have been initiated to counter the
effects of the current economic situation and foster the
adoption of certain health information technologies, we cannot
assure you that we will receive any funds from, or have our
services approved under, those programs. For example, the HITECH
Act has authorized approximately $17 billion in
expenditures to further adoption of electronic health records,
and entities such as the Massachusetts Healthcare Consortium
have offered to subsidize such adoption, as permitted by recent
changes in federal regulations.
While we believe that our service offerings will meet the
requirements of the HITECH Act and other programs in order for
our clients to qualify for additional reimbursement for
implementing and using our services, there can be no certainty
that any of the planned additional reimbursements, if made, will
be made in regard to our services. To the extent that we do not
qualify for or participate in such subsidy programs, demand for
our services may be reduced, which may result in decreased
revenues, perhaps material decreases. Furthermore, we have
offered certain existing and prospective clients a guarantee
that they will receive Medicare incentive reimbursement under
the 2011 HITECH Act program year for meaningful use of our
athenaClinicals EHR service. If such reimbursements are delayed
or not made because of a failure on our part, we could be
obligated to credit up to six months of our EHR services fees
for each client participating in our guarantee program.
In addition, if our services are not approved or included as a
preferred solution under certain programs, our access to the
market could be reduced. For example, the Health Information
Technology Extension Program under the HITECH Act provides for
70 or more regional centers that will assist local healthcare
providers in selecting and using EHR products and services. If
any of our services are not approved, or not included in a list
of preferred products and services, under one or more programs,
demand for our services and our access to the market could be
reduced, which could have a material adverse effect on our
business, including a material decrease in revenues and possibly
market share.
24
If
participants in our channel marketing and sales lead programs do
not maintain appropriate relationships with current and
potential clients, our sales accomplished with their help or
data may be unwound and our payments to them may be deemed
improper.
We maintain a series of relationships with third parties that we
term channel relationships. These relationships take different
forms under different contractual language. Some relationships
help us identify sales leads. Other relationships permit third
parties to act as value-added resellers or as independent sales
representatives for our services. In some cases, for example in
the case of some membership organizations, these relationships
involve endorsement of our services as well as other marketing
activities. In each of these cases, we require contractually
that the third party disclose information to
and/or limit
their relationships with potential purchasers of our services
for regulatory compliance reasons. If these third parties do not
comply with these regulatory requirements or if our requirements
are deemed insufficient, sales accomplished with the data or
help that they have provided as well as the channel relationship
themselves may not be enforceable, may be unwound, and may be
deemed to violate relevant laws or regulations. Third parties
that, despite our requirements, exercise undue influence over
decisions by current and prospective clients, occupy positions
with obligations of fidelity or fiduciary obligations to current
and prospective clients, or who offer bribes or kickbacks to
current and prospective clients or their employees may be
committing wrongful or illegal acts that could render any
resulting contract between us and the client unenforceable or in
violation of relevant laws or regulations. Any misconduct by
these third parties with respect to current or prospective
clients, any failure to follow contractual requirements, or any
insufficiency of those contractual requirements may result in
allegations that we have encouraged or participated in wrongful
or illegal behavior and that payments to such third parties
under our channel contracts are improper. This misconduct could
subject us to civil or criminal claims and liabilities, require
us to change or terminate some portions of our business, require
us to refund portions of our services fees, and adversely affect
our revenue and operating margin. Even an unsuccessful challenge
of our activities could result in adverse publicity, require
costly response from us, impair our ability to attract and
maintain clients, and lead analysts or investors to reduce their
expectations of our performance, resulting in reduction in the
market price of our stock.
Failure
to manage our rapid growth effectively could increase our
expenses, decrease our revenue, and prevent us from implementing
our business strategy.
We have been experiencing a period of rapid growth. To manage
our anticipated future growth effectively, we must continue to
maintain, and may need to enhance, our information technology
infrastructure and financial and accounting systems and
controls, as well as manage expanded operations in
geographically distributed locations. We also must attract,
train, and retain a significant number of qualified sales and
marketing personnel, professional services personnel, software
engineers, technical personnel, and management personnel.
Failure to manage our rapid growth effectively could lead us to
over-invest or under-invest in technology and operations; result
in weaknesses in our infrastructure, systems, or controls; give
rise to operational mistakes, losses, or loss of productivity or
business opportunities; and result in loss of employees and
reduced productivity of remaining employees. Our growth could
require significant capital expenditures and may divert
financial resources from other projects, such as the development
of new services. If our management is unable to effectively
manage our growth, our expenses may increase more than expected,
our revenue could decline or may grow more slowly than expected,
and we may be unable to implement our business strategy.
We
depend upon two third-party service providers for important
processing functions. If either of these third-party providers
does not fulfill its contractual obligations or chooses to
discontinue its services, our business and operations could be
disrupted and our operating results would be
harmed.
We have entered into service agreements with International
Business Machines Corporation and Vision Business Process
Solutions Inc., a subsidiary of Dell, Inc. (formerly Perot
Systems Corporation), to provide data entry and other services
from facilities located in India and the Philippines to support
our client service operations. Among other things, these
providers process critical claims data and clinical documents.
If these services fail or are of poor quality, our business,
reputation, and operating results could be harmed. Failure of
25
either service provider to perform satisfactorily could result
in client dissatisfaction, disrupt our operations, and adversely
affect operating results. With respect to these service
providers, we have significantly less control over the systems
and processes involved than if we maintained and operated them
ourselves, which increases our risk. In some cases, functions
necessary to our business are performed on proprietary systems
and software to which we have no access. If we need to find an
alternative source for performing these functions, we may have
to expend significant money, resources, and time to develop the
alternative, and if this development is not accomplished in a
timely manner and without significant disruption to our
business, we may be unable to fulfill our responsibilities to
clients or the expectations of clients, with the attendant
potential for liability claims and a loss of business
reputation, loss of ability to attract or maintain clients, and
reduction of our revenue or operating margin.
Various
risks could affect our worldwide operations, exposing us to
significant costs.
We conduct operations throughout the world, including the United
States, India, and the Philippines, either directly or through
our service providers. Such worldwide operations expose us to
potential operational disruptions and costs as a result of a
wide variety of events, including local inflation or economic
downturn, currency exchange fluctuations, political turmoil,
terrorism, labor issues, natural disasters, and pandemics. Any
such disruptions or costs could have a negative effect on our
ability to provide our services or meet our contractual
obligations, the cost of our services, client satisfaction, our
ability to attract or maintain clients, and, ultimately, our
profits.
Because
competition for our target employees is intense, we may not be
able to attract and retain the highly skilled employees we need
to support our planned growth.
To continue to execute on our growth plan, we must attract and
retain highly qualified personnel. Competition for these
personnel is intense, especially for senior sales executives and
engineers with high levels of experience in designing and
developing software and Internet-related services. We may not be
successful in attracting and retaining qualified personnel. We
have from time to time in the past experienced, and we expect to
continue to experience in the future, difficulty in hiring and
retaining highly skilled employees with appropriate
qualifications. Many of the companies with which we compete for
experienced personnel have greater resources than we have. In
addition, in making employment decisions, particularly in the
Internet and high-technology industries, job candidates often
consider the value of the equity awards they are to receive in
connection with their employment. Volatility in the price of our
stock may, therefore, adversely affect our ability to attract or
retain key employees. Furthermore, the requirements to expense
equity awards may discourage us from granting the size or type
of equity awards that job candidates require to join our
company. If we fail to attract new personnel or fail to retain
and motivate our current personnel, our business and future
growth prospects could be severely harmed.
If we
acquire companies or technologies in the future, they could
prove difficult to integrate, disrupt our business, dilute
stockholder value, and adversely affect our operating results
and the value of our common stock.
As part of our business strategy, we may acquire, enter into
joint ventures with, or make investments in complementary
companies, services, and technologies in the future.
Acquisitions and investments involve numerous risks, including:
|
|
|
|
|
difficulties in identifying and acquiring products,
technologies, or businesses that will help our business;
|
|
|
|
difficulties in integrating operations, technologies, services,
and personnel;
|
|
|
|
diversion of financial and managerial resources from existing
operations;
|
|
|
|
the risk of entering new markets in which we have little to no
experience;
|
|
|
|
risks related to the assumption of known and unknown liabilities;
|
26
|
|
|
|
|
the risk of write-offs and the amortization of expenses related
intangible assets and
|
|
|
|
delays in client purchases due to uncertainty and the inability
to maintain relationships with clients of the acquired
businesses.
|
As a result, if we fail to properly evaluate acquisitions or
investments, we may not achieve the anticipated benefits of any
such acquisitions, we may incur costs in excess of what we
anticipate, and management resources and attention may be
diverted from other necessary or valuable activities.
We may
require additional capital to support business growth, and this
capital might not be available.
We intend to continue to make investments to support our
business growth and may require additional funds to respond to
business challenges or opportunities, including the need to
develop new services or enhance our existing service, enhance
our operating infrastructure, or acquire complementary
businesses and technologies. Accordingly, we may need to engage
in equity or debt financings to secure additional funds. If we
raise additional funds through further issuances of equity or
convertible debt securities, our existing stockholders could
suffer significant dilution, and any new equity securities we
issue could have rights, preferences, and privileges superior to
those of holders of our common stock. Any debt financing secured
by us in the future could involve restrictive covenants relating
to our capital-raising activities and other financial and
operational matters, which may make it more difficult for us to
obtain additional capital and to pursue business opportunities,
including potential acquisitions. In addition, we may not be
able to obtain additional financing on terms favorable to us or
as a result of the current condition of the equity and debt
markets limited financing may be available, if at all. If we are
unable to obtain adequate financing or financing on terms
satisfactory to us when we require it, our ability to continue
to support our business growth and to respond to business
challenges could be significantly limited.
If we
are required to collect sales and use taxes on the services we
sell in additional jurisdictions, we may be subject to liability
for past sales and incur additional related costs and expenses,
and our future sales may decrease.
We may lose sales or incur significant expenses should states be
successful in imposing state sales and use taxes on our
services. A successful assertion by one or more states that we
should collect sales or other taxes on the sale of our services
could result in substantial tax liabilities for past sales,
decrease our ability to compete with traditional retailers, and
otherwise harm our business. Each state has different rules and
regulations governing sales and use taxes, and these rules and
regulations are subject to varying interpretations that may
change over time. We review these rules and regulations
periodically and, when we believe our services are subject to
sales and use taxes in a particular state, voluntarily engage
state tax authorities in order to determine how to comply with
their rules and regulations. For example, in April 2006 we
entered into a settlement agreement with the Ohio Department of
Taxation after it determined that we owed sales and use taxes
for sales made in the State of Ohio between July 2005 and
January 2006. In connection with this settlement, we paid the
State of Ohio $0.2 million in taxes, interest, and
penalties. Additionally, in November 2004, we began paying sales
and use taxes in the State of Texas. We cannot assure you that
we will not be subject to sales and use taxes or related
penalties for past sales in states where we believe no
compliance is necessary.
Vendors of services, like us, are typically held responsible by
taxing authorities for the collection and payment of any
applicable sales and similar taxes. If one or more taxing
authorities determines that taxes should have, but have not,
been paid with respect to our services, we may be liable for
past taxes in addition to taxes going forward. Liability for
past taxes may also include very substantial interest and
penalty charges. Our client contracts provide that our clients
must pay all applicable sales and similar taxes. Nevertheless,
clients may be reluctant to pay back taxes and may refuse
responsibility for interest or penalties associated with those
taxes. If we are required to collect and pay back taxes and the
associated interest and penalties, and if our clients fail or
refuse to reimburse us for all or a portion of these amounts, we
will have incurred unplanned expenses that may be substantial.
Moreover, imposition of such taxes on our services going forward
27
will effectively increase the cost of such services to our
clients and may adversely affect our ability to retain existing
clients or to gain new clients in the areas in which such taxes
are imposed.
We may also become subject to tax audits or similar procedures
in states where we already pay sales and use taxes. For example,
in October 2007, we received an audit notification from the
Commonwealth of Massachusetts Department of Revenue requesting
materials relating to the amount of use tax we paid on account
of our purchases for the audit periods between January 1,
2004, and December 31, 2006. The audit was resolved in
2008. We paid a liability of approximately $0.1 million in
connection with this audit. The incurrence of additional
accounting and legal costs and related expenses in connection
with, and the assessment of taxes, interest, and penalties as a
result of, audits, litigation, or otherwise could be materially
adverse to our current and future results of operations and
financial condition.
From
time to time we may become subject to income tax audits or
similar proceedings, and as a result we may incur additional
costs and expenses or owe additional taxes, interest, and
penalties in amounts that may be material.
We are subject to income taxes in the United States at both the
federal and state levels. In determining our provision for
income taxes, we are required to exercise judgment and make
estimates where the ultimate tax determination is uncertain.
While we believe that our estimates are reasonable, we cannot
assure you that the final determination of any tax audit or
tax-related litigation will not be materially different from
that reflected in our income tax provisions and accruals. The
incurrence of additional accounting and legal costs and related
expenses in connection with, and the assessment of taxes,
interest, and penalties as a result of, audits, litigation, or
otherwise could be materially adverse to our current and future
results of operations and financial condition.
In December 2009, the IRS completed the audit of our 2006, 2007,
and 2008 tax returns commenced earlier in the year and found
that no amounts were due from us in connection with either
return.
Unanticipated
changes in our tax rates or our exposure to additional income
tax liabilities could affect our operating results and financial
condition.
Our future effective tax rates could be favorably or unfavorably
affected by unanticipated changes in the valuation of our
deferred tax assets and liabilities, the geographic mix of our
revenue, or changes in tax laws or their interpretation.
Significant judgment is required in determining our provision
for income taxes. In addition, we are subject to the continuous
examination of our income tax returns by tax authorities. We
regularly assess the likelihood of adverse outcomes resulting
from these examinations to determine the adequacy of our
provision for income taxes. There can be no assurance, however,
that the outcomes from these continuous examinations will not
have an adverse effect on our operating results and financial
condition. Additionally, due to the evolving nature of tax rules
combined with the number of jurisdictions in which we operate,
it is possible that our estimates of our tax liability and our
ability to realize our deferred tax assets could change in the
future, which may result in additional tax liabilities and
adversely affect our results of operations, financial condition,
and cash flows.
The
results of our review of our revenue recognition practices and
resulting restatement may continue to have adverse effects on
our financial results.
Our review of our revenue recognition practices and our
restatement of our historical financial statements have resulted
in the deferral of previously recognized revenue and have
required and may continue to require us to expend significant
management time and incur significant accounting, legal, and
other expenses, all of which may have an adverse effect on our
financial results.
As a result of our revenue recognition review and related
restatement, approximately $22.3 million of implementation
services revenue previously recognized through
September 30, 2009, will be deferred to periods after that
date. See the Explanatory Note Regarding Restatement
immediately preceding Item 1 of Part I; Part II,
Item 7, Managements Discussion and Analysis of
Financial Condition and Results of Operations; and
Note 2, Restatement and Reclassification of
Previously Issued Consolidated Financial Statements, and
Note 20, Summarized Quarterly Unaudited Financial
Data, in Notes to Consolidated
28
Financial Statements in Part II, Item 8 for further
discussion. The accounting, legal, and other expenses associated
with this restatement may also have a material adverse effect on
our results of operations.
In addition, future private or government actions may be brought
against us or our current or former officers relating to a
failure to apply generally accepted accounting principles in the
reporting of quarterly and annual financial statements and
securities prospectuses from the time of our initial public
offering to our most recent filing with the SEC. Such actions
could have a material adverse effect on our business, financial
condition, results of operations, and cash flows and the trading
price for our securities. Litigation would be time-consuming,
expensive, and disruptive to normal business operations, and the
outcome of litigation is difficult to predict. The defense of
any litigation would result in significant expenditures and the
continued diversion of our managements time and attention
from the operation of our business, which could impede our
business. In addition, while we maintain standard directors and
officers insurance, all or a portion of any amount we may be
required to pay to satisfy a judgment or settlement of any or
all of these claims may not be covered by insurance.
We cannot be certain that the measures we have taken that
address this restatement will ensure that restatements will not
occur in the future. Execution of restatements like the one
described above could create a significant strain on our
internal resources, cause delays in our filing of quarterly or
annual financial results, increase our costs, and cause
management distraction.
We
have identified a material weakness in our internal control over
financial reporting, which has required us to incur substantial
costs and diverted management resources in connection with our
efforts to remediate this material weakness
In connection with our internal accounting policy review of our
revenue recognition policies for the fiscal year ended
December 31, 2009, and as discussed in Item 9A,
Controls and Procedures, of this Annual Report on
Form 10-K,
we have identified a control deficiency relating to the
application of generally accepted accounting principles to
revenue recognition. Management has concluded that this control
deficiency constituted a material weakness in internal control
over financial reporting as of December 31, 2009. A
material weakness in internal control over financial
reporting is one or more deficiencies in process that
create a reasonable possibility that a material misstatement of
a companys annual or interim financial statements will not
be prevented or detected on a timely basis. The deficiency in
the application of our controls relating to the review of our
revenue recognition policy resulted in a reasonable possibility
that a material misstatement of our financial statements would
not have been prevented or detected by us in the normal course
of our financial statement close process.
We have discussed the identified control deficiency in our
financial reporting and the remediation of such deficiency with
the audit committee of our board of directors and will continue
to do so as necessary. We believe that recent key additions to
our financial staff, the use of external experts, and revisions
to our internal training programs have remediated this control
deficiency. However, we cannot be certain that the remedial
measures that we have taken will ensure that we maintain
adequate controls over our financial reporting in the future
and, accordingly, additional material weaknesses could occur or
be identified. Any future deficiencies could materially and
adversely affect our ability to provide timely and accurate
financial information, and the current and future deficiencies
may impact investors confidence in our internal controls
and our company, which could cause our stock price to decline.
We may
be unable to adequately protect, and we may incur significant
costs in enforcing, our intellectual property and other
proprietary rights.
Our success depends in part on our ability to enforce our
intellectual property and other proprietary rights. We rely upon
a combination of trademark, trade secret, copyright, patent, and
unfair competition laws, as well as license and access
agreements and other contractual provisions, to protect our
intellectual property and other proprietary rights. In addition,
we attempt to protect our intellectual property and proprietary
information by requiring certain of our employees and
consultants to enter into confidentiality, noncompetition, and
assignment of inventions agreements. Our attempts to protect our
intellectual property may be challenged by others or invalidated
through administrative process or litigation. While we have one
issued U.S. patent and have nine
29
more U.S. patent applications and two provisional patent
applications pending, we may be unable to obtain further
meaningful patent protection for our technology. In addition,
any patents issued in the future may not provide us with any
competitive advantages or may be successfully challenged by
third parties. Agreement terms that address non-competition are
difficult to enforce in many jurisdictions and may not be
enforceable in any particular case. To the extent that our
intellectual property and other proprietary rights are not
adequately protected, third parties might gain access to our
proprietary information, develop and market products or services
similar to ours, or use trademarks similar to ours, each of
which could materially harm our business. Existing
U.S. federal and state intellectual property laws offer
only limited protection. Moreover, the laws of other countries
in which we now or may in the future conduct operations or
contract for services may afford little or no effective
protection of our intellectual property. Further, our platform
incorporates open source software components that are licensed
to us under various public domain licenses. While we believe
that we have complied with our obligations under the various
applicable licenses for open source software that we use, there
is little or no legal precedent governing the interpretation of
many of the terms of certain of these licenses, and therefore
the potential impact of such terms on our business is somewhat
unknown. The failure to adequately protect our intellectual
property and other proprietary rights could materially harm our
business.
In addition, if we resort to legal proceedings to enforce our
intellectual property rights or to determine the validity and
scope of the intellectual property or other proprietary rights
of others, the proceedings could be burdensome and expensive,
even if we were to prevail. Any litigation that may be necessary
in the future could result in substantial costs and diversion of
resources and could have a material adverse effect on our
business, operating results, or financial condition.
We may
be sued by third parties for alleged infringement of their
proprietary rights.
The software and Internet industries are characterized by the
existence of a large number of patents, trademarks, and
copyrights and by frequent litigation based on allegations of
infringement or other violations of intellectual property
rights. Moreover, our business involves the systematic gathering
and analysis of data about the requirements and behaviors of
payers and other third parties, some or all of which may be
claimed to be confidential or proprietary. We have received in
the past, and may receive in the future, communications from
third parties claiming that we have infringed on the
intellectual property rights of others. For example, in 2005,
Billingnetwork Patent, Inc. sued us in Florida federal court
alleging infringement of its patent issued in 2002 entitled
Integrated Internet Facilitated Billing, Data Processing
and Communications System. Although we settled this case
in 2008, the prospect of similar litigation remains. Our
technologies may not be able to withstand third-party claims of
rights against their use. Any intellectual property claims, with
or without merit, could be time-consuming and expensive to
resolve, divert management attention from executing our business
plan, and require us to pay monetary damages or enter into
royalty or licensing agreements. In addition, many of our
contracts contain warranties with respect to intellectual
property rights, and some require us to indemnify our clients
for third-party intellectual property infringement claims, which
would increase the cost to us of an adverse ruling on such a
claim.
Moreover, any settlement or adverse judgment resulting from such
a claim could require us to pay substantial amounts of money or
obtain a license to continue to use the technology or
information that is the subject of the claim, or otherwise
restrict or prohibit our use of the technology or information.
There can be no assurance that we would be able to obtain a
license on commercially reasonable terms, if at all, from third
parties asserting an infringement claim; that we would be able
to develop alternative technology on a timely basis, if at all;
or that we would be able to obtain a license to use a suitable
alternative technology to permit us to continue offering, and
our clients to continue using, our affected services.
Accordingly, an adverse determination could prevent us from
offering our services to others. In addition, we may be required
to indemnify our clients for third-party intellectual property
infringement claims, which would increase the cost to us of an
adverse ruling for such a claim.
We are
bound by exclusivity provisions that restrict our ability to
enter into certain sales and marketing relationships in order to
market and sell our services.
Our marketing and sales agreement with Worldmed Shared Services,
Inc. (d/b/a PSS World Medical Shared Services, Inc.), or PSS,
restricts us during the term of the agreement from certain sales
and marketing relationships, including relationships with
certain competitors of PSS and certain distributors and
30
manufacturers of medical, surgical, or pharmaceutical supplies.
This restriction may make it more difficult for us to realize
sales, distribution, and income opportunities with certain
potential clients in particular small physician
practices which could adversely affect our operating
results.
Our
loan and capital lease agreements contain operating and
financial covenants that may restrict our business and financing
activities.
We have loan and capital lease agreements with
$12.4 million outstanding at December 31, 2009.
Borrowings are secured by substantially all of our assets,
including our intellectual property. Our loan agreements
restrict our ability to:
|
|
|
|
|
incur additional indebtedness;
|
|
|
|
create liens;
|
|
|
|
make investments;
|
|
|
|
sell assets;
|
|
|
|
pay dividends or make distributions on and, in certain cases,
repurchase our stock; or
|
|
|
|
consolidate or merge with other entities.
|
In addition, our credit facilities require us to meet specified
minimum financial measurements. The operating and financial
restrictions and covenants in these credit facilities, as well
as any future financing agreements that we may enter into, may
restrict our ability to finance our operations, engage in
business activities, or expand or fully pursue our business
strategies. Our loan agreements also contain certain financial
and nonfinancial covenants, including limitations on our
consolidated leverage ratio and capital expenditures, as well as
defaults relating to non-payment, breach of covenants,
inaccuracy of representations and warranties, default under
other indebtedness (including a cross-default with our interest
rate swap), bankruptcy and insolvency, inability to pay debts,
attachment of assets, adverse judgments, ERISA violations,
invalidity of loan and collateral documents, and change of
control. Our ability to comply with these covenants may be
affected by events beyond our control, and we may not be able to
meet those covenants. A breach of any of these covenants could
result in a default under either or both of the loan agreements,
which could cause all of the outstanding indebtedness under both
credit facilities to become immediately due and payable and
terminate all commitments to extend further credit.
We
have entered into a derivative contract with a financial
counterparty, the effectiveness of which is dependent on the
continued viability of this financial counterparty, and its
nonperformance could harm our financial condition.
We have entered into an interest rate swap contract as part of
our strategy to mitigate risks related to fluctuations in cash
flow from movement in interest rates. The effectiveness of our
hedging programs using this instrument is dependent, in part,
upon the counterparty to this contract honoring its financial
obligations. The recent upheaval in the capital markets has
caused the viability of certain counterparties to be questioned.
While we have not experienced any losses due to counterparty
nonperformance, if our counterparty is unable to perform its
obligations in the future, we could be exposed to increased
earnings and cash flow volatility.
We may
incur additional costs as a result of continuing to operate as a
public company, and our management may be required to devote
substantial time to new compliance initiatives.
As a public company, we incur significant legal, accounting, and
other expenses that we did not incur as a private company, and
greater expenditures may be necessary in the future with the
advent of new laws and regulations pertaining to public
companies. In addition, the Sarbanes-Oxley Act of 2002, as well
as rules subsequently implemented by the Securities and Exchange
Commission and the NASDAQ Global Select Market, have imposed
various requirements on public companies, including requiring
changes in corporate governance practices. Our management and
other personnel continue to devote a substantial amount of time
to these compliance initiatives, and additional laws and
regulations may divert further management resources. Moreover,
if we are not able to comply with the requirements of new
compliance initiatives in a timely
31
manner, the market price of our stock could decline, and we
could be subject to sanctions or investigations by the NASDAQ
Global Select Market, the Securities and Exchange Commission, or
other regulatory authorities, which would require additional
financial and management resources.
Changes
in accounting standards issued by the Financial Accounting
Standards Board (FASB) or other standard-setting
bodies may adversely affect our financial
statements.
Our financial statements are subject to the application of
U.S. GAAP, which are periodically revised or expanded.
Accordingly, from time to time we are required to adopt new or
revised accounting standards issued by recognized authoritative
bodies, including the FASB and the SEC. It is possible that
future accounting standards we are required to adopt could
change the current accounting treatment that we apply to our
consolidated financial statements and that such changes could
have a material adverse impact on our results of operations and
financial condition.
Current
and future litigation against us could be costly and
time-consuming to defend.
We are from time to time subject to legal proceedings and claims
that arise in the ordinary course of business, such as claims
brought by our clients in connection with commercial disputes
and employment claims made by our current or former employees.
Litigation may result in substantial costs and may divert
managements attention and resources, which may seriously
harm our business, overall financial condition, and operating
results. In addition, legal claims that have not yet been
asserted against us may be asserted in the future. Insurance may
not cover such claims, be sufficient for one or more such
claims, or continue to be available on terms acceptable to us. A
claim brought against us that is uninsured or underinsured could
result in unanticipated costs, thereby reducing our operating
results and leading analysts or potential investors to reduce
their expectations of our performance resulting in a reduction
in the trading price of our stock.
RISKS
RELATED TO OUR SERVICE OFFERINGS
Our
proprietary software or our services may not operate properly,
which could damage our reputation, give rise to claims against
us, or divert application of our resources from other purposes,
any of which could harm our business and operating
results.
Proprietary software development is time-consuming, expensive,
and complex. Unforeseen difficulties can arise. We may encounter
technical obstacles, and it is possible that we discover
additional problems that prevent our proprietary athenaNet
application from operating properly. If athenaNet does not
function reliably or fails to achieve client expectations in
terms of performance, clients could assert liability claims
against us
and/or
attempt to cancel their contracts with us. This could damage our
reputation and impair our ability to attract or maintain clients.
Moreover, information services as complex as those we offer have
in the past contained, and may in the future develop or contain,
undetected defects or errors. We cannot assure you that material
performance problems or defects in our services will not arise
in the future. Errors may result from receipt, entry, or
interpretation of patient information or from interface of our
services with legacy systems and data that we did not develop
and the function of which is outside of our control. Despite
testing, defects or errors may arise in our existing or new
software or service processes. Because changes in payer
requirements and practices are frequent and sometimes difficult
to determine except through trial and error, we are continuously
discovering defects and errors in our software and service
processes compared against these requirements and practices.
These defects and errors and any failure by us to identify and
address them could result in loss of revenue or market share,
liability to clients or others, failure to achieve market
acceptance or expansion, diversion of development resources,
injury to our reputation, and increased service and maintenance
costs. Defects or errors in our software and service processes
might discourage existing or potential clients from purchasing
services from us. Correction of defects or errors could prove to
be impossible or impracticable. The costs incurred in correcting
any defects or errors or in responding to resulting claims or
liability may be substantial and could adversely affect our
operating results.
32
In addition, clients relying on our services to collect, manage,
and report clinical, business, and administrative data may have
a greater sensitivity to service errors and security
vulnerabilities than clients of software products in general. We
market and sell services that, among other things, provide
information to assist care providers in tracking and treating
ill patients. Any operational delay in or failure of our
technology or service processes may result in the disruption of
patient care and could cause harm to patients and thereby harm
our business and operating results.
Our clients or their patients may assert claims against us
alleging that they suffered damages due to a defect, error, or
other failure of our software or service processes. A product
liability claim or errors or omissions claim could subject us to
significant legal defense costs and adverse publicity,
regardless of the merits or eventual outcome of such a claim.
If our
security measures are breached or fail, and unauthorized access
is obtained to a clients data, our services may be
perceived as not being secure, clients may curtail or stop using
our services, and we may incur significant
liabilities.
Our services involve the storage and transmission of
clients proprietary information and protected health
information of patients. Because of the sensitivity of this
information, security features of our software are very
important. If our security measures are breached or fail as a
result of third-party action, employee error, malfeasance,
insufficiency, defective design, or otherwise, someone may be
able to obtain unauthorized access to client or patient data. As
a result, our reputation could be damaged, our business may
suffer, and we could face damages for contract breach, penalties
for violation of applicable laws or regulations, and significant
costs for remediation and remediation efforts to prevent future
occurrences. We rely upon our clients as users of our system for
key activities to promote security of the system and the data
within it, such as administration of client-side access
credentialing and control of client-side display of data. On
occasion, our clients have failed to perform these activities.
Failure of clients to perform these activities may result in
claims against us that this reliance was misplaced, which could
expose us to significant expense and harm to our reputation.
Because techniques used to obtain unauthorized access or to
sabotage systems change frequently and generally are not
recognized until launched against a target, we may be unable to
anticipate these techniques or to implement adequate preventive
measures. If an actual or perceived breach of our security
occurs, the market perception of the effectiveness of our
security measures could be harmed and we could lose sales and
clients. In addition, our clients may authorize or enable third
parties to access their client data or the data of their
patients on our systems. Because we do not control such access,
we cannot ensure the complete propriety of that access or
integrity or security of such data in our systems.
Failure
by our clients to obtain proper permissions and waivers may
result in claims against us or may limit or prevent our use of
data, which could harm our business.
We require our clients to provide necessary notices and to
obtain necessary permissions and waivers for use and disclosure
of the information that we receive, and we require contractual
assurances from them that they have done so and will do so. If
they do not obtain necessary permissions and waivers, then our
use and disclosure of information that we receive from them or
on their behalf may be limited or prohibited by state or federal
privacy laws or other laws. This could impair our functions,
processes, and databases that reflect, contain, or are based
upon such data and may prevent use of such data. In addition,
this could interfere with or prevent creation or use of rules,
and analyses or limit other data-driven activities that benefit
us. Moreover, we may be subject to claims or liability for use
or disclosure of information by reason of lack of valid notice,
permission, or waiver. These claims or liabilities could subject
us to unexpected costs and adversely affect our operating
results.
Various
events could interrupt clients access to athenaNet,
exposing us to significant costs.
The ability to access athenaNet is critical to our clients
administering care, cash flow, and business viability. Our
operations and facilities are vulnerable to interruption
and/or
damage from a number of sources, many of which are beyond our
control, including, without limitation: (i) power loss and
telecommunications failures; (ii) fire, flood, hurricane,
and other natural disasters; (iii) software and hardware
errors, failures, or crashes in our own systems or in other
systems; and (iv) computer viruses, hacking, and similar
disruptive problems in our own systems and in other systems. We
attempt to mitigate these risks through various means,
33
including redundant infrastructure, disaster recovery plans,
business continuity plans, separate test systems, and change
control and system security measures, but our precautions will
not protect against all potential problems. If clients
access is interrupted because of problems in the operation of
our facilities, we could be exposed to significant claims by
clients or their patients, particularly if the access
interruption is associated with problems in the timely delivery
of funds due to clients or medical information relevant to
patient care. Our plans for disaster recovery and business
continuity rely upon third-party providers of related services,
and if those vendors fail us at a time that our systems are not
operating correctly, we could incur a loss of revenue and
liability for failure to fulfill our obligations. Any
significant instances of system downtime could negatively affect
our reputation and ability to retain clients and sell our
services, which would adversely impact our revenues.
In addition, retention and availability of patient care and
physician reimbursement data are subject to federal and state
laws governing record retention, accuracy, and access. Some laws
impose obligations on our clients and on us to produce
information to third parties and to amend or expunge data at
their direction. Our failure to meet these obligations may
result in liability that could increase our costs and reduce our
operating results.
Interruptions
or delays in service from our third-party data-hosting
facilities could impair the delivery of our services and harm
our business.
We currently serve our clients from a third-party data-hosting
facility located in Bedford, Massachusetts, operated by Digital
55 Middlesex, LLC (as successor to Sentinel Properties-Bedford,
LLC). In addition, in December 2009 we signed a contract with a
major provider of disaster recovery services, SunGard
Availability Services, LP, to store our disaster recovery plans,
deepen the resiliency of our technology recovery infrastructure,
and provide disaster recovery testing services. In the case of a
significant event at our primary data center, we could become
operational in a reasonable timeframe at our backup data center.
However, we do not control the operation of any of these
facilities, and they are vulnerable to damage or interruption
from earthquakes, floods, fires, power loss, telecommunications
failures, and similar events. They are also subject to
break-ins, sabotage, intentional acts of vandalism, and similar
misconduct. Despite precautions taken at these facilities, the
occurrence of a natural disaster or an act of terrorism, a
decision to close the facilities without adequate notice, or
other unanticipated problems at both facilities could result in
lengthy interruptions in our service. Even with the disaster
recovery arrangements, our services could be interrupted.
We
rely on Internet infrastructure, bandwidth providers, data
center providers, other third parties, and our own systems for
providing services to our users, and any failure or interruption
in the services provided by these third parties or our own
systems could expose us to litigation and negatively impact our
relationships with users, adversely affecting our brand and our
business.
Our ability to deliver our Internet- and
telecommunications-based services is dependent on the
development and maintenance of the infrastructure of the
Internet and other telecommunications services by third parties.
This includes maintenance of a reliable network backbone with
the necessary speed, data capacity, and security for providing
reliable Internet access and services and reliable telephone,
facsimile, and pager systems. Our services are designed to
operate without interruption in accordance with our service
level commitments. However, we have experienced and expect that
we will in the future experience interruptions and delays in
services and availability from time to time. We rely on internal
systems as well as third-party vendors, including data center,
bandwidth, and telecommunications equipment providers, to
provide our services. We do not maintain redundant systems or
facilities for some of these services. In the event of a
catastrophic event with respect to one or more of these systems
or facilities, we may experience an extended period of system
unavailability, which could negatively impact our relationship
with users. To operate without interruption, both we and our
service providers must guard against:
|
|
|
|
|
damage from fire, power loss, and other natural disasters;
|
|
|
|
communications failures;
|
34
|
|
|
|
|
software and hardware errors, failures, and crashes;
|
|
|
|
security breaches, computer viruses, and similar disruptive
problems; and
|
|
|
|
other potential interruptions.
|
Any disruption in the network access, telecommunications, or
co-location services provided by these third-party providers or
any failure of or by these third-party providers or our own
systems to handle current or higher volume of use could
significantly harm our business. We exercise limited control
over these third-party vendors, which increases our
vulnerability to problems with services they provide.
Any errors, failures, interruptions, or delays experienced in
connection with these third-party technologies and information
services or our own systems could negatively impact our
relationships with users and adversely affect our business and
could expose us to third-party liabilities. Although we maintain
insurance for our business, the coverage under our policies may
not be adequate to compensate us for all losses that may occur.
In addition, we cannot provide assurance that we will continue
to be able to obtain adequate insurance coverage at an
acceptable cost.
The reliability and performance of the Internet may be harmed by
increased usage or by
denial-of-service
attacks. The Internet has experienced a variety of outages and
other delays as a result of damages to portions of its
infrastructure, and it could face outages and delays in the
future. These outages and delays could reduce the level of
Internet usage as well as the availability of the Internet to us
for delivery of our Internet-based services.
We
rely on third-party computer hardware and software that may be
difficult to replace or that could cause errors or failures of
our services, which could damage our reputation, harm our
ability to attract and maintain clients, and decrease our
revenue.
We rely on computer hardware purchased or leased and software
licensed from third parties in order to offer our services,
including database software from Oracle Corporation and storage
devices from International Business Machines Corporation and EMC
Corporation. These licenses are generally commercially available
on varying terms; however, it is possible that this hardware and
software may not continue to be available on commercially
reasonable terms, or at all. Any loss of the right to use any of
this hardware or software could result in delays in the
provisioning of our services until equivalent technology is
either developed by us, or, if available, is identified,
obtained, and integrated, which could harm our business. Any
errors or defects in third-party hardware or software could
result in errors or a failure of our services, which could
damage our reputation, harm our ability to attract and maintain
clients, and decrease our revenue.
We are
subject to the effect of payer and provider conduct that we
cannot control and that could damage our reputation with clients
and result in liability claims that increase our
expenses.
We offer certain electronic claims submission services for which
we rely on content from clients, payers, and others. While we
have implemented certain features and safeguards designed to
maximize the accuracy and completeness of claims content, these
features and safeguards may not be sufficient to prevent
inaccurate claims data from being submitted to payers. Should
inaccurate claims data be submitted to payers, we may experience
poor operational results and may be subject to liability claims,
which could damage our reputation with clients and result in
liability claims that increase our expenses.
If our
services fail to provide accurate and timely information, or if
our content or any other element of any of our services is
associated with faulty clinical decisions or treatment, we could
have liability to clients, clinicians, or patients, which could
adversely affect our results of operations.
Our software, content, and services are used to assist clinical
decision-making and provide information about patient medical
histories and treatment plans. If our software, content, or
services fail to provide accurate and timely information or are
associated with faulty clinical decisions or treatment, then
clients, clinicians, or their patients could assert claims
against us that could result in substantial costs to us, harm
our reputation in the industry, and cause demand for our
services to decline.
35
Our proprietary athenaClinicals service is utilized in clinical
decision-making, provides access to patient medical histories,
and assists in creating patient treatment plans, including the
issuance of prescription drugs. If our athenaClinicals service
fails to provide accurate and timely information, or if our
content or any other element of that service is associated with
faulty clinical decisions or treatment, we could have liability
to clients, clinicians, or patients.
The assertion of such claims and ensuing litigation, regardless
of its outcome, could result in substantial cost to us, divert
managements attention from operations, damage our
reputation, and decrease market acceptance of our services. We
attempt to limit by contract our liability for damages and to
require that our clients assume responsibility for medical care
and approve key system rules, protocols, and data. Despite these
precautions, the allocations of responsibility and limitations
of liability set forth in our contracts may not be enforceable,
be binding upon patients, or otherwise protect us from liability
for damages.
We maintain general liability and insurance coverage, but this
coverage may not continue to be available on acceptable terms or
may not be available in sufficient amounts to cover one or more
large claims against us. In addition, the insurer might disclaim
coverage as to any future claim. One or more large claims could
exceed our available insurance coverage.
Our proprietary software may contain errors or failures that are
not detected until after the software is introduced or updates
and new versions are released. It is challenging for us to test
our software for all potential problems because it is difficult
to simulate the wide variety of computing environments or
treatment methodologies that our clients may deploy or rely
upon. From time to time we have discovered defects or errors in
our software, and such defects or errors can be expected to
appear in the future. Defects and errors that are not timely
detected and remedied could expose us to risk of liability to
clients, clinicians, and patients and cause delays in
introduction of new services, result in increased costs and
diversion of development resources, require design
modifications, or decrease market acceptance or client
satisfaction with our services.
If any of these risks occur, they could materially adversely
affect our business, financial condition, or results of
operations.
We may
be liable for use of incorrect or incomplete data that we
provide, which could harm our business, financial condition, and
results of operations.
We store and display data for use by healthcare providers in
treating patients. Our clients or third parties provide us with
most of these data. If these data are incorrect or incomplete or
if we make mistakes in the capture or input of these data,
adverse consequences, including death, may occur and give rise
to product liability and other claims against us. In addition, a
court or government agency may take the position that our
storage and display of health information exposes us to personal
injury liability or other liability for wrongful delivery or
handling of healthcare services or erroneous health information.
While we maintain insurance coverage, we cannot assure that this
coverage will prove to be adequate or will continue to be
available on acceptable terms, if at all. Even unsuccessful
claims could result in substantial costs and diversion of
management resources. A claim brought against us that is
uninsured or under-insured could harm our business, financial
condition, and results of operations.
RISKS
RELATED TO REGULATION
Government
regulation of healthcare creates risks and challenges with
respect to our compliance efforts and our business
strategies.
The healthcare industry is highly regulated and is subject to
changing political, legislative, regulatory, and other
influences. Existing and new laws and regulations affecting the
healthcare industry could create unexpected liabilities for us,
cause us to incur additional costs, and restrict our operations.
Many healthcare laws are complex, and their application to
specific services and relationships may not be clear. In
particular, many existing healthcare laws and regulations, when
enacted, did not anticipate the healthcare information services
that we provide, and these laws and regulations may be applied
to our services in ways that we do not anticipate. Our failure
to accurately anticipate the application of these laws and
regulations, or our other
36
failure to comply, could create liability for us, result in
adverse publicity, and negatively affect our business. Some of
the risks we face from healthcare regulation are described below:
|
|
|
|
|
False or Fraudulent Claim Laws. There are
numerous federal and state laws that forbid submission of false
information or the failure to disclose information in connection
with submission and payment of physician claims for
reimbursement. In some cases, these laws also forbid abuse of
existing systems for such submission and payment. Any failure of
our services to comply with these laws and regulations could
result in substantial liability (including, but not limited to,
criminal liability), adversely affect demand for our services,
and force us to expend significant capital, research and
development, and other resources to address the failure. Errors
by us or our systems with respect to entry, formatting,
preparation, or transmission of claim information may be
determined or alleged to be in violation of these laws and
regulations. Any determination by a court or regulatory agency
that our services violate these laws could subject us to civil
or criminal penalties, invalidate all or portions of some of our
client contracts, require us to change or terminate some
portions of our business, require us to refund portions of our
services fees, cause us to be disqualified from serving clients
doing business with government payers, and have an adverse
effect on our business.
|
In most cases where we are permitted to do so, we calculate
charges for our services based on a percentage of the
collections that our clients receive as a result of our
services. To the extent that violations or liability for
violations of these laws and regulations require intent, it may
be alleged that this percentage calculation provides us or our
employees with incentive to commit or overlook fraud or abuse in
connection with submission and payment of reimbursement claims.
The U.S. Centers for Medicare and Medicaid Services has
stated that it is concerned that percentage-based billing
services may encourage billing companies to commit or to
overlook fraudulent or abusive practices.
In addition, we may contract with third parties that offer
software relating to the selection or verification of codes used
to identify and classify the services for which reimbursement is
sought. Submission of codes that do not accurately reflect the
services provided or the location or method of their provision
may constitute a violation of false or fraudulent claims laws.
Our ability to comply with these laws depends on the coding
decisions made by our clients and the accuracy of our
vendors software and services in suggesting possible codes
to our clients and verifying that proper codes have been
selected.
|
|
|
|
|
HIPAA and other Health Privacy
Regulations. There are numerous federal and state
laws related to patient privacy. In particular, the Health
Insurance Portability and Accountability Act of 1996, or HIPAA,
includes privacy standards that protect individual privacy by
limiting the uses and disclosures of individually identifiable
health information and implementing data security standards that
require covered entities to implement administrative, physical,
and technological safeguards to ensure the confidentiality,
integrity, availability, and security of individually
identifiable health information in electronic form. HIPAA also
specifies formats that must be used in certain electronic
transactions, such as claims, payment advice, and eligibility
inquiries. Because we translate electronic transactions to and
from HIPAA-prescribed electronic formats and other forms, we are
a clearinghouse and, as such, a covered entity. In addition, our
clients are also covered entities and are mandated by HIPAA to
enter into written agreements with us known as
business associate agreements that require us to
safeguard individually identifiable health information. Business
associate agreements typically include:
|
|
|
|
a description of our permitted uses of individually identifiable
health information;
|
|
|
|
a covenant not to disclose the information except as permitted
under the agreement and to make our subcontractors, if any,
subject to the same restrictions;
|
|
|
|
assurances that appropriate administrative, physical, and
technical safeguards are in place to prevent misuse of the
information;
|
|
|
|
an obligation to report to our client any use or disclosure of
the information other than as provided for in the agreement;
|
37
|
|
|
|
|
a prohibition against our use or disclosure of the information
if a similar use or disclosure by our client would violate the
HIPAA standards;
|
|
|
|
the ability of our clients to terminate the underlying support
agreement if we breach a material term of the business associate
agreement and are unable to cure the breach;
|
|
|
|
the requirement to return or destroy all individually
identifiable health information at the end of our support
agreement; and
|
|
|
|
access by the Department of Health and Human Services to our
internal practices, books, and records to validate that we are
safeguarding individually identifiable health information.
|
We may not be able to adequately address the business risks
created by HIPAA implementation. Furthermore, we are unable to
predict what changes to HIPAA or other laws or regulations might
be made in the future or how those changes could affect our
business or the costs of compliance. For example, the provisions
of the HITECH Act and the regulations issued under it have
provided and are expected to provide clarification of certain
aspects of both the Privacy and Security Rules, expansion of the
disclosure requirements for a breach of the Security Rule, and
strengthening of the civil and criminal penalties for failure to
comply with HIPAA. In addition, the federal Office of the
National Coordinator for Health Information Technology, or
ONCHIT, is coordinating the ongoing development of national
standards for creating an interoperable health information
technology infrastructure based on the widespread adoption of
electronic health records in the healthcare sector. We are
unable to predict what, if any, impact the changes in such
standards will have on our compliance costs or our services.
In addition, some payers and clearinghouses with which we
conduct business interpret HIPAA transaction requirements
differently than we do. Where clearinghouses or payers require
conformity with their interpretations as a condition of
effecting transactions, we seek to comply with their
interpretations.
The HIPAA transaction standards include proper use of procedure
and diagnosis codes. Since these codes are selected or approved
by our clients, and since we do not verify their propriety, some
of our capability to comply with the transaction standards is
dependent on the proper conduct of our clients.
Among our services, we provide telephone reminder services to
patients, Internet- and telephone-based access to medical test
results, pager and email notification to practices of patient
calls, and patient call answering services. We believe that
reasonable efforts to prevent disclosure of individually
identifiable health information have been and are being taken in
connection with these services, including the use of
multiple-password security. However, any failure of our clients
to provide accurate contact information for their patients or
physicians or any breach of our telecommunications systems could
result in a disclosure of individually identifiable health
information.
In addition to the HIPAA Privacy and Security Rules and the
HITECH Act requirements, most states have enacted patient
confidentiality laws that protect against the disclosure of
confidential medical information, and many states have adopted
or are considering further legislation in this area, including
privacy safeguards, security standards, and data security breach
notification requirements. Such state laws, if more stringent
than HIPAA and HITECH Act requirements, are not preempted by the
federal requirements, and we are required to comply with them.
Failure by us to comply with any of the federal and state
standards regarding patient privacy may subject us to penalties,
including civil monetary penalties and, in some circumstances,
criminal penalties. In addition, such failure may injure our
reputation and adversely affect our ability to retain clients
and attract new clients.
We are subject to a variety of other regulatory schemes,
including:
|
|
|
|
|
Red Flag Rules. Although the federal and state
laws regarding patient privacy help to maintain the
confidentiality of personal information that could be used in
identity theft, they were not drafted with that risk in mind. To
fill this gap, the Federal Trade Commission has issued new rules
under the Fair and Accurate Credit Transactions Act of 2003 that
go into effect on June 1, 2010. These rules require medical
practices that act as creditors to their patients to
adopt policies and procedures that identify
|
38
|
|
|
|
|
patterns, practices, or activities that indicate possible
identity theft (called red flags); detect those red
flags; and respond appropriately to those red flags to prevent
or mitigate any theft. The rules also require creditors to
update their policies and procedures on a regular basis. Because
most practices treat their patients without receiving full
payment at the time of service, our clients are generally
considered creditors for purposes of these rules and
are required to comply with them. Although we are not directly
subject to these rules since we do not extend credit
to customers we do handle patient data that, if
improperly disclosed, could be used in identity theft. If we are
not successful in assisting our clients in implementing
necessary procedures, such failure may injure our reputation and
adversely affect our ability to retain clients and attract new
clients.
|
|
|
|
|
|
Anti-Kickback and Anti-Bribery Laws. There are
federal and state laws that govern patient referrals, physician
financial relationships, and inducements to healthcare providers
and patients. For example, the federal healthcare programs
anti-kickback law prohibits any person or entity from offering,
paying, soliciting, or receiving anything of value, directly or
indirectly, for the referral of patients covered by Medicare,
Medicaid, and other federal healthcare programs or the leasing,
purchasing, ordering, or arranging for or recommending the
lease, purchase, or order of any item, good, facility, or
service covered by these programs. Many states also have similar
anti-kickback laws that are not necessarily limited to items or
services for which payment is made by a federal healthcare
program. Moreover, both federal and state laws forbid bribery
and similar behavior. Any determination by a state or federal
regulatory agency that any of our activities or those of our
clients, vendors, or channel partners violate any of these laws
could subject us to civil or criminal penalties, require us to
change or terminate some portions of our business, require us to
refund a portion of our service fees, disqualify us from
providing services to clients doing business with government
programs, and have an adverse effect on our business. Even an
unsuccessful challenge by regulatory authorities of our
activities could result in adverse publicity and could require a
costly response from us.
|
|
|
|
Anti-Referral Laws. There are federal and
state laws that forbid payment for patient referrals, patient
brokering, remuneration of patients, or billing based on
referrals between individuals
and/or
entities that have various financial, ownership, or other
business relationships with health care providers. In many
cases, billing for care arising from such actions is illegal.
These vary widely from state to state, and one of the federal
laws called the Stark Law is very
complex in its application. Any determination by a state or
federal regulatory agency that any of our clients violate or
have violated any of these laws may result in allegations that
claims that we have processed or forwarded are improper. This
could subject us to civil or criminal penalties, require us to
change or terminate some portions of our business, require us to
refund portions of our services fees, and have an adverse effect
on our business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
|
|
|
Corporate Practice of Medicine Laws and Fee-Splitting
Laws. Many states have laws forbidding physicians
from practicing medicine in partnership with non-physicians,
such as business corporations. In some states, including New
York, these take the form of laws or regulations forbidding
splitting of physician fees with non-physicians or others. In
some cases, these laws have been interpreted to prevent business
service providers from charging their physician clients on the
basis of a percentage of collections or charges. We have varied
our charge structure in some states to comply with these laws,
which may make our services less desirable to potential clients.
Any determination by a state court or regulatory agency that our
service contracts with our clients violate these laws could
subject us to civil or criminal penalties, invalidate all or
portions of some of our client contracts, require us to change
or terminate some portions of our business, require us to refund
portions of our services fees, and have an adverse effect on our
business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
|
|
|
Anti-Assignment Laws. There are federal and
state laws that forbid or limit assignment of claims for
reimbursement from government-funded programs. In some cases,
these laws have been interpreted in regulations or policy
statements to limit the manner in which business service
companies may handle checks or other payments for such claims
and to limit or prevent such companies from charging their
|
39
|
|
|
|
|
physician clients on the basis of a percentage of collections or
charges. Any determination by a state court or regulatory agency
that our service contracts with our clients violate these laws
could subject us to civil or criminal penalties, invalidate all
or portions of some of our client contracts, require us to
change or terminate some portions of our business, require us to
refund portions of our services fees, and have an adverse effect
on our business. Even an unsuccessful challenge by regulatory
authorities of our activities could result in adverse publicity
and could require a costly response from us.
|
|
|
|
|
|
Prescribing Laws. The use of our software by
physicians to perform a variety of functions relating to
prescriptions, including electronic prescribing, electronic
routing of prescriptions to pharmacies, and dispensing of
medication, is governed by state and federal law, including
fraud and abuse laws, drug control regulations, and state
department of health regulations. States have differing
prescription format requirements, and, due in part to recent
industry initiatives, federal law and the laws of all
50 states now provide a regulatory framework for the
electronic transmission of prescription orders. Regulatory
authorities such as the U.S. Department of Health and Human
Services Centers for Medicare and Medicaid Services may
impose functionality standards with regard to electronic
prescribing and EHR technologies. Any determination that we or
our clients have violated prescribing laws may expose us to
liability, loss of reputation, and loss of business. These laws
and requirements may also increase the cost and time necessary
to market new services and could affect us in other respects not
presently foreseeable.
|
|
|
|
Electronic Medical Records Laws. A number of
federal and state laws govern the use and content of electronic
health record systems, including fraud and abuse laws that may
affect how such technology is provided. As a company that
provides EHR functionality, our systems and services must be
designed in a manner that facilitates our clients
compliance with these laws. Because this is a topic of
increasing state and federal regulation, we expect additional
and continuing modification of the current legal and regulatory
environment. We cannot predict the content or effect of possible
future regulation on our business activities. The software
component of our athenaClinicals service complies with the CCHIT
criteria for ambulatory electronic health records for 2008. Due
to the possible incorporation of CCHITs criteria into the
meaningful use standards under the HITECH Act such certification
may become a de facto requirement for selling EHR systems
in the future; however, CCHITs certification requirements
may change substantially. ONCHIT may approve another
certification body for EHRs and we plan on meeting ONCHIT
certification criteria. While we believe that our system is well
designed in terms of function and interoperability, we cannot be
certain that it will meet future requirements.
|
|
|
|
Claims Transmission Laws. Our services include
the manual and electronic transmission of our clients
claims for reimbursement from payers. Federal and various state
laws provide for civil and criminal penalties for any person who
submits, or causes to be submitted, a claim to any payer
(including, without limitation, Medicare, Medicaid, and any
private health plans and managed care plans) that is false or
that overbills or bills for items that have not been provided to
the patient. Although we do not determine what is billed to a
payer, to the extent that such laws apply to a service that
merely transmits claims on behalf of others, we could be subject
to the same civil and criminal penalties as our clients.
|
|
|
|
Prompt Pay Laws. Laws in many states govern
prompt payment obligations for healthcare services. These laws
generally define claims payment processes and set specific time
frames for submission, payment, and appeal steps. They
frequently also define and require clean claims. Failure to meet
these requirements and timeframes may result in rejection or
delay of claims. Failure of our services to comply may adversely
affect our business results and give rise to liability claims by
clients.
|
|
|
|
Medical Device Laws. The U.S. Food and
Drug Administration (FDA) has promulgated a draft policy for the
regulation of computer software products as medical devices
under the 1976 Medical Device Amendments to the Federal Food,
Drug and Cosmetic Act. To the extent that computer software is a
medical device under the policy, we, as a provider of
application functionality, could be required, depending on the
functionality, to:
|
|
|
|
register and list our products with the FDA;
|
40
|
|
|
|
|
notify the FDA and demonstrate substantial equivalence to other
products on the market before marketing our
functionality; or
|
|
|
|
obtain FDA approval by demonstrating safety and effectiveness
before marketing our functionality.
|
The FDA can impose extensive requirements governing pre- and
post-market conditions such as service investigation and others
relating to approval, labeling, and manufacturing. In addition,
the FDA can impose extensive requirements governing development
controls and quality assurance processes.
Potential
healthcare reform and new regulatory requirements placed on our
software, services, and content could impose increased costs on
us, delay or prevent our introduction of new services types, and
impair the function or value of our existing service
types.
Our services may be significantly impacted by healthcare reform
initiatives and are subject to increasing regulatory
requirements, either of which could affect our business in a
multitude of ways. If substantive healthcare reform or
applicable regulatory requirements are adopted, we may have to
change or adapt our services and software to comply. Reform or
changing regulatory requirements may render our services
obsolete or may block us from accomplishing our work or from
developing new services. This may in turn impose additional
costs upon us to adapt to the new operating environment or to
further develop services or software. It may also make
introduction of new service types more costly or more time
consuming than we currently anticipate. Such changes may even
prevent introduction by us of new services or make the
continuation of our existing services unprofitable or impossible.
Potential
additional regulation of the disclosure of health information
outside the United States may adversely affect our operations
and may increase our costs.
Federal or state governmental authorities may impose additional
data security standards or additional privacy or other
restrictions on the collection, use, transmission, and other
disclosures of health information. Legislation has been proposed
at various times at both the federal and the state level that
would limit, forbid, or regulate the use or transmission of
medical information outside of the United States. Such
legislation, if adopted, may render our use of our off-shore
partners, such as our data-entry and customer service providers,
International Business Machines Corporation and Vision Business
Process Solutions Inc., for work related to such data
impracticable or substantially more expensive. Alternative
processing of such information within the United States may
involve substantial delay in implementation and increased cost.
Changes
in the healthcare industry could affect the demand for our
services, cause our existing contracts to terminate, and
negatively impact the process of negotiating future
contracts.
As the healthcare industry evolves, changes in our client and
vendor bases may reduce the demand for our services, result in
the termination of existing contracts, and make it more
difficult to negotiate new contracts on terms that are
acceptable to us. For example, the current trend toward
consolidation of healthcare providers within hospital systems
may cause our existing client contracts to terminate as
independent practices are merged into hospital systems. Such
larger healthcare organizations may also have their own practice
management services and health IT systems, reducing demand for
our services. Similarly, client and vendor consolidation results
in fewer, larger entities with increased bargaining power and
the ability to demand terms that are unfavorable to us. If these
trends continue, we cannot assure you that we will be able to
continue to maintain or expand our client base, negotiate
contracts with acceptable terms, or maintain our current pricing
structure, and our revenues may decrease.
Errors
or illegal activity on the part of our clients may result in
claims against us.
We require our clients to provide us with accurate and
appropriate data and directives for our actions. We also rely
upon our clients as users of our system to perform key
activities in order to produce proper claims for reimbursement.
Failure of our clients to provide these data and directives or
to perform these activities may result in claims against us
alleging that our reliance was misplaced or unreasonable or that
we have facilitated or otherwise participated in submission of
false claims.
41
Our
services present the potential for embezzlement, identity theft,
or other similar illegal behavior by our employees or
subcontractors with respect to third parties.
Among other things, our services involve handling mail from
payers and from patients for many of our clients, and this mail
frequently includes original checks
and/or
credit card information and occasionally includes currency. Even
in those cases in which we do not handle original documents or
mail, our services also involve the use and disclosure of
personal and business information that could be used to
impersonate third parties or otherwise gain access to their data
or funds. If any of our employees or subcontractors takes,
converts, or misuses such funds, documents, or data, we could be
liable for damages, and our business reputation could be damaged
or destroyed. In addition, we could be perceived to have
facilitated or participated in illegal misappropriation of
funds, documents, or data and therefore be subject to civil or
criminal liability.
Potential
subsidy of services similar to ours may reduce client
demand.
Recently, entities such as the Massachusetts Healthcare
Consortium have offered to subsidize adoption by physicians of
electronic health record technology. In addition, federal
regulations have been changed to permit such subsidy from
additional sources subject to certain limitations, and the
current administration has passed the HITECH Act, which will
provide federal support for EHR initiatives. To the extent that
we do not qualify or participate in such subsidy programs,
demand for our services may be reduced, which may decrease our
revenues.
RISKS
RELATED TO OWNERSHIP OF OUR COMMON STOCK
An
orderly market for our common stock may not be
sustained.
The trading price of our common stock has been and is likely to
remain highly volatile and could be subject to wide fluctuations
in response to various factors, some of which are beyond our
control. In addition to the factors discussed in this Risk
Factors section and elsewhere in this Annual Report on
Form 10-K,
these factors include:
|
|
|
|
|
our operating performance and the operating performance of
similar companies;
|
|
|
|
the overall performance of the equity markets;
|
|
|
|
announcements by us or our competitors of acquisitions, business
plans, or commercial relationships;
|
|
|
|
threatened or actual litigation;
|
|
|
|
changes in laws or regulations relating to the sale of health
insurance;
|
|
|
|
any major change in our board of directors or management;
|
|
|
|
publication of research reports or news stories about us, our
competitors, or our industry or positive or negative
recommendations or withdrawal of research coverage by securities
analysts;
|
|
|
|
large volumes of sales of our shares of common stock by existing
stockholders; and
|
|
|
|
general political and economic conditions.
|
In addition, the stock market in general, and the market for
Internet-related companies in particular, has experienced
extreme price and volume fluctuations that have often been
unrelated or disproportionate to the operating performance of
those companies. Securities class action litigation has often
been instituted against companies following periods of
volatility in the overall market and in the market price of a
companys securities. This litigation, if instituted
against us, could result in very substantial costs; divert our
managements attention and resources; and harm our
business, operating results, and financial condition.
42
If a
substantial number of shares become available for sale and are
sold in a short period of time, the market price of our common
stock could decline.
If our existing stockholders sell a large number of shares of
our common stock or the public market perceives that these sales
may occur, the market price of our common stock could decline.
As of December 31, 2009, we had approximately
33.9 million shares of common stock outstanding. Moreover,
the holders of shares of common stock have rights, subject to
some conditions, to require us to file registration statements
covering the shares they currently hold, or to include these
shares in registration statements that we may file for ourselves
or other stockholders.
We have also registered all common stock that we may issue under
our 1997 Stock Plan, 2000 Stock Plan, 2007 Stock Option and
Incentive Plan, and 2007 Employee Stock Purchase Plan. As of
December 31, 2009, we had outstanding options to purchase
approximately 3.4 million shares of common stock
(approximately 1.6 million of which were exercisable at
December 31, 2009) that, if exercised, will result in
those shares becoming available for sale in the public market.
If a large number of these shares are sold in the public market,
the sales could reduce the trading price of our common stock.
Actual
or potential sales of our stock by our employees, including
members of our senior management team, pursuant to pre-arranged
stock trading plans could cause our stock price to fall or
prevent it from increasing for numerous reasons, and actual or
potential sales by such persons could be viewed negatively by
other investors.
In accordance with the guidelines specified under
Rule 10b5-1
of the Securities and Exchange Act of 1934 and our policies
regarding stock transactions, a number of our employees,
including members of our senior management team, have adopted
and will continue to adopt pre-arranged stock trading plans to
sell a portion of our common stock. Generally, stock sales under
such plans by members of our senior management team and
directors require public filings. Actual or potential sales of
our stock by such persons could cause our stock price to fall or
prevent it from increasing for numerous reasons. For example, a
substantial amount of our common stock becoming available (or
being perceived to become available) for sale in the public
market could cause the market price of our common stock to fall
or prevent it from increasing. Also, actual or potential sales
by such persons could be viewed negatively by other investors.
Provisions
in our certificate of incorporation and by-laws or Delaware law
might discourage, delay, or prevent a change of control of our
company or changes in our management and, therefore, depress the
trading price of our common stock.
Provisions of our certificate of incorporation and by-laws and
Delaware law may discourage, delay, or prevent a merger,
acquisition, or other change in control that stockholders may
consider favorable, including transactions in which you might
otherwise receive a premium for your shares of our common stock.
These provisions may also prevent or frustrate attempts by our
stockholders to replace or remove our management. These
provisions include:
|
|
|
|
|
limitations on the removal of directors;
|
|
|
|
advance notice requirements for stockholder proposals and
nominations;
|
|
|
|
the inability of stockholders to act by written consent or to
call special meetings; and
|
|
|
|
the ability of our board of directors to make, alter, or repeal
our by-laws.
|
The affirmative vote of the holders of at least 75% of our
shares of capital stock entitled to vote is necessary to amend
or repeal the above provisions of our certificate of
incorporation. As our board of directors has the ability to
designate the terms of and issue new series of preferred stock
without stockholder approval, the effective number of votes
required to make such changes could increase. Also, absent
approval of our board of directors, our by-laws may only be
amended or repealed by the affirmative vote of the holders of at
least 75% of our shares of capital stock entitled to vote.
43
In addition, Section 203 of the Delaware General
Corporation Law prohibits a publicly held Delaware corporation
from engaging in a business combination with an interested
stockholder (generally an entity that, together with its
affiliates, owns, or within the last three years has owned, 15%
or more of our voting stock) for a period of three years after
the date of the transaction in which the entity became an
interested stockholder, unless the business combination is
approved in a prescribed manner.
The existence of the foregoing provisions and anti-takeover
measures could limit the price that investors might be willing
to pay in the future for shares of our common stock. They could
also deter potential acquirers of our company, thereby reducing
the likelihood that you could receive a premium for your common
stock in an acquisition.
We do
not currently intend to pay dividends on our common stock, and,
consequently, your ability to achieve a return on your
investment will depend on appreciation in the price of our
common stock.
We have never declared or paid any cash dividends on our common
stock and do not currently intend to do so for the foreseeable
future. We currently intend to invest our future earnings, if
any, to fund our growth. Therefore, you are not likely to
receive any dividends on your common stock for the foreseeable
future, and the success of an investment in shares of our common
stock will depend upon any future appreciation in its value.
There is no guarantee that shares of our common stock will
appreciate in value or even maintain the price at which our
stockholders have purchased their shares.
|
|
Item 1B.
|
Unresolved
Staff Comments.
|
None.
As of December 31, 2009, we own a complex of buildings,
including approximately 133,000 square feet of office
space, on approximately 53 acres of land in Belfast, Maine.
We lease the remainder of our facilities. Our primary location
is 311 Arsenal Street in Watertown, Massachusetts, where we
lease 133,616 square feet, which is under lease until
July 1, 2015. We also lease 2,562 square feet in Rome,
Georgia, on a
month-to-month
basis; 5,087 square feet in Alpharetta, Georgia, through
our domestic operating subsidiary, Anodyne Health Partners, Inc.
through October 31, 2012; and 22,295 square feet in
Chennai, India, through our Indian subsidiary, athenahealth
Technology Private Limited, until April 27, 2012, with the
option to extend the lease for up to two additional three-year
periods. Our servers are housed at our headquarters and our
Belfast, Maine, offices and also in data centers in Bedford,
Massachusetts, and Somerville, Massachusetts. Our owned property
in Belfast, Maine, is subject to a mortgage that secures any and
all amounts we may from time to time owe under our credit
facility or any other transaction with Bank of America, N.A.
|
|
Item 3.
|
Legal
Proceedings.
|
From time to time, we may be subject to legal proceedings and
claims in the ordinary course of business. We are not currently
aware of any such proceedings or claims that we believe will
have, individually or in the aggregate, a material adverse
effect on our business, results of operations, or financial
condition.
|
|
Item 4.
|
(Removed
and Reserved)
|
44
PART II
|
|
Item 5.
|
Market
for Registrants Common Equity, Related Stockholder Matters
and Issuer Purchases of Equity Securities.
|
Market
Information
Our common stock is listed on the NASDAQ Global Select Market
under the trading symbol ATHN. Prior to our initial
public offering on September 20, 2007, there was no public
market for our common stock. The following table sets forth the
high and low closing sales prices of our common stock, as
reported by the NASDAQ Global Market in 2008 and the NASDAQ
Global Select Market in 2009, for each of the periods listed.
|
|
|
|
|
|
|
|
|
Fiscal Year December 31, 2009, Quarters Ended:
|
|
High
|
|
Low
|
|
First Quarter
|
|
$
|
38.20
|
|
|
$
|
23.59
|
|
Second Quarter
|
|
$
|
37.01
|
|
|
$
|
23.74
|
|
Third Quarter
|
|
$
|
40.78
|
|
|
$
|
32.34
|
|
Fourth Quarter
|
|
$
|
46.74
|
|
|
$
|
35.75
|
|
Fiscal Year December 31, 2008, Quarters Ended:
|
|
|
|
|
|
|
|
|
First Quarter
|
|
$
|
37.25
|
|
|
$
|
22.10
|
|
Second Quarter
|
|
$
|
34.10
|
|
|
$
|
22.15
|
|
Third Quarter
|
|
$
|
36.82
|
|
|
$
|
25.04
|
|
Fourth Quarter
|
|
$
|
37.62
|
|
|
$
|
21.20
|
|
Holders
The last reported sale price of our common stock on the NASDAQ
Global Select Market on March 12, 2010, was $38.13 per
share. As of March 12, 2010, we had 163 holders of record
of our common stock. Because many shares of common stock are
held by brokers and other institutions on behalf of
stockholders, we are unable to estimate the total number of
stockholders represented by these record holders.
Dividends
We have never declared or paid any dividends on our capital
stock, and our loan agreements restrict our ability to pay
dividends. We currently intend to retain any future earnings and
do not intend to declare or pay cash dividends on our common
stock in the foreseeable future. Any future determination to pay
dividends will be, subject to applicable law, at the discretion
of our board of directors and will depend upon, among other
factors, our results of operations, financial condition,
contractual restrictions, and capital requirements.
45
Performance
Graph
The following performance graph and related information shall
not be deemed soliciting material or to be
filed with the Securities and Exchange Commission,
nor shall such information be incorporated by reference into any
future filing under the Securities Act of 1933 or Securities
Exchange Act of 1934, each as amended, except to the extent that
we specifically incorporate it by reference into such filing.
Set forth below is a graph comparing the cumulative total
stockholder return on our common stock with the NASDAQ
Composite-Total Returns Index and the NASDAQ Computer and Data
Processing Index for the period starting with our initial public
offering on September 20, 2007, through the end of our
fiscal year ended December 31, 2009. The graph assumes an
investment of $100.00 made at the closing of trading on
September 20, 2007, in each of (i) our common stock,
(ii) the stocks comprising the NASDAQ Composite-Total
Returns Index, and (iii) stocks comprising the NASDAQ
Computer and Data Processing Index. All values assume
reinvestment of the full amount of all dividends, if any, into
additional shares of the same class of equity securities at the
frequency with which dividends are paid on such securities
during the applicable time period.
Recent
Sales of Unregistered Securities
None.
Use of
Proceeds from Registered Securities
We registered shares of our common stock in connection with our
initial public offering under the Securities Act of 1933, as
amended. Our Registration Statement on
Form S-1
(No. 333-143998)
in connection with our initial public offering was declared
effective by the SEC on September 20, 2007. The offering
commenced as of September 25, 2007, and did not terminate
before all securities were sold. The offering was co-managed by
the underwriters Goldman, Sachs & Co; Merrill Lynch,
Pierce, Fenner & Smith, Incorporated; Piper
Jaffray &Co.; and Jefferies & Company, Inc.
A total of 7,229,842 shares of common stock was registered
and sold in the initial public offering, including
943,023 shares of common stock sold upon exercise of the
underwriters over-allotment option, at a price to the
public of $18.00 per share. The offering closed on
September 25, 2007, and we received net proceeds of
approximately $81.3 million (after underwriters
discounts and commissions of approximately $6.3 million and
additional offering-related costs of approximately
$2.4 million). No underwriting discounts and commissions or
offering expenses were paid directly or indirectly to any of our
directors or officers (or their associates) or persons owning
ten percent or more of any class of our equity securities or to
any other affiliates.
46
There has been no material change in the planned use of proceeds
from our initial public offering as described in our final
prospectus filed with the SEC pursuant to Rule 424(b). We
expect to use the remaining net proceeds for capital
expenditures, working capital, and other general corporate
purposes. We may also use a portion of our net proceeds to fund
acquisitions of complementary businesses, products, or
technologies or to fund expansion of our operations facilities.
However, we do not have agreements or commitments for any
specific acquisitions at this time. Pending the uses described
above, we have invested the net proceeds in a variety of
short-term, interest-bearing, investment-grade securities.
At December 31, 2009, we had approximately
$30.5 million invested in cash and cash equivalents and
$52.3 million in short-term investments.
Issuer
Purchases of Equity Securities
During the quarter ended December 31, 2009, there were no
purchases made by us, on our behalf, or by any affiliated
purchasers of shares of our common stock.
47
|
|
Item 6.
|
Selected
Financial Data.
|
The consolidated statement of operations data for the years
ended December 31, 2005, 2006, 2007, and 2008, and the
consolidated balance sheet data as of December 31, 2005,
2006, 2007, and 2008, have been restated as set forth in this
Annual Report on
Form 10-K.
You should read the following financial information together
with the information under Managements Discussion
and Analysis of Financial Condition and Results of
Operations and our consolidated financial statements and
the related notes to these consolidated financial statements
appearing elsewhere in this Annual Report on
Form 10-K.
The information presented in the following tables has been
adjusted to reflect our restatement resulting from our review of
our revenue recognition practices, as is more fully described in
the Explanatory Note Regarding Restatement
immediately preceding Part I, Item 1 and in
Note 2, Restatement of Consolidated Financial
Statements, of the Notes to Consolidated Financial
Statements in Part II, Item 8. We have not amended our
previously filed Annual Reports on
Form 10-K
or Quarterly Reports on
Form 10-Q
for the periods affected by the restatement. Historical results
are not necessarily indicative of the results to be expected in
future periods.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008(1)
|
|
|
2007(1)
|
|
|
2006(2)
|
|
|
2005(2)
|
|
|
|
|
|
|
As restated
|
|
|
As restated
|
|
|
As reported
|
|
|
Adjustments
|
|
|
As restated
|
|
|
As reported
|
|
|
Adjustments
|
|
|
As restated
|
|
|
|
(In thousands, except per share data)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
|
$
|
94,182
|
|
|
$
|
70,652
|
|
|
$
|
|
|
|
$
|
70,652
|
|
|
$
|
48,958
|
|
|
$
|
|
|
|
$
|
48,958
|
|
Implementation and other
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
3,436
|
|
|
|
5,161
|
|
|
|
(2,496
|
)
|
|
|
2,665
|
|
|
|
4,582
|
|
|
|
(2,383
|
)
|
|
|
2,199
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
188,527
|
|
|
|
136,282
|
|
|
|
97,618
|
|
|
|
75,813
|
|
|
|
(2,496
|
)
|
|
|
73,317
|
|
|
|
53,540
|
|
|
|
(2,383
|
)
|
|
|
51,157
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses(3):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
79,017
|
|
|
|
59,947
|
|
|
|
46,978
|
|
|
|
36,530
|
|
|
|
642
|
|
|
|
37,172
|
|
|
|
27,545
|
|
|
|
555
|
|
|
|
28,100
|
|
Selling and marketing
|
|
|
34,072
|
|
|
|
22,827
|
|
|
|
17,212
|
|
|
|
15,645
|
|
|
|
|
|
|
|
15,645
|
|
|
|
11,680
|
|
|
|
|
|
|
|
11,680
|
|
Research and development
|
|
|
14,348
|
|
|
|
10,600
|
|
|
|
7,476
|
|
|
|
6,903
|
|
|
|
|
|
|
|
6,903
|
|
|
|
2,925
|
|
|
|
|
|
|
|
2,925
|
|
General and administrative
|
|
|
36,111
|
|
|
|
29,330
|
|
|
|
19,922
|
|
|
|
16,347
|
|
|
|
|
|
|
|
16,347
|
|
|
|
15,545
|
|
|
|
|
|
|
|
15,545
|
|
Depreciation and amortization
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
5,541
|
|
|
|
6,238
|
|
|
|
|
|
|
|
6,238
|
|
|
|
5,483
|
|
|
|
|
|
|
|
5,483
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
171,315
|
|
|
|
128,697
|
|
|
|
97,129
|
|
|
|
81,663
|
|
|
|
642
|
|
|
|
82,305
|
|
|
|
63,178
|
|
|
|
555
|
|
|
|
63,733
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
17,212
|
|
|
|
7,585
|
|
|
|
489
|
|
|
|
(5,850
|
)
|
|
|
(3,138
|
)
|
|
|
(8,988
|
)
|
|
|
(9,638
|
)
|
|
|
(2,938
|
)
|
|
|
(12,576
|
)
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
1,016
|
|
|
|
1,942
|
|
|
|
1,415
|
|
|
|
372
|
|
|
|
|
|
|
|
372
|
|
|
|
106
|
|
|
|
|
|
|
|
106
|
|
Interest expense
|
|
|
(968
|
)
|
|
|
(428
|
)
|
|
|
(3,682
|
)
|
|
|
(2,671
|
)
|
|
|
|
|
|
|
(2,671
|
)
|
|
|
(1,861
|
)
|
|
|
|
|
|
|
(1,861
|
)
|
Gain (loss) on interest rate derivative contract
|
|
|
590
|
|
|
|
(881
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense)
|
|
|
255
|
|
|
|
182
|
|
|
|
(5,689
|
)
|
|
|
(702
|
)
|
|
|
|
|
|
|
(702
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
893
|
|
|
|
815
|
|
|
|
(7,956
|
)
|
|
|
(3,001
|
)
|
|
|
|
|
|
|
(3,001
|
)
|
|
|
(1,755
|
)
|
|
|
|
|
|
|
(1,755
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes and cumulative effect of
change in accounting principle
|
|
|
18,105
|
|
|
|
8,400
|
|
|
|
(7,467
|
)
|
|
|
(8,851
|
)
|
|
|
(3,138
|
)
|
|
|
(11,989
|
)
|
|
|
(11,393
|
)
|
|
|
(2,938
|
)
|
|
|
(14,331
|
)
|
Income tax (provision) benefit(4)
|
|
|
(8,829
|
)
|
|
|
23,202
|
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before cumulative effect of change in accounting
principle
|
|
|
9,276
|
|
|
|
31,602
|
|
|
|
(7,501
|
)
|
|
|
(8,851
|
)
|
|
|
(3,138
|
)
|
|
|
(11,989
|
)
|
|
|
(11,393
|
)
|
|
|
(2,938
|
)
|
|
|
(14,331
|
)
|
Cumulative effect of change in accounting principle
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(373
|
)
|
|
|
|
|
|
|
(373
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
|
$
|
(9,224
|
)
|
|
$
|
(3,138
|
)
|
|
$
|
(12,362
|
)
|
|
$
|
(11,393
|
)
|
|
$
|
(2,938
|
)
|
|
$
|
(14,331
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before cumulative effect of change in accounting principle
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(0.67
|
)
|
|
$
|
(2.55
|
)
|
|
$
|
(2.51
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(3.16
|
)
|
Cumulative effect of change in accounting principle(5)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
$
|
(1.96
|
)
|
|
$
|
(0.67
|
)
|
|
$
|
(2.63
|
)
|
|
$
|
(2.51
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(3.16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Before cumulative effect of change in accounting principle
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
$
|
(1.88
|
)
|
|
$
|
(0.67
|
)
|
|
$
|
(2.55
|
)
|
|
$
|
(2.51
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(3.16
|
)
|
Cumulative effect of change in accounting principle
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
(0.08
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
$
|
(1.96
|
)
|
|
$
|
(0.67
|
)
|
|
$
|
(2.63
|
)
|
|
$
|
(2.51
|
)
|
|
$
|
(0.65
|
)
|
|
$
|
(3.16
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in net income (loss) per
share basic
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
12,568
|
|
|
|
4,708
|
|
|
|
4,708
|
|
|
|
4,708
|
|
|
|
4,532
|
|
|
|
4,532
|
|
|
|
4,532
|
|
Weighted average shares used in net income (loss) per
share diluted
|
|
|
34,917
|
|
|
|
34,777
|
|
|
|
12,568
|
|
|
|
4,708
|
|
|
|
4,708
|
|
|
|
4,708
|
|
|
|
4,532
|
|
|
|
4,532
|
|
|
|
4,532
|
|
48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2009
|
|
|
2008(1)
|
|
|
2007(2)
|
|
|
2006(2)
|
|
|
2005(2)
|
|
|
|
|
|
|
As restated
|
|
|
As reported
|
|
|
Adjustments
|
|
|
As restated
|
|
|
As reported
|
|
|
Adjustments
|
|
|
As restated
|
|
|
As reported
|
|
|
Adjustments
|
|
|
As restated
|
|
|
|
(In thousands)
|
|
|
Balance Sheet Data:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash, cash equivalants and short-term investments
|
|
$
|
82,849
|
|
|
$
|
86,994
|
|
|
$
|
71,891
|
|
|
|
|
|
|
$
|
71,891
|
|
|
$
|
9,736
|
|
|
$
|
|
|
|
$
|
9,736
|
|
|
$
|
9,309
|
|
|
$
|
|
|
|
$
|
9,309
|
|
Current assets
|
|
|
126,379
|
|
|
|
123,816
|
|
|
|
88,689
|
|
|
|
|
|
|
|
88,689
|
|
|
|
21,355
|
|
|
|
|
|
|
|
21,355
|
|
|
|
17,722
|
|
|
|
|
|
|
|
17,722
|
|
Total assets
|
|
|
211,077
|
|
|
|
169,571
|
|
|
|
103,636
|
|
|
|
|
|
|
|
103,636
|
|
|
|
39,973
|
|
|
|
|
|
|
|
39,973
|
|
|
|
38,345
|
|
|
|
|
|
|
|
38,345
|
|
Current liabilities
|
|
|
37,489
|
|
|
|
25,310
|
|
|
|
16,959
|
|
|
|
(2,109
|
)
|
|
|
14,850
|
|
|
|
23,646
|
|
|
|
(2,210
|
)
|
|
|
21,436
|
|
|
|
16,947
|
|
|
|
(2,072
|
)
|
|
|
14,875
|
|
Total non-current liabilities
|
|
|
46,270
|
|
|
|
39,226
|
|
|
|
11,158
|
|
|
|
15,780
|
|
|
|
26,938
|
|
|
|
30,504
|
|
|
|
11,883
|
|
|
|
42,387
|
|
|
|
25,640
|
|
|
|
8,607
|
|
|
|
34,247
|
|
Total liabilities
|
|
|
83,759
|
|
|
|
64,536
|
|
|
|
28,117
|
|
|
|
13,671
|
|
|
|
41,788
|
|
|
|
54,150
|
|
|
|
9,673
|
|
|
|
63,823
|
|
|
|
42,587
|
|
|
|
6,535
|
|
|
|
49,122
|
|
Convertible preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,094
|
|
|
|
|
|
|
|
50,094
|
|
|
|
50,094
|
|
|
|
|
|
|
|
50,094
|
|
Total indebtedness including current portion
|
|
|
12,388
|
|
|
|
10,416
|
|
|
|
1,398
|
|
|
|
|
|
|
|
1,398
|
|
|
|
27,293
|
|
|
|
|
|
|
|
27,293
|
|
|
|
20,137
|
|
|
|
|
|
|
|
20,137
|
|
Total stockholders equity (deficit)
|
|
|
127,318
|
|
|
|
105,035
|
|
|
|
75,519
|
|
|
|
(13,671
|
)
|
|
|
61,848
|
|
|
|
(64,271
|
)
|
|
|
(9,673
|
)
|
|
|
(73,944
|
)
|
|
|
(54,336
|
)
|
|
|
(6,535
|
)
|
|
|
(60,871
|
)
|
|
|
|
(1) |
|
See Note 2 Restatement and Reclassification of
Previously Issued Consolidated Financial Statements of the
Notes to Consolidated Financial Statements for a discussion of
these adjustments. |
|
(2) |
|
The consolidated statements of operations data for the years
ended December 31, 2006 and 2005, and the consolidated
balance sheet data as of December 31, 2007, 2006 and 2005
have been revised to reflect adjustments related to the
restatement described below under Managements
Discussion and Analysis of Financial Condition and Results of
Operations Restatement and Note 2 of the
Notes to Consolidated Financial Statements. The amortization of
the implementation fees over an expected performance period of
the longer of the estimated expected customer life, currently
twelve years, or the contract term, decreased previously
reported revenue by $3.1 million and $2.9 million for
the years ended December 31, 2006 and 2005, respectively.
The reporting of the reimbursement of
out-of-pocket
expenses gross in revenue and direct operating costs increased
previously reported revenue and direct operating costs by
$0.6 million and $0.6 million for the years ended
December 31, 2006 and 2005, respectively. |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
2009
|
|
2008
|
|
2007
|
|
2006
|
|
2005
|
|
|
(In thousands)
|
|
(3) Amounts include stock-based compensation expense as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
$
|
1,589
|
|
|
$
|
872
|
|
|
$
|
181
|
|
|
$
|
63
|
|
|
$
|
|
|
Selling and marketing
|
|
|
2,126
|
|
|
|
1,383
|
|
|
|
97
|
|
|
|
44
|
|
|
|
|
|
Research and development
|
|
|
1,015
|
|
|
|
1,086
|
|
|
|
260
|
|
|
|
53
|
|
|
|
|
|
General and administrative
|
|
|
3,584
|
|
|
|
2,217
|
|
|
|
773
|
|
|
|
196
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
8,314
|
|
|
$
|
5,558
|
|
|
$
|
1,311
|
|
|
$
|
356
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(4) |
|
In the year ended December 31, 2008, we determined that a
valuation allowance was no longer needed on its deferred tax
assets. Accordingly, the 2008 results include the reversal of a
$23.9 million valuation allowance. |
|
(5) |
|
Change in accounting principle Effective
January 1, 2006, freestanding warrants and other similar
instruments related to shares that are redeemable are accounted
for in accordance with authoritative guidance on freestanding
warrants and other similar instruments on shares that are
redeemable. Under this guiadance, freestanding warrants
exercisable for shares of the Companys redeemable
convertible preferred stock are classified as a warrant
liability on the Companys balance sheet. The warrants
issued for the purchase of the Companys Series D and
Series E Preferred Stock are subject to the provisions of
this guidance. The Company accounted for the adoption of this
guidance as a cumulative effect of change in accounting
principle of $373 recorded on January 1, 2006, the date of
the Companys adoption of this guidance. The cumulative
effect adjustment was calculated as the difference in the fair
value of the warrants from the historical carrying value as of
January 1, 2006. The original carrying value of the
warrants, $1,229, was reclassified to liabilities from
additional paid-in capital at the date of adoption. |
49
|
|
Item 7.
|
Managements
Discussion and Analysis of Financial Condition and Results of
Operations -Restatement.
|
The following discussion and analysis should be read in
conjunction with our consolidated financial statements, the
accompanying notes to these financial statements, and the other
financial information that appear elsewhere in this Annual
Report on
Form 10-K.
This discussion contains predictions, estimates, and other
forward-looking statements that involve a number of risks and
uncertainties. In some cases, you can identify forward-looking
statements by terminology such as may,
will, should, expects,
plans, anticipates,
believes, estimates,
predicts, potential, or
continue; the negative of these terms; or other
comparable terminology. Actual results may differ materially
from those discussed in these forward-looking statements due to
a number of factors, including those set forth in the section
entitled Risk Factors and elsewhere in this Annual
Report on
Form 10-K.
Although we believe that the expectations reflected in the
forward-looking statements are reasonable, we cannot guarantee
future results, levels of activity, performance, or
achievements. Except as required by law, we are under no duty to
update or revise any of the forward-looking statements, whether
as a result of new information, future events, or otherwise,
after the date of Annual Report on
Form 10-K.
Restatement
With this Annual Report on
Form 10-K,
we have restated the following previously filed consolidated
financial statements, data, and related disclosures:
(1) Our consolidated balance sheet as of December 31,
2008, and the related consolidated statements of operations,
stockholders equity, and cash flows for each of the fiscal
years ended December 31, 2007 and 2008 located in Part II,
Item 8 of this Annual Report on
Form 10-K;
(2) Our selected financial data as of and for our fiscal
years ended December 31, 2005, 2006, 2007, and 2008 located
in Part II, Item 6 of this Annual Report on
Form 10-K;
(3) Our managements discussion and analysis of
financial condition and results of operations as of and for our
fiscal years ended December 31, 2007 and 2008, contained
herein; and
(4) Our unaudited quarterly financial information for each
quarter in our fiscal year ended December 31, 2008, and for
the quarters ended March 31, 2009, June 30, 2009, and
September 30, 2009, in Note 20, Summarized
Quarterly Unaudited Financial Data of the Notes to
Consolidated Financial Statements in Item 8 of this Annual
Report on
Form 10-K.
The restatement results from our review of revenue recognition
practices. See Explanatory Note Regarding
Restatement immediately preceding Part I, Item 1
and Note 2, Restatement and Reclassification of
Previously Issued Consolidated Financial Statements of the
Notes to Consolidated Financial Statements in Part II,
Item 8 for a detailed discussion of the review and effect
of the restatement.
The following discussion and analysis of our financial condition
and results of operations incorporates the restated amounts. For
this reason the data set forth in this section may not be
comparable to discussions and data in our previously filed
Annual Reports of
Form 10-K.
Overview
athenahealth is a leading provider of Internet-based business
services for physician practices. Our service offerings are
based on four integrated components: our proprietary
Internet-based software, our continually updated database of
payer reimbursement process rules, our back-office service
operations that perform administrative aspects of billing and
clinical data management for physician practices, and our
automated and live patient communication services. Our principal
offering, athenaCollector, automates and manages billing-related
functions for physician practices and includes a medical
practice management platform. We have also developed a service
offering, athenaClinicals, that automates and manages
medical-record-related functions for physician practices and
includes an electronic health record, or EHR, platform.
ReminderCall, which we added to our service suite in September
2008, is our automated appointment reminder system that allows
patients to
50
either confirm the appointment or request rescheduling. We have
now combined ReminderCall with other automated patient messaging
services, live operator services, and a patient web portal in
the first edition of our athenaCommunicator services suite that
we beta launched in 2009 and expect to offer commercially in the
first half of 2010. We refer to athenaCollector as our revenue
cycle management service, athenaClinicals as our clinical cycle
management service, and athenaCommunicator as our patient cycle
management service. As a complement to these services, our
newest offering, Anodyne Analytics, is a web-based,
Software-as-a-Service business intelligence platform that
organizes and displays detailed and insightful practice
performance data for decision makers at our client practices.
Our services are designed to help our clients achieve faster
reimbursement from payers, reduce error rates, increase
collections, lower operating costs, improve operational workflow
controls, improve patient satisfaction and compliance, and more
efficiently manage clinical and billing information.
In 2009, we generated revenue of $188.5 million from the
sale of our services compared to $136.3 million in 2008 and
$97.6 million in 2007. Given the scope of our market
opportunity, we have increased our spending each year on growth,
innovation, and infrastructure. Despite increased spending in
these areas, higher revenue and lower direct operating expense
as a percentage of revenue have led to greater operating income.
However, the reversal of a valuation allowance against deferred
tax assets that occurred in the fourth quarter of 2008 has had
and will have an impact on net profits as our results are now
fully taxed.
Our revenues are predominately derived from business services
that we provide on an ongoing basis. This revenue is generally
determined as a percentage of payments collected by us on behalf
of our clients, so the key drivers of our revenue include growth
in the number of physicians working within our client accounts
and the collections of these physicians. To provide these
services, we incur expense in several categories, including
direct operating, selling and marketing, research and
development, general and administrative, and depreciation and
amortization expense. In general, our direct operating expense
increases as our volume of work increases, whereas our selling
and marketing expense increases in proportion to our rate of
adding new accounts to our network of physician clients. Our
other expense categories are less directly related to growth of
revenues and relate more to our planning for the future, our
overall business management activities, and our infrastructure.
As our revenues have grown, the difference between our revenue
and our direct operating expense also has grown, which has
afforded us the ability to spend more in other categories of
expense and to experience an increase in operating margin. We
manage our cash and our use of credit facilities to ensure
adequate liquidity, in adherence to related financial covenants.
Sources
of Revenue
We derive our revenue from two sources: from business services
associated with our revenue cycle and clinical cycle offerings
and from implementation and other services. Implementation and
other services consist primarily of professional services fees
related to assisting clients with the initial implementation of
our services and for ongoing training and related support
services. Business services accounted for approximately 97%,
97%, and 96% of our total revenues for the years ended
December 31, 2009, 2008, and 2007, respectively. Business
services fees are typically 2% to 8% of a practices total
collections depending upon the size, complexity, and other
characteristics of the practice, plus a per-statement charge for
billing statements that are generated for patients. Accordingly,
business services fees are largely driven by: the number of
physician practices we serve, the number of physicians and other
medical providers working in those physician practices, the
volume of activity and related collections of those physicians
and other medical providers, and our contracted rates. There is
moderate seasonality in the activity level of physician
practices. Typically, discretionary use of physician services
declines in the late summer and during the holiday season, which
leads to a decline in collections by our physician clients about
30 to 50 days later. None of our clients accounted for more
than 10% of our total revenues for the years ended
December 31, 2009, 2008, or 2007.
Operating
Expense
Direct Operating Expense. Direct operating
expense consists primarily of salaries, benefits, claim
processing costs, other direct costs, and stock-based
compensation related to personnel who provide services to
clients, including staff who implement new clients. We expense
implementation costs as incurred. Although
51
we expect that direct operating expense will increase in
absolute terms for the foreseeable future, the direct operating
expense is expected to decline as a percentage of revenues as we
further increase the percentage of transactions that are
resolved on the first attempt and as we decrease the cost of
implementation for new clients. In addition, over the longer
term, we expect to increase our overall level of automation and
to reduce our direct operating expense as a percentage of
revenues as we become a larger operation, with higher volumes of
work in particular functions, geographies, and medical
specialties. In 2009 and 2008, we include in direct operating
expense the service costs associated with our athenaClinicals
offering, which includes transaction handling related to lab
requisitions, lab results entry, fax classification, and other
services. We also expect these costs to increase in absolute
terms for the foreseeable future but to decline as a percentage
of revenue. This decrease will be driven by increased levels of
automation and by economies of scale. Direct operating expense
does not include allocated amounts for rent, depreciation, and
amortization, except for amortization related to purchased
intangible assets.
Selling and Marketing Expense. Selling and
marketing expense consists primarily of marketing programs
(including trade shows, brand messaging, and on-line
initiatives) and personnel-related expense for sales and
marketing employees (including salaries, benefits, commissions,
stock-based compensation, non-billable travel, lodging, and
other
out-of-pocket
employee-related expense). Although we recognize substantially
all of our revenue when services have been delivered, we
recognize a large portion of our sales commission expense at the
time of contract signature and at the time our services
commence. Accordingly, we incur a portion of our sales and
marketing expense prior to the recognition of the corresponding
revenue. We plan to continue to invest in sales and marketing by
hiring additional direct sales personnel to add new clients and
increase sales to our existing clients. We also plan to expand
our marketing activities in certain areas, such as attending
trade shows, expanding user groups, and creating new printed
materials. As a result, we expect that, in the future, sales and
marketing expense will increase in absolute terms but remain
relatively consistent over time as a percentage of revenue.
Research and Development Expense. Research and
development expense consists primarily of personnel-related
expenses for research and development employees (including
salaries, benefits, stock-based compensation, non-billable
travel, lodging, and other
out-of-pocket
employee-related expense) and consulting fees for third-party
developers. We expect that, in the future, research and
development expense will increase in absolute terms but not as a
percentage of revenue as new services and more mature products
require incrementally less new research and development
investment.
General and Administrative Expense. General
and administrative expense consists primarily of
personnel-related expense for administrative employees
(including salaries, benefits, stock-based compensation,
non-billable travel, lodging, and other
out-of-pocket
employee-related expense), occupancy and other indirect costs
(including building maintenance and utilities), and insurance,
as well as software license fees; outside professional fees for
accountants, lawyers, and consultants; and compensation for
temporary employees. We expect that general and administrative
expense will increase in absolute terms for the foreseeable
future as we invest in infrastructure to support our growth and
incur additional expense related to being a publicly traded
company. Though expenses are expected to continue to rise in
absolute terms, we expect general and administrative expense to
decline as a percentage of overall revenues.
Depreciation and Amortization
Expense. Depreciation and amortization expense
consists primarily of depreciation of fixed assets and
amortization of capitalized software development costs, which we
amortize over a two-year period from the time of release of
related software code. Because our core revenue cycle
application is relatively mature, we expense those costs as
incurred, and, as a result, in 2009 approximately 85% of our
software development expenditures were expensed rather than
capitalized. In the year ended December 31, 2008,
approximately 87% were expensed rather than capitalized. In the
year ended December 31, 2007, approximately 85% were
expensed rather than capitalized. As we grow, we will continue
to make capital investments in the infrastructure of the
business, and we will continue to develop software that we
capitalize. At the same time, because we are spreading fixed
costs over a larger client base, we expect related depreciation
and amortization expense to decline as a percentage of revenues
over time.
52
Other Income (Expense). Interest expense
consists primarily of interest costs related to our former
working capital line of credit, our equipment-related term
leases, our term loan and revolving loans under our credit
facility, and our former subordinated term loan, offset by
interest income on investments. Interest income represents
earnings from our cash, cash equivalents, and investments. The
gain or loss on interest rate derivative contract represents the
change in the fair market value of a derivative instrument that
is not designated a hedge under the authoritative accounting
guidance. Although this derivative has not been designated for
hedge accounting, we believe that such instrument is correlated
with the underlying cash flow exposure related to variability in
interest rate movements on our term loan. In 2007, the
unrealized loss on warrant liability represents the change in
the fair value of our warrants to purchase shares of our
preferred stock at the end of each reporting period. This
warrant liability and associated accounting to recognize this
liability at its fair value, ceased upon the completion of our
initial public offering, at which time the associated liability
converted to additional
paid-in-capital.
Acquisitions
2009
Acquisition
In October 2009, the Company acquired Anodyne Health Partners,
Inc., a software as a service business intelligence company
based in Alpharetta, Georgia. We believe that the acquisition of
Anodyne provides us with expanded service offerings that will
better enable us to compete in the large medical group market.
The Anodyne software as a service business intelligence tool
enhances customers ability to view all facets of its
revenue cycle information and to access and extract critical
operational and administrative information from various data
systems. Consideration for this transaction was
$22.3 million plus potential additional consideration of
$7.7 million which will be paid over a three-year period if
Anodyne achieves certain business and financial milestones.
2008
Acquisition
In September 2008, we acquired specified assets and assumed
specified liabilities of Crest Line Technologies, LLC (d.b.a.
MedicalMessaging.net). MedicalMessaging is a provider of live
and automated calling services for healthcare professionals. The
purpose of the acquisition is to augment our core business
service offering with MedicalMessagings automated and live
communication services. We believe the purchase of
MedicalMessaging gave us access to a developed technology that
could speed the time to market versus internal development of
our own similar product. In addition, we plan to leverage its
existing customer base to increase revenues of the
MedicalMessaging services. Consideration for this transaction
was $7.1 million plus potential additional consideration of
$1.0 million which will be paid over a three-year period if
MedicalMessaging achieves certain financial milestones. As of
December 31, 2009, we have paid $0.7 million of the
additional consideration.
Critical
Accounting Policies
Our discussion and analysis of our results of operations and
liquidity and capital resources are based on our consolidated
financial statements, which have been prepared in accordance
with generally accepted accounting principles in the United
States (GAAP). In connection with the preparation of our
consolidated financial statements, we are required to make
assumptions and estimates about future events, and apply
judgments that affect the reported amounts of assets,
liabilities, revenue, expenses, and the related disclosures. We
base our assumptions, estimates and judgments on historical
experience, current trends and other factors we believe to be
relevant at the time we prepared our consolidated financial
statements. On a regular basis, we review the accounting
policies, assumptions, estimates and judgments to ensure that
our consolidated financial statements are presented fairly and
in accordance with GAAP. However, because future events and
their effects cannot be determined with certainty, actual
results could differ from our assumptions and estimates, and
such differences could be material.
The preparation of our consolidated financial statements in
conformity with GAAP requires us to make estimates and
assumptions. These estimates and assumptions affect the reported
amounts of assets and
53
liabilities and the disclosures of contingent assets and
liabilities as of the date of the financial statements, and the
reported amounts of revenues and expenses during the reporting
periods. Significant estimates and assumptions are used for, but
are not limited to: (1) revenue recognition; including our
estimated expected customer life; (2) allowance for
doubtful accounts; (3) asset impairments
(4) depreciable lives of assets; (5) economic lives
and fair value of leased assets; (6) income tax reserves
and valuation allowances; (7) fair value of stock options;
(8) allocation of direct and indirect cost of sales; and
(9) litigation reserves. Future events and their effects
cannot be predicted with certainty, and accordingly, our
accounting estimates require the exercise of judgment. The
accounting estimates used in the preparation of our consolidated
financial statements will change as new events occur, as more
experience is acquired, as additional information is obtained
and as our operating environment changes. We evaluate and update
our assumptions and estimates on an ongoing basis and may employ
outside experts to assist in our evaluations. Actual results
could differ from the estimates we have used.
Our significant accounting policies are discussed in
Note 3, Business and Summary of Significant Accounting
Policies, to our accompanying consolidated financial
statements. We believe the following accounting policies are the
most critical to aid in fully understanding and evaluating our
reported financial results, as they require management to make
difficult, subjective or complex judgments, and to make
estimates about the effect of matters that are inherently
uncertain. We have reviewed these critical accounting policies
and related disclosures with the Audit Committee of our board of
directors.
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
Revenue recognition
|
|
|
|
|
We derive its revenue from business services associated with our
revenue cycle and clinical cycle offerings and from
implementation and other services.
|
|
We recognize revenue when all of the following conditions are satisfied:
there is evidence of an arrangement;
the service has been provided to the client;
the collection of the fees is reasonably assured; and
the amount of fees to be paid by the client is fixed or determinable.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in revenue that
could be material.
|
|
|
|
|
|
|
|
Our arrangements do not contain general rights of return. All
revenue, other than implementation revenue, is recognized when
the service is performed. Relative to our business services
offering that is based on the collections of amounts by our
customers; we do not recognize revenue until our customers have
been paid. As the implementation service is not separable from
the ongoing business services, we record implementation fees as
deferred revenue until the implementation service is complete,
at which time we recognize revenue ratably on a monthly basis
over the longer of the estimated expected customer life or
contract life.
|
|
|
54
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
|
|
Our clients typically purchase one-year contracts that renew
automatically upon completion. In most cases, our clients may
terminate their agreements with 90 days notice without
cause. We typically retain the right to terminate client
agreements in a similar timeframe. Our clients are billed
monthly, in arrears, based either upon a percentage of
collections posted to athenaNet, minimum fees, flat fees, or
per-claim fees where applicable. Invoices are generated within
the first two weeks of the month and delivered to clients
primarily by email. For most of our clients, fees are then
deducted from a pre-defined bank account one week after invoice
receipt via an auto-debit transaction. Amounts that have been
invoiced are recorded as revenue or deferred revenue, as
appropriate, and are included in our accounts receivable
balances.
|
|
|
|
|
We maintain allowances for doubtful accounts based on an
assessment of the collectability of specific customer accounts,
the aging of accounts receivable, and other economic information
on both an historical and prospective basis. Customer account
balances are charged against the allowance when it is probable
the receivable will not be recovered. Changes in the allowance
during fiscal 2009 and 2008 were not material. There is no
off-balance sheet credit exposure related to customer receivable
balances.
|
|
|
We are required to recognize our non-refundable up-front fees
over the contract term or estimated expected customer life,
whichever is longer.
|
|
The determination of the amount of revenue we can recognize each accounting period requires management to make estimates and judgments on the estimated expected customer life. We determined the estimated customer life considering the following key factors:
Renewal rate considerations
Economic life of the product or service
Industry data
Marketing studies
Data used to set the pricing terms of the arrangement.
|
|
Our estimate of expected customer life may prove to be
inaccurate, in which case we may have understated or overstated
the revenue recognized in an accounting period. For example, if
in the future, we need to increase our estimated expected
performance period to a period longer than 12 years, the
amount we would recognize in each accounting period would
decrease. On the other hand, if in the future, we need to
decrease our estimated expected customer life to a period
shorter than 12 years, the amount we would recognize in
each accounting period would increase. The amount of deferred
revenue related to non-refundable up-front fees is $32.1 million
as of December 31, 2009.
|
55
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
Income taxes
|
|
|
|
|
We account for income taxes using the asset and liability
method. Under this method, deferred tax assets and liabilities
are recognized for the estimated future tax consequences
attributable to differences between the financial statement
carrying values of existing assets and liabilities and their
respective tax bases. Deferred tax assets are also recorded with
respect to net operating losses and other tax attribute carry
forwards. Deferred tax assets and liabilities are measured using
enacted tax rates in effect for the years in which temporary
differences are expected to be recovered or settled. Valuation
allowances are established when it is more likely than not that
deferred tax assets will not be realized. The effect on deferred
tax assets and liabilities of a change in tax rates is
recognized in the income of the period that includes the
enactment date.
|
|
A high degree of judgment is required to determine if, and the
extent to which, valuation allowances should be recorded against
deferred tax assets. Since December 31, 2008, we have not had a
valuation allowance recorded against our net deferred tax
asset.
Contingent tax liabilities are based on our assessment of the
likelihood that we have incurred a liability. Such liabilities
are reviewed based on recent changes in tax laws and
regulations, including judicial rulings.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in income taxes
that could be material.
|
In addition, we are required to establish reserves for tax
contingencies.
|
|
|
|
|
|
|
|
|
|
Share-based Compensation
|
|
|
|
|
Athenahealth grants various nonqualified stock-based
compensation awards, including stock options. The share-based
compensation expense and related income tax benefit recognized
in the consolidated statement of operations in fiscal year 2009
was $8.3 million and $2.5 million, respectively. As of
December 31, 2009, there was $25.5 million of total
unrecognized compensation cost related to unvested stock
options, which is expected to be recognized through 2013.
|
|
We estimate the fair value of each stock option award on the
date of grant using the Black-Scholes valuation model, which
requires us to make estimates regarding expected option life,
stock price volatility and other assumptions. we have not had
sufficient history as a publicly traded company to evaluate its
volatility factor and expected term. As such, we analyzed the
volatilities and expected terms of a group of peer companies to
support the assumptions used in its calculations for the years
ended December 31, 2009, 2008, and 2007. We averaged the
volatilities of the peer companies with in-the-money options,
sufficient trading history and similar vesting terms to generate
the assumptions detailed above. We have not paid and do not
anticipate paying cash dividends on our shares of common stock;
therefore, the expected dividend yield is assumed to be zero. In
addition, we are required to utilize an estimated forfeiture
rate when calculating the expense for the period.
|
|
We believe that there is a high degree of subjectivity involved
when using option-pricing models to estimate share-based
compensation under the authoritative guidance. If factors change
and we employ different assumptions in the application of the
authoritative guidance in future periods than those currently,
the compensation expense that we record in the future may differ
significantly from what we have historically reported for future
grants. if the volatility percentage used in calculating our
stock compensation expense had fluctuated by 10%, the total
stock compensation expense to be recognized over the stock
options four-year vesting period would have increased or
decreased by approximately $2.6 million. If the forfeiture rate
used in calculating our stock compensation expense had
fluctuated by 10%, the total stock compensation expense to be
recognized over the stock options four-year vesting period
would have decreased or increased by approximately $0.2 million.
|
56
|
|
|
|
|
|
|
|
|
Effect if Actual Results
|
Description
|
|
Judgments and Uncertainties
|
|
Differ from Assumptions
|
|
Software Development Costs
|
|
|
|
|
Software development costs for internal use are expensed or
capitalized based on the stage of development for the software.
|
|
Under this guidance, costs related to the preliminary project
stage of subsequent versions of athenaNet and/or other
technology are expensed as incurred. Costs incurred in the
application development stage are capitalized. Such costs are
amortized over the softwares estimated economic life of
two years. In 2009, approximately 85% of our software
development expenditures were expensed rather than capitalized,
based upon the stage of development of the software. In the year
ended December 31, 2008, approximately 87% of our software
development expenditures were expensed rather than capitalized.
In the year ended December 31, 2007, approximately 85% of our
software development expenditures were expensed rather than
capitalized.
|
|
Although we believe that our approach to estimates and judgments
as described herein is reasonable, actual results could differ
and we may be exposed to increases or decreases in software
development costs that could be material.
|
|
|
|
|
|
Contingent consideration
|
|
|
|
|
Contingent consideration in a business combination is measured
at fair value at the acquisition date, with changes in the fair
value after the acquisition date affecting earnings.
|
|
Significant judgment is employed in determining the
appropriateness of these assumptions as of the acquisition date
and for each subsequent period. Accordingly, future business and
economic conditions, as well as changes in any of the
assumptions described above, can materially impact the amount of
contingent consideration expense we record in any given period.
Each period we revalue the contingent consideration obligations
associated with certain acquisitions to their then fair value
and record increases in the fair value as contingent
consideration expense and record decreases in the fair value as
a reduction of contingent consideration expense.
|
|
Increases or decreases in the fair value of the contingent
consideration obligations can result from changes in assumed
discount periods and rates, changes in the assumed timing and
amount of revenue and expense estimates. We recorded potential
contingent consideration of $7.7 million in the initial purchase
price allocation at its estimated fair value of $5.1 million
related to the Anodyne Health Partners, Inc acquisition in
October 2009.
|
57
Consolidated
Results of Operations
The following table sets forth our consolidated results of
operations as a percentage of total revenue for the periods
shown:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
|
97.2
|
%
|
|
|
96.8
|
%
|
|
|
96.5
|
%
|
Implementation and other
|
|
|
2.8
|
|
|
|
3.2
|
|
|
|
3.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
100
|
|
|
|
100
|
|
|
|
100
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
41.9
|
|
|
|
44.0
|
|
|
|
48.1
|
|
Selling and marketing
|
|
|
18.1
|
|
|
|
16.7
|
|
|
|
17.6
|
|
Research and development
|
|
|
7.6
|
|
|
|
7.8
|
|
|
|
7.7
|
|
General and administrative
|
|
|
19.2
|
|
|
|
21.5
|
|
|
|
20.4
|
|
Depreciation and amortization
|
|
|
4.1
|
|
|
|
4.4
|
|
|
|
5.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
90.9
|
|
|
|
94.4
|
|
|
|
99.5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
9.1
|
|
|
|
5.6
|
|
|
|
0.5
|
|
Other income (expenses):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
0.5
|
|
|
|
1.4
|
|
|
|
1.4
|
|
Interest expense
|
|
|
(0.5
|
)
|
|
|
(0.3
|
)
|
|
|
(3.7
|
)
|
Gain (loss) on interest rate derivative contract
|
|
|
0.3
|
|
|
|
(0.6
|
)
|
|
|
|
|
Other income (expense)
|
|
|
0.2
|
|
|
|
0.1
|
|
|
|
(5.8
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
0.5
|
|
|
|
0.6
|
|
|
|
(8.1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income taxes
|
|
|
9.6
|
|
|
|
6.2
|
|
|
|
(7.6
|
)
|
Income tax (provision) benefit
|
|
|
(4.7
|
)
|
|
|
17.0
|
|
|
|
(0.1
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
4.9
|
%
|
|
|
23.2
|
%
|
|
|
(7.7
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
We have restated our audited consolidated statement of
operations and cash flows for the years ended December 31,
2008 and 2007. For additional information about the restatement,
please see the Explanatory Note Regarding
Restatement immediately preceding Part I, Item 1
and Note 2 of the Notes to Consolidated Financial
Statements, Restatement and Reclassification of Previously
Issued Consolidated Financial Statements, in Part II, Item
8. The following discussion and analysis of our financial
results of operations incorporates the restated amounts.
Comparison
of the Years Ended December 31, 2009 and 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Business services
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
|
$
|
51,351
|
|
|
|
39
|
%
|
Implementation and other
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
894
|
|
|
|
20
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
188,527
|
|
|
$
|
136,282
|
|
|
$
|
52,245
|
|
|
|
38
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Total revenue for the year ended
December 31, 2009, was $188.5 million, an increase of
$52.2 million, or 38%, over revenue of $136.3 million
for the year ended December 31, 2008. This increase was due
almost entirely to an increase in business services revenue.
58
Business Services Revenue. Revenue from
business services for the year ended December 31, 2009, was
$183.2 million, an increase of $51.4 million, or 39%,
over revenue of $131.9 million for the year ended
December 31, 2008. This increase was primarily due to the
growth in the number of physicians and other medical providers
using our services. The number of physicians using our revenue
cycle management service, athenaCollector, at December 31,
2009, was 15,719, an increase of 3,130, or 25%, from 12,589
physicians at December 31, 2008. The number of active
medical providers using our revenue cycle management service,
athenaCollector, at December 31, 2009, was 23,366, an
increase of 4,598, or 24%, from 18,768 active medical providers
at December 31, 2008. The number of physicians using our
clinical cycle management service, athenaClinicals, at
December 31, 2009, was 920, an increase of 435, or 90%,
from 485 physicians at December 31, 2008. The number of
active medical providers using our clinical cycle management
service, athenaClinicals, at December 31, 2009, was 1,471,
an increase of 673, or 84%, from 798 active medical providers at
December 31, 2008. Also contributing to this increase was
the growth in related collections on behalf of these physicians
and medical providers. Total collections generated by these
physicians and other medical providers that was posted for the
year ended December 31, 2009, was $4.9 billion, an
increase of $1.2 billion, or 32%, over posted collections
of $3.7 billion for the year ended December 31, 2008.
Implementation and Other Revenue. Revenue from
implementations and other sources was $5.3 million for the
year ended December 31, 2009, an increase of
$0.9 million, or 20%, over revenue of $4.4 million for
the year ended December 31, 2008. This increase was driven
by new client implementations and increased professional
services for our larger client base. As of December 31,
2009, the numbers of accounts live on our revenue cycle
management service, athenaCollector, increased by 366 accounts
since December 31, 2008. As of December 31, 2009, the
numbers of accounts live on our clinical cycle management
service, athenaClinicals, increased by 116 accounts since
December 31, 2008. The increase in implementation and other
revenue is the result of the increase in the volume of our
business.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2009
|
|
2008
|
|
Change
|
|
|
Amount
|
|
Amount
|
|
Amount
|
|
Percent
|
|
Direct operating costs
|
|
$
|
79,017
|
|
|
$
|
59,947
|
|
|
$
|
19,070
|
|
|
|
32
|
%
|
Direct Operating Costs. Direct operating costs
for the year ended December 31, 2009, was
$79.0 million, an increase of $19 million, or 32%,
over direct operating costs of $60.0 million for the year
ended December 31, 2008. This increase was primarily due to
an increase in the number of claims that we processed on behalf
of our clients and the related expense of providing services,
including transactions expense and salary and benefits expense.
The amount of collections processed for the year ended
December 31, 2009, was $4.9 billion, which was
$1.2 billion, or 32% higher than the $3.7 billion of
collection processed for the year ended December 31, 2008.
The increase in collections increased at a higher rate than the
increase in the related direct operating expense as we benefited
from economies of scale.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Selling and marketing
|
|
$
|
34,072
|
|
|
$
|
22,827
|
|
|
$
|
11,245
|
|
|
|
49
|
%
|
Research and development
|
|
|
14,348
|
|
|
|
10,600
|
|
|
|
3,748
|
|
|
|
35
|
|
General and administrative
|
|
|
36,111
|
|
|
|
29,330
|
|
|
|
6,781
|
|
|
|
23
|
|
Depreciation and amortization
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
1,774
|
|
|
|
30
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
92,298
|
|
|
$
|
68,750
|
|
|
$
|
23,548
|
|
|
|
34
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and Marketing Expense. Selling and
marketing expense for the year ended December 31, 2009, was
$34.1 million, an increase of $11.3 million, or 49%,
over costs of $22.8 million for the year ended
December 31, 2008. This increase was primarily due to
increases in external commissions of $1.5 million, a
$0.7 million increase in stock-based compensation expense,
and an increase in salaries, internal commissions and benefits
of $4.9 million. Additional increases were due to increases
in online and offline marketing-related
59
expenses totaling $3.3 million, a $0.5 million
increase in travel related expense, and a $0.4 million
increase in consulting costs.
Research and Development Expense. Research and
development expense for the year ended December 31, 2009,
was $14.3 million, an increase of $3.7 million, or
35%, over research and development expense of $10.6 million
for the year ended December 31, 2008. This increase was
primarily due to a $3.7 million increase in salaries and
benefits.
General and Administrative Expense. General
and administrative expense for the year ended December 31,
2009, was $36.1 million, an increase of $6.8 million,
or 23%, over general and administrative expenses of
$29.3 million for the year ended December 31, 2008.
This increase was primarily due to a $3.8 million increase
in employee-related costs due to an increase in headcount, a
$1.4 million increase in stock compensation expense, and a
$1.0 million increase in audit-related and legal fees due
to the costs of being a public company and acquisition related
costs. The remaining portion of the increase relates to an
increase in our bad debt expense.
Depreciation and Amortization. Depreciation
and amortization expense for the year ended December 31,
2009, was $7.8 million, an increase of $1.8 million,
or 30%, from depreciation and amortization of $6.0 million
for the year ended December 31, 2008. This increase was
primarily due to the addition of assets during 2009 and 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Interest income
|
|
$
|
1,016
|
|
|
$
|
1,942
|
|
|
$
|
(926
|
)
|
|
|
(48
|
)%
|
Interest expense
|
|
|
(968
|
)
|
|
|
(428
|
)
|
|
|
(540
|
)
|
|
|
*
|
|
Gain (loss) on interest rate derivative contract
|
|
|
590
|
|
|
|
(881
|
)
|
|
|
1,471
|
|
|
|
*
|
|
Other income
|
|
|
255
|
|
|
|
182
|
|
|
|
73
|
|
|
|
40
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
893
|
|
|
$
|
815
|
|
|
$
|
78
|
|
|
|
10
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense). Interest income for
the year ended December 31, 2009, was $1.0 million, a
decrease of $0.9 million from interest income of
$1.9 million for the year ended December 31, 2008. The
decrease was directly related to the lower interest rates during
the year. Interest expense for the year ended December 31,
2009, was $1.0 million, an increase of approximately
$0.6 million over interest expense of $0.4 million for
the year ended December 31, 2008. The increase is related
to an increase in the balance outstanding on our capital leases
during 2009 and a full year of interest expense relating to our
term and revolving loans. The loss on interest rate derivative
for the year ended December 31, 2008, was
$0.9 million, compared to a gain on interest rate
derivative for the year ended December 31, 2009, of
$0.6 million. The gain was the result of the change in the
fair market value of a derivative instrument that was not
designated a hedge instrument under the authoritative guidance.
Although this derivative does not qualify for hedge accounting,
we believe that the instrument is closely correlated with the
underlying exposure, thus managing the associated risk. The
gains or losses from changes in the fair value of derivative
instruments that are not accounted for as hedges are recognized
in earnings.
Income Tax Provision. We recorded a provision
of $8.8 million for the income taxes for the year ended
December 31, 2009 based upon an effective tax rate of 49%.
We recorded a benefit of $23.2 million for income taxes for
the period of December 31, 2008, which included a reversal
of the valuation allowance against the deferred tax assets of
the Company. We consider whether a valuation allowance is needed
on its deferred tax assets by evaluating all positive and
negative evidence relative to its ability to recover deferred
tax assets. Prior to the year ended December 31, 2008, we
had incurred losses and it is difficult to assert that deferred
tax assets are recoverable with this negative evidence. During
the fourth quarter of 2008, our results of operations generated
a cumulative profit as measured over the current and prior two
years. In addition, we had been profitable for six consecutive
quarters before releasing the allowance. Based on consideration
of the
60
weight of positive and negative evidence, including forecasted
operating results, we concluded that there was sufficient
positive evidence that our deferred tax assets were more likely
than not recoverable as of December 31, 2008. Accordingly,
the remaining valuation allowance was reversed as of
December 31, 2008.
Comparison
of the Years Ended December 31, 2008 and 2007
We have restated our audited consolidated statement of
operations and cash flows for the years ended December 31,
2008 and 2007. For additional information about the restatement,
please see the Explanatory Note Regarding
Restatement immediately preceding Part I, Item 1
and Note 2 of the Notes to Consolidated Financial
Statements, Restatement and Reclassification of Previously
Issued Consolidated Financial Statements in Part II, Item
8. The following discussion and analysis of our financial
results of operations incorporates the restated amounts.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Business services
|
|
$
|
131,879
|
|
|
$
|
94,182
|
|
|
$
|
37,697
|
|
|
|
40
|
%
|
Implementation and other
|
|
|
4,403
|
|
|
|
3,436
|
|
|
|
967
|
|
|
|
28
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
$
|
136,282
|
|
|
$
|
97,618
|
|
|
$
|
38,664
|
|
|
|
40
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Revenue. Total revenue for the year ended
December 31, 2008, was $136.3 million, an increase of
$38.7 million, or 40%, over revenue of $97.6 million
for the year ended December 31, 2007. This increase was
almost entirely due to an increase in business services revenue.
Business Services Revenue. Revenue from
business services for the year ended December 31, 2008, was
$131.9 million, an increase of $37.7 million, or 40%,
over revenue of $94.2 million for the year ended
December 31, 2007. This increase was primarily due to the
growth in the number of physicians using our services. The
number of physicians using our services at December 31,
2008, was 12,589, an increase of 3,166, or 34%, over the 9,423
physicians at December 31, 2007. Also contributing to this
increase was growth in related collections on behalf of these
physicians. Total collections generated by these providers
posted for the year ended December 31, 2008, was
$3.7 billion, an increase of $1.0 billion, or 37%,
over $2.7 billion for the year ended December 31, 2007.
Implementation and Other Revenue. Revenue from
implementations and other sources was $4.4 million for the
year ended December 31, 2008, an increase of
$1.0 million, or 28%, over revenue of $3.4 million for
the year ended December 31, 2007. This increase was driven
by new client implementations and increased professional
services for our larger client base. As of December 31,
2008, the number of accounts live on our revenue cycle
management system, athenaCollector increased by 305 since
December 31, 2007. As of December 31, 2008, the number
of accounts live on our clinical cycle management service,
athenaClinicals increased by 80 since December 31, 2007.
The increase in implementation and other revenue is the result
of the increase in the volume of our business.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2008
|
|
2007
|
|
Change
|
|
|
Amount
|
|
Amount
|
|
Amount
|
|
Percent
|
|
Direct operating expense
|
|
$
|
59,947
|
|
|
$
|
46,978
|
|
|
$
|
12,969
|
|
|
|
28
|
%
|
Direct Operating Expense. Direct operating
expense for the year ended December 31, 2008, was
$59.9 million, an increase of 28% over direct operating
expense of $47.0 million for the year ended
December 31, 2007. This increase was primarily due to an
increase in the number of claims that we processed on behalf of
our clients and the related expense of providing services,
including transactions expense and salary and benefits expense.
The amount of collections processed for our clients for the year
ended
61
December 31, 2008, was $3.7 billion, which was 37%
higher than the $2.7 billion of collections processed for
the year ended December 31, 2007. The increase in
collections increased at a higher rate than the increase in the
related direct operating expense, as we benefited from economies
of scale.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Selling and marketing
|
|
$
|
22,827
|
|
|
$
|
17,212
|
|
|
$
|
5,615
|
|
|
|
33
|
%
|
Research and development
|
|
|
10,600
|
|
|
|
7,476
|
|
|
|
3,124
|
|
|
|
42
|
|
General and administrative
|
|
|
29,330
|
|
|
|
19,922
|
|
|
|
9,408
|
|
|
|
47
|
|
Depreciation and amortization
|
|
|
5,993
|
|
|
|
5,541
|
|
|
|
452
|
|
|
|
8
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
68,750
|
|
|
$
|
50,151
|
|
|
$
|
18,599
|
|
|
|
37
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Selling and Marketing Expense. Selling and
marketing expense for the year ended December 31, 2008, was
$22.8 million, an increase of $5.6 million, or 33%,
over sales and marketing expense of $17.2 million for the
year ended December 31, 2007. This increase was primarily
due to increases in internal and external commissions of
$1.7 million, a $1.3 million increase in stock
compensation expense, an increase in salaries and benefits of
$2.3 million, and an increase in marketing expenses of
$0.3 million.
Research and Development Expense. Research and
development expense for the year ended December 31, 2008,
was $10.6 million, an increase of $3.1 million, or
42%, over research and development expense of $7.5 million
for the year ended December 31, 2007. This increase was
primarily due to a $1.9 million increase in salaries, a
$0.8 million increase in stock compensation expense, and a
$0.4 million increase in consulting related to our
athenaClinicals product.
General and Administrative Expense. General
and administrative expense for the year ended December 31,
2008, was $29.3 million, an increase of $9.4 million,
or 47%, over general and administrative expense of
$19.9 million for the year ended December 31, 2007.
This increase was primarily due to a $6.5 million increase
in salaries and benefits resulting from an increase in
headcount, a $1.4 million increase in stock compensation
expense, and a $1.5 million increase in audit-related and
legal fees due to the costs of being a public company.
Depreciation and Amortization. Depreciation
and amortization expense for the year ended December 31,
2008, was $6.0 million, an increase of $0.5 million,
or 8%, from depreciation and amortization expense of
$5.5 million for the year ended December 31, 2007.
This increase was primarily due to the addition of property and
equipment during 2008.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Change
|
|
|
|
Amount
|
|
|
Amount
|
|
|
Amount
|
|
|
Percent
|
|
|
Interest income
|
|
$
|
1,942
|
|
|
$
|
1,415
|
|
|
$
|
527
|
|
|
|
37
|
%
|
Interest expense
|
|
|
(428
|
)
|
|
|
(3,682
|
)
|
|
|
3,254
|
|
|
|
(88
|
)
|
Gain (loss) on interest rate derivative contract
|
|
|
(881
|
)
|
|
|
|
|
|
|
(881
|
)
|
|
|
*
|
|
Other income
|
|
|
182
|
|
|
|
(5,689
|
)
|
|
|
5,871
|
|
|
|
*
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
815
|
|
|
$
|
(7,956
|
)
|
|
$
|
8,771
|
|
|
|
(110
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other Income (Expense). Interest income for
the year ended December 31, 2008, was $1.9 million, an
increase of $0.5 million from interest income of
$1.4 million for the year ended December 31, 2007. The
increase was directly related to the higher cash and short-term
investments balance during the year. Interest expense for the
year ended December 31, 2008, was $0.4 million, a
decrease of $3.3 million, or 88%, over interest expense of
$3.7 million for the year ended December 31, 2007. The
decrease is related to a decrease in bank debt during 2008. The
loss on interest rate derivative for the year ended
December 31, 2008, was
62
$0.9 million, which was the result of the change in the
fair market value of a derivative instrument that was not
designated a hedge under the authoritative guidance. Although
this derivative does not qualify for hedge accounting, we
believe that the instrument is closely correlated with the
underlying exposure, thus managing the associated risk. The
gains or losses from changes in the fair value of derivative
instruments that are not accounted for as hedges are recognized
in earnings. The loss on warrant liability for the year ended
December 31, 2007, was $5.0 million, which was the
result of the change in the fair value of the warrants prior to
our initial public offering, or IPO. This change in the fair
value of the warrants is attributable to the appreciation in the
fair value of our common and preferred stock during this period,
as the common stock increased from $7.20 per share as of
December 31, 2006, to $18.00 per share at the time of our
IPO. These warrants converted to warrants to purchase shares of
common stock upon the consummation of our IPO, at which time the
existing liability was reclassified to additional
paid-in-capital.
Therefore there was no such expense in 2008. Also included in
other expense for the year ended December 31, 2007, was
$0.1 million in loss on disposal of assets and
$0.6 million of financial advisor fees paid by
shareholders. Included in other expense for the year ended
December 31, 2008, was $0.2 million in gain on
disposal of assets.
Income Tax Provision. We recorded a benefit of
$23.2 million for income taxes for the period of
December 31, 2008, which included a reversal of the
valuation allowance against the deferred tax assets of the
company. We consider whether a valuation allowance is needed on
its deferred tax assets by evaluating all positive and negative
evidence relative to its ability to recover deferred tax assets.
Prior to the year ended December 31, 2008, we had incurred
losses and it is difficult to assert that deferred tax assets
are recoverable with this negative evidence. During the fourth
quarter of 2008, our results of operations generated a
cumulative profit as measured over the current and prior two
years. In addition, we have been profitable for six consecutive
quarters. Based on consideration of the weight of positive and
negative evidence, including forecasted operating results, we
concluded that there was sufficient positive evidence that its
deferred tax assets are more likely than not recoverable as of
December 31, 2008. Accordingly, the remaining valuation
allowance was reversed as of December 31, 2008. We recorded
a provision for income taxes for the year ended
December 31, 2007, of less than $0.1 million, which
represents income tax expense for the alternative minimum tax
(AMT).
Liquidity
and Capital Resources
Since our inception, we have funded our growth primarily through
the private sale of equity securities, totaling approximately
$50.6 million, as well as through long-term debt, working
capital, equipment-financing loans, and the completion of our
initial public offering, which provided net proceeds of
approximately $81.3 million. As of December 31, 2009,
our principal sources of liquidity were cash and cash
equivalents totaling $30.5 million and short term
investments of $52.3 million. Our total indebtedness was
$12.4 million at December 31, 2009, and was comprised
of capital leases and amounts borrowed under our credit facility
with Bank of America, N.A.
Looking forward to 2010, we anticipate sufficient liquidity from
cash flows and access to existing credit facilities to meet our
operational needs and financial obligations. Our liquidity
derived from cash flows is, to a large degree, predicated on our
ability to collect our receivables in a timely manner and the
cost of operating our business.
Cash provided by operating activities during the year ended
December 31, 2009, was $32.3 million and consisted of
a net income of $9.3 million and $2.4 million utilized
by working capital and other activities. This is offset by
positive non-cash adjustments of $8.4 million related to
depreciation and amortization expense, $8.3 million in
non-cash stock compensation expense, $1.0 million for a
provision for uncollectible accounts, a $0.3 million loss
on disposal of assets, and $5.9 million relating to changes
in our deferred tax assets and liabilities. Negative non-cash
adjustments relate to amortization of discounts on investments
of $0.1 million, a $2.5 million from excess tax
benefit from stock-based awards, and a $0.6 million from a
non-cash gain on interest rate swap. Cash used by working
capital and other activities was primarily attributable to a
$1.1 million decrease in deferred rent, a
$10.5 million increase in accounts receivable and a
$0.2 million increase in other long-term assets, offset in
part by a $7.4 million increase in deferred revenue, a
$6.4 million increase in accrued expenses, a
$0.9 million increase in prepaid expenses and other current
assets, and a
63
$1.4 million increase in accounts payables. These changes
were attributable to growth in the size of our business and in
the related direct operating expense.
Cash provided by operating activities during the year ended
December 31, 2008, was $21.1 million and consisted of
a net income of $31.6 million and $1.8 million
utilized by working capital and other activities. This is offset
by positive non-cash adjustments of $6.1 million related to
depreciation and amortization expense, $5.6 million in
non-cash stock compensation expense, a $0.9 million from a
non-cash loss on interest rate swap, a $0.5 million from
excess tax benefit from stock-based awards, and
$0.4 million for a provision for uncollectible accounts.
Negative non-cash adjustments relate to amortization of
discounts on investments for $0.9 million and
$23.8 million increase in deferred provision. Cash used by
working capital and other activities was primarily attributable
to a $7.4 million increase in accrued expense, a
$1.4 million decrease in deferred rent, a $9.3 million
increase in accounts receivable, a $0.9 million increase in
prepaid expenses and other current assets, and a
$0.1 million increase in other long-term assets, offset in
part by a $7.1 million increase in deferred revenue and a
$1.2 million increase in accounts payables. These changes
were attributable to growth in the size of our business and in
the related direct operating expense.
Net cash used by investing activities was $33.2 million for
the year ended December 31, 2009, which consisted of
purchases of investments of $78.6 million; purchases of
property and equipment of $10.3 million; net cash paid for
acquisition and other purchased intangible assets of
$22.4 million; expenditures for internal development of the
athenaClinicals and athenaCommunicator applications of
$2.6 million; increase in restricted cash balance of
$7.4 million; and purchase of investment in unconsolidated
company of $0.6 million. This outgoing investment cash flow
was offset by positive investment cash flow of
$84.0 million from proceeds of the maturities of
investments and proceeds from sale of equipment of
$4.5 million.
Net cash used by investing activities was $74.8 million for
the year ended December 31, 2008, which consisted of
purchases of investments of $130.0 million; purchases of
plant, property, and equipment of $13.5 million; net cash
paid for acquisition and other purchased intangible assets of
$6.7 million; expenditures for internal development of the
athenaClinicals application of $1.4 million; and purchase
of investment in unconsolidated company of $0.6 million.
This outgoing investment cash flow was offset by positive
investment cash flow of $73.3 million from proceeds of the
maturities of investments and proceeds from disposals and sale
of equipment of $4.1 million.
Net cash provided by financing activities was $2.6 million
for the year ended December 31, 2009. The majority of the
cash provided in the period resulted from proceeds from the
issuance of common stock under stock plans of $2.7 million,
and an excess tax benefit from stock-based awards of
$2.4 million. This was offset by payments on long-term debt
of $2.5 million. The $12.4 million of debt was either
issued as fixed-interest-rate debt or has been effectively
converted to fixed-rate debt through the use of interest rate
swaps that change floating rates to fixed rates. The
weighted-average interest rate on fixed-rate long-term debt is
5%, including the effects of the interest rate swaps. At
December 31, 2009, the current fair value of the swap is a
liability of $0.3 million.
Net cash provided by financing activities was $10.8 million
for the year ended December 31, 2008. The majority of the
cash provided in the period resulted from proceeds from
long-term debt of $6.0 million, $5.2 million in
proceeds from the exercise of stock options and warrants, and a
tax benefit from stock-based awards of $0.5 million. This
was offset by payments on long-term debt of $0.8 million
and $0.2 million of deferred financing fees. The debt was
either issued as fixed-interest-rate debt or has been
effectively converted to fixed-rate debt through the use of
interest rate swaps that change floating rates to fixed rates.
The weighted-average interest rate on fixed-rate long-term debt
is 4.55%, including the effects of the interest rate swaps. At
December 31, 2008, the current fair value of the swap was a
liability of $0.9 million.
We make investments in property and equipment and in software
development on an ongoing basis. Our property and equipment
investments consist primarily of technology infrastructure to
provide capacity for expansion of our client base, including
computers and related equipment in our data centers and
infrastructure in our service operations. Our software
development investments consist primarily of company-managed
design, development, testing, and deployment of new application
functionality. Because the practice management component of
athenaNet is considered mature, we expense nearly all software
maintenance costs for this
64
component of our platform as incurred. For the electronic health
records (EHR) component of athenaNet, which is the
platform for our athenaClinicals offering, we capitalize nearly
all software development. In the year ended December 31,
2009, we capitalized $10.3 million in property and
equipment and $2.6 million in software development. In the
year ended December 31, 2008, we capitalized
$13.5 million of property and equipment and
$1.4 million of software development. Included in the
capitalized property and equipment during 2008 was a complex of
buildings totaling 186,000 square feet, including
approximately 133,000 square feet of office space, on
approximately 53 acres of land located in Belfast, Maine,
for a total price of $6.2 million. We currently anticipate
making aggregate capital expenditures of approximately
$16.3 million over the next twelve months. In the years
ended December 31, 2009 and 2008, we paid cash for
acquisitions of $22.4 million and $6.7 million. We
believe that the acquisitions provide us with expanded service
offerings that will better enable it to compete in this market.
Given our current cash and cash equivalents, short-term
investments, accounts receivable, and funds available under our
existing revolving credit facility with Bank of America, N.A.,
we believe that we will have sufficient liquidity to fund our
business and meet our contractual obligations for at least the
next twelve months. We may increase our capital expenditures
consistent with our anticipated growth in infrastructure and
personnel and as we expand our national presence. In addition,
we may pursue acquisitions or investments in complementary
businesses or technologies or experience unexpected operating
losses, in which case we may need to raise additional funds
sooner than expected. Accordingly, we may need to engage in
private or public equity or debt financings to secure additional
funds. If we raise additional funds through further issuances of
equity or convertible debt securities, our existing stockholders
could suffer significant dilution, and any new equity securities
we issue could have rights, preferences, and privileges superior
to those of holders of our common stock. Any debt financing
obtained by us in the future could involve restrictive covenants
relating to our capital-raising activities and other financial
and operational matters, which may make it more difficult for us
to obtain additional capital and to pursue business
opportunities, including potential acquisitions. In addition, we
may not be able to obtain additional financing on terms
favorable to us, if at all. If we are unable to obtain required
financing on terms satisfactory to us, our ability to continue
to support our business growth and to respond to business
challenges could be significantly limited. Beyond the
twelve-month period, we intend to maintain sufficient liquidity
through continued improvements in the size and profitability of
our business and through prudent management of our cash
resources and our credit arrangements.
Credit
Facilities
Capital
Leases
As of December 31, 2009, there was a net present value of
$6.8 million in aggregate principal amount outstanding
under a series of capital leases with one finance company. They
accrue interest at a weighted average rate of 3.5% per annum,
and they are payable on a monthly basis through December 2012.
Term
and Revolving Loans
On September 30, 2008, we entered into a credit agreement
with Bank of America, N.A. This credit agreement consists of a
revolving credit facility in the amount of $15.0 million
and a term loan facility in the amount of $6.0 million. The
revolving credit facility may be extended by up to an additional
$15.0 million on the satisfaction of certain conditions and
includes a $10.0 million sublimit for the issuance of
standby letters of credit. The revolving credit facility matures
on September 30, 2011, and the term facility matures on
September 30, 2013, although either facility may be
voluntarily prepaid in whole or in part at any time without
premium or penalty. On September 30, 2008, we borrowed a
total of $6.0 million under the term loan facility for
general working capital purposes and as of December 31,
2009, the outstanding balance on the term loan facility was
$5.6 million. As of December 31, 2009 and 2008, there
were no amounts outstanding under the revolving credit facility.
The revolving credit loans and term loans bear interest, at our
option, at either (i) the British Bankers Association
London Interbank Offered Rate (known as LIBOR), or (ii) the
higher of (a) the Federal Funds Rate plus 0.50% or
(b) Bank of Americas prime rate. For term loans,
these rates are adjusted up 100 basis
65
points for LIBOR loans and down 100 basis points for all
other loans. For revolving credit loans, a margin is added to
the chosen interest rate that is based on our consolidated
leverage ratio, as defined in the credit agreement, which margin
can range from 100 to 275 basis points for LIBOR loans and
from 0 to 50 basis points for all other loans. A default
rate applies on all obligations in the event of a default under
the credit agreement at an annual rate equal to 2% above the
applicable interest rate. We were also required to pay other
customary commitment fees and upfront fees for this credit
facility. The interest rate as of December 31, 2009, for
the term loan and for the revolving credit facility was 4.55%.
Our obligations under the credit agreement and all related
documents are collateralized by a security interest in our
personal and fixture property, instruments, documents, chattel
paper, deposit accounts, claims, investment property, contract
rights, general intangibles, and certain intellectual property
rights. As additional security, we have granted to Bank of
America, N.A. a mortgage, assignment of rents, and security
interest in fixtures relating to our property in Belfast, Maine,
and pledged all stock of any domestic subsidiary that may be
formed or acquired and 65% of our foreign subsidiaries
stock. If we acquire or form any United States subsidiary, that
subsidiary shall be required to provide a joint and several
guaranty of all of our obligations under the credit agreement as
primary obligor.
The credit agreement contains customary default provisions,
including, without limitation, defaults relating to non-payment,
breach of covenants, inaccuracy of representations and
warranties, default under other indebtedness (including a
cross-default with our interest rate swap with Bank of America,
N.A.), bankruptcy and insolvency, inability to pay debts,
attachment of assets, adverse judgments, ERISA violations,
invalidity of loan and collateral documents, and change of
control. Upon an event of default, the lenders may terminate the
commitment to make loans and the obligation to extend letters of
credit, declare the unpaid principal amount of all outstanding
loans and interest accrued under the credit agreement to be
immediately due and payable, require us to provide cash and
deposit account collateral for our letter of credit obligations,
and exercise their security interests and other rights under the
credit agreement. The credit agreement also contains certain
financial and nonfinancial covenants, including limitations on
our consolidated leverage ratio and capital expenditures. As of
December 31, 2009 and 2008, we were in compliance with our
covenants under the credit agreement.
Contractual
Obligations
We have contractual obligations under our bank debt, equipment
line of credit, and revolving and term loans. We also maintain
operating leases for property and certain office equipment. The
following table summarizes our long-term contractual obligations
and commitments as of December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments Due by Period
|
|
|
|
|
|
|
Less than 1
|
|
|
2 - 3
|
|
|
4 -5
|
|
|
After 5
|
|
|
|
|
|
|
Total
|
|
|
Year
|
|
|
Years
|
|
|
Years
|
|
|
Years
|
|
|
Other
|
|
|
Long-term debt obligations
|
|
$
|
5,625
|
|
|
$
|
300
|
|
|
$
|
600
|
|
|
$
|
4,725
|
|
|
$
|
|
|
|
$
|
|
|
Capital lease obligations
|
|
|
6,763
|
|
|
|
3,137
|
|
|
|
3,626
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating lease obligations
|
|
|
30,778
|
|
|
|
5,357
|
|
|
|
10,651
|
|
|
|
10,629
|
|
|
|
4,141
|
|
|
|
|
|
Other
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
986
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
43,166
|
|
|
$
|
8,794
|
|
|
$
|
14,877
|
|
|
$
|
15,354
|
|
|
$
|
4,141
|
|
|
$
|
986
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
These amounts exclude interest payments of $0.3 million
that are due in the next three years on the capital lease
obligations and $1.0 million that are due in the next four
years on our long-term debt obligations.
The commitments under our operating leases shown above consist
primarily of lease payments for our Watertown, Massachusetts,
corporate headquarters; our Rome, Georgia, offices; our
Alpharetta, Georgia, subsidiary location; and our Chennai,
India, subsidiary location.
On February 15, 2008, we purchased a complex of buildings,
including approximately 133,000 square feet of office
space, on approximately 53 acres of land located in
Belfast, Maine, for a total purchase price of
66
$6.2 million from a wholly owned subsidiary of Bank of
America Corporation. We use this facility as a second
operational service site and intend to lease a small portion of
the space to commercial tenants.
Other amount consists of uncertain tax benefits. We have not
utilized these uncertain tax benefits, nor do we have an
expectation of when these uncertain tax benefits would be
challenged. As of December 31, 2009, we cannot reasonably
estimate when any future cash outlays would occur related to
these uncertain tax positions.
Off-Balance
Sheet Arrangements
As of December 31, 2009, 2008, and 2007, we did not have
any relationships with unconsolidated entities or financial
partnerships, such as entities often referred to as
structured finance or special purpose
entities, which would have been established for the purpose of
facilitating off-balance sheet arrangements or other
contractually narrow or limited purposes. Other than our
operating leases for office space and computer equipment, we do
not engage in off-balance sheet financing arrangements.
Recent
Accounting Pronouncements
In December 2007, the Financial Accounting Standards Board
(FASB) issued authoritative guidance on business
combinations. This guidance establishes principles and
requirements for how an acquirer recognizes and measures in its
financial statements significant aspects of a business
combination. Under this guidance, acquisition costs are
generally expensed as incurred; noncontrolling interests are
reflected at fair value at the acquisition date; in-process
research and development (IPR&D) is recorded at
fair value as an intangible asset at the acquisition date;
restructuring costs associated with a business combination are
generally expensed rather than capitalized; contingent
consideration is measured at fair value at the acquisition date,
with changes in the fair value after the acquisition date
affecting earnings; and changes in deferred tax asset valuation
allowances and income tax uncertainties after the measurement
period will affect income tax expense. We adopted this guidance
on January 1, 2009 and during the year ended
December 31, 2009, expensed approximately $0.8 million
of acquisition costs that, prior to the change in accounting,
would have been included as part of the purchase price. In
addition, under the provisions of guidance, future reversal of
our current acquisition-related tax reserves of approximately
$0.7 million (excluding interest and penalties) will be
recorded in earnings, rather than as an adjustment to goodwill
or acquisition related other intangible assets and will affect
the Companys annual effective income tax rate. The
potential contingent consideration of $7.7 million was
recorded in the initial purchase price allocation at its
estimated fair value of $5.1 million. The contingent
consideration will be accreted to the amount payable when, and
if, earned. The difference between the estimated and earn-out
amount will be charged or credited to expense. The contingent
consideration for acquisitions which occurred prior to this
change will be recorded as additional goodwill when it is earned.
In October 2009, the FASB issued authoritative guidance on
revenue recognition that will become effective for periods
beginning January 1, 2011, with earlier adoption permitted.
Under the new guidance on arrangements that include software
elements, tangible products that have software components that
are essential to the functionality of the tangible product will
no longer be within the scope of the software revenue
recognition guidance, and software-enabled products will now be
subject to other relevant revenue recognition guidance.
Additionally, the FASB issued authoritative guidance on revenue
arrangements with multiple deliverables that are outside the
scope of the software revenue recognition guidance. Under the
new guidance, when vendor specific objective evidence or third
party evidence for deliverables in an arrangement cannot be
determined, a best estimate of the selling price is required to
separate deliverables and allocate arrangement consideration
using the relative selling price method. The new guidance
includes new disclosure requirements on how the application of
the relative selling price method affects the timing and amount
of revenue recognition. We are currently evaluating the impact
of adoption of this authoritative guidance might have on our
financial statements, if any.
From time to time, new accounting pronouncements are issued
by FASB and are adopted by us as of the specified effective
date. Unless otherwise discussed, we believe that the impact of
recently issued
67
accounting pronouncements will not have a material impact on
consolidated financial position, results of operations, and cash
flows, or do not apply to our operations.
|
|
Item 7A.
|
Quantitative
and Qualitative Disclosures About Market Risk.
|
Foreign Currency Exchange Risk. Our results of
operations and cash flows are subject to fluctuations due to
changes in the Indian rupee. None of our consolidated revenues
are generated outside the United States. None of our vendor
relationships, including our contracts with our offshore service
providers, International Business Machines Corporation and
Vision Process Business Solutions Inc., for work performed in
India or the Philippines, is denominated in any currency other
than the U.S. dollar. Although the contracts are
denominated in U.S. dollars, the fees in one of our vendor
contracts are subject to adjustment based upon fluctuation in
exchange rates between the India Rupees and the
U.S. dollar. In 2009 and 2008, 0.9% and 1.0%, respectively,
of our expenses occurred in our direct subsidiary in Chennai,
India, and were incurred in Indian rupees. We therefore believe
that the risk of a significant impact on our operating income
from foreign currency fluctuations is not substantial.
Interest Rate Sensitivity. We had unrestricted
cash and cash equivalents totaling $30.5 million at
December 31, 2009. These amounts are held for working
capital purposes and were invested primarily in deposits, money
market funds, and short-term, interest-bearing, investment-grade
securities. Due to the short-term nature of these investments,
we believe that we do not have any material exposure to changes
in the fair value of our investment portfolio as a result of
changes in interest rates. The value of these securities,
however, will be subject to interest rate risk and could fall in
value if interest rates rise.
Interest
Rate Risk
As of December 31, 2009, we had long-term debt and capital
lease obligations totaling $12.4 million, which have both
variable and fixed interest rate components. We have entered
into interest rate swaps as a hedge relating to variability in
interest rate movements on our term loan. For floating rate
debt, interest rate changes generally do not affect the fair
market value, but do impact future earnings and cash flows,
assuming other factors are held constant.
The table below summarizes the principal terms of our interest
rate swap transaction, including the notional amount of the
swap, the interest rate payment we receive from and pay to our
swap counterparty, the term of the transaction, and its fair
market value at December 31, 2009.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Market
|
|
|
|
|
|
|
|
|
|
|
Fiscal Year
|
|
|
|
Value at
|
|
|
|
|
Notional
|
|
|
|
|
|
Entered
|
|
Maturity
|
|
December 31,
|
Description
|
|
Borrowing
|
|
Amount
|
|
Receive
|
|
Pay
|
|
Into
|
|
(Fiscal Year)
|
|
2009
|
|
Interest rate swap
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
variable to fixed
|
|
Revolving
Credit
Facility
|
|
$5,625
|
|
LIBOR
plus
1.0%
|
|
4.55%
Fixed
|
|
2008
|
|
2028
|
|
$(291)
|
|
|
Item 8.
|
Financial
Statements and Supplementary Data.
|
The financial statements required by this Item are located
beginning on
page F-1
of this report.
|
|
Item 9.
|
Changes
in and Disagreements with Accountants on Accounting and
Financial Disclosure.
|
None.
|
|
Item 9A.
|
Controls
and Procedures.
|
Evaluation
of Disclosure Controls and Procedures
Our management, with the participation of our Chief Executive
Officer and Chief Financial Officer, evaluated the effectiveness
of our disclosure controls and procedures as of
December 31, 2009. The term disclosure controls and
procedures, as defined in
Rules 13a-15(e)
and
15d-15(e)
under the Securities and Exchange Act of 1934,
68
means controls and other procedures of a company that are
designed to ensure that information required to be disclosed by
a company in the reports that it files or submits under the
Securities Exchange Act of 1934 is recorded, processed,
summarized, and reported within the time periods specified in
the SECs rules and forms. Disclosure controls and
procedures include, without limitation, controls and procedures
designed to ensure that information required to be disclosed by
a company in the reports that it files or submits under the
Securities Exchange Act of 1934 is accumulated and communicated
to that companys management, including its principal
executive and principal financial officers, as appropriate to
allow timely decisions regarding required disclosure. Management
recognizes that any controls and procedures, no matter how well
designed and operated, can provide only reasonable assurance of
achieving their objectives, and management necessarily applies
its judgment in evaluating the cost-benefit relationship of
possible controls and procedures.
Based on this evaluation, our Chief Executive Officer and Chief
Financial Officer have concluded that our financial disclosure
controls and procedures were not effective as of
December 31, 2009, due to the material weakness in our
internal control over financial reporting as described below.
Managements
Report on Internal Control over Financial Reporting
Our management is responsible for establishing and maintaining
adequate internal control over financial reporting for our
company. Internal control over financial reporting is defined in
Rules 13a-15(f)
and 15(d)-15(f) promulgated under the Securities Exchange Act of
1934, as amended, as a process designed by, or under the
supervision of, our Chief Executive and Chief Financial Officers
and effected by our board of directors, management, and other
personnel to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles and includes those
policies and procedures that:
|
|
|
|
|
pertain to the maintenance of records that in reasonable detail
accurately and fairly reflect the transactions and disposition
of our assets;
|
|
|
|
provide reasonable assurance that transactions are recorded as
necessary to permit preparation of financial statements in
accordance with generally accepted accounting principles;
|
|
|
|
provide reasonable assurance that our receipts and expenditures
are being made only in accordance with authorization of our
management and directors; and
|
|
|
|
provide reasonable assurance regarding prevention or timely
detection of unauthorized acquisition, use, or disposition of
our assets that could have a material effect on the financial
statements.
|
Because of inherent limitations, internal controls over
financial reporting may not prevent or detect misstatements.
Projections of any evaluation of effectiveness to future periods
are subject to the risks that controls may become inadequate
because of changes in conditions or that the degree of
compliance with the policies or procedures may deteriorate.
Our management, including our Chief Executive and Chief
Financial Officers, assessed the effectiveness of our internal
control over financial reporting as of December 31, 2009,
and identified a material weakness in internal control over
financial reporting as of that date. A material weakness is a
deficiency, or combination of deficiencies, in internal control
over financial reporting such that there is a reasonable
possibility that a material misstatement of the annual or
interim financial statement will not be prevented or detected on
a timely basis. In making this assessment, we used the criteria
set forth by the Committee of Sponsoring Organizations of the
Treadway Commission (COSO), in Internal Control-Integrated
Framework. Because of the material weakness described below,
management concluded that, as of December 31, 2009, our
internal control over financial reporting was not effective.
Based upon managements evaluation, we concluded that we
did not maintain adequate and effective internal control in the
area of technical accounting relating to the application of
applicable accounting literature related to revenue recognition
for implementation fees. Specifically, the control deficiency
related to our interpretation of the Revenue Recognition Topic
of the FASB Accounting Standards Codification in
69
determining the proper period over which to amortize
implementation fees. It was discovered during the preparation of
our year-end financial statements for fiscal year 2009 that
certain prior technical accounting judgments and conclusions
related to revenue recognition were not supportable, leading
management to conclude that the execution of certain internal
control activities had not been adequate. Specifically, we
believe that, in the context of the rapid growth of our
business, we did not have sufficient staffing and technical
expertise in the area of revenue recognition accounting to
provide adequate review and control with respect to accounting
for implementation revenue accounting. The material weakness
contributed to material post-closing adjustments and restatement
of prior period financial statements, which have been reflected
in the financial statements for the three years ended
December 31, 2009.
Deloitte and Touche LLP, our independent registered public
accounting firm, has audited our consolidated financial
statements and the effectiveness of our internal control over
financial reporting as of December 31, 2009. This report
appears below.
Changes
in Internal Control over Financial Reporting
Other than as described below, there was no change in our
internal control over financial reporting during the fourth
quarter of 2009 that has materially affected, or is reasonably
likely to materially affect, our internal control over financial
reporting.
Remediation
of Material Weakness Technical Accounting Related to
Revenue Recognition for Implementation Fees
On February 25, 2010, we announced that we were conducting
an internal accounting policy review related to the timing of
amortization for deferred implementation revenue to determine
whether these policies were appropriate and in accordance with
the generally accepted accounting principles. As a result, under
the direction of the Audit Committee, we commenced a process to
review our deferred implementation revenue policies. On
March 15, 2010, we announced that certain previously issued
financial statements would be restated to correct items relating
to the timing of revenue recognition for implementation fees.
See the Explanatory Note Regarding Restatement
immediately preceding Part I, Item 1, and Note 2
of the Notes to Consolidated Financial Statements in
Part II, Item 8.
In connection with such review, we identified a control
deficiency relating to the application of applicable accounting
literature related to revenue recognition for implementation
fees. Specifically, the control deficiency related to our
interpretation of the Revenue Recognition topic of the FASB
Accounting Standards Codification in determining the proper
period over which to amortize implementation fees.
Management, with the input, oversight, and support of the Audit
Committee has identified and taken the following steps, which
management believes have corrected the material weakness
described above subsequent to December 31, 2009:
|
|
|
|
|
in January 2010, we hired a new Chief Financial Officer, who has
extensive experience leading the accounting and finance
functions at publicly traded companies and adds accounting
expertise to our staff;
|
|
|
|
in February 2010, we engaged external advisors knowledgeable in
revenue recognition to assist us in the interpretation of key
technical revenue recognition standards and associated
interpretations and the determination of how they apply to our
software-enabled service business model; and
|
|
|
|
we revised our internal training program to ensure that our
finance personnel have the competence and the on-going
accounting and financial reporting training necessary for their
assigned duties, including specific technical training courses
related to revenue recognition topics. To that end, we increased
our training budget significantly over the amount spent in 2009
for technical training and development.
|
70
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of athenahealth, Inc.
Watertown, Massachusetts
We have audited the internal control over financial reporting of
athenahealth, Inc. and subsidiaries (the Company) as
of December 31, 2009, based on criteria established in
Internal Control Integrated Framework
issued by the Committee of Sponsoring Organizations of the
Treadway Commission. The Companys management is
responsible for maintaining effective internal control over
financial reporting and for its assessment of the effectiveness
of internal control over financial reporting, included in the
accompanying Managements Report on Internal Control Over
Financial Reporting. Our responsibility is to express an opinion
on the Companys internal control over financial reporting
based on our audit.
We conducted our audit in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether effective internal control
over financial reporting was maintained in all material
respects. Our audit included obtaining an understanding of
internal control over financial reporting, assessing the risk
that a material weakness exists, testing and evaluating the
design and operating effectiveness of internal control based on
the assessed risk, and performing such other procedures as we
considered necessary in the circumstances. We believe that our
audit provides a reasonable basis for our opinion.
A companys internal control over financial reporting is a
process designed by, or under the supervision of, the
companys principal executive and principal financial
officers, or persons performing similar functions, and effected
by the companys board of directors, management, and other
personnel to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of
financial statements for external purposes in accordance with
generally accepted accounting principles. A companys
internal control over financial reporting includes those
policies and procedures that (1) pertain to the maintenance
of records that, in reasonable detail, accurately and fairly
reflect the transactions and dispositions of the assets of the
company; (2) provide reasonable assurance that transactions
are recorded as necessary to permit preparation of financial
statements in accordance with generally accepted accounting
principles, and that receipts and expenditures of the company
are being made only in accordance with authorizations of
management and directors of the company; and (3) provide
reasonable assurance regarding prevention or timely detection of
unauthorized acquisition, use, or disposition of the
companys assets that could have a material effect on the
financial statements.
Because of the inherent limitations of internal control over
financial reporting, including the possibility of collusion or
improper management override of controls, material misstatements
due to error or fraud may not be prevented or detected on a
timely basis. Also, projections of any evaluation of the
effectiveness of the internal control over financial reporting
to future periods are subject to the risk that the controls may
become inadequate because of changes in conditions, or that the
degree of compliance with the policies or procedures may
deteriorate.
A material weakness is a deficiency, or a combination of
deficiencies, in internal control over financial reporting, such
that there is a reasonable possibility that a material
misstatement of the companys annual or interim financial
statements will not be prevented or detected on a timely basis.
The following material weakness has been identified and included
in managements assessment:
The Company did not maintain effective internal control over
their application of applicable accounting literature related to
revenue recognition for implementation fees. The control
deficiency related to the Companys interpretation of the
Revenue Recognition Topic of the FASB Accounting Standards
Codification in determining the proper period over which to
amortize implementation fees. The material weakness contributed
to material post-closing adjustments and restatement of prior
period financial statements.
This material weakness was considered in determining the nature,
timing, and extent of audit tests applied in our audit of the
consolidated financial statements as of and for the year ended
December 31, 2009, of the Company and this report does not
affect our report on such financial statements.
In our opinion, because of the effect of the material weakness
identified above on the achievement of the objectives of the
control criteria, the Company has not maintained effective
internal control over financial reporting as of
December 31, 2009, based on the criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
consolidated financial statements as of and for the year ended
December 31, 2009 of the Company and our report dated
March 15, 2010, expressed an unqualified opinion on those
financial statements and included explanatory paragraphs
relating to the change in the companys method of
accounting for business combinations on January 1, 2009 and
the restatement of the Companys 2008 and 2007 consolidated
financial statements.
/s/ Deloitte &
Touche LLP
Boston, Massachusetts
March 15, 2010
71
|
|
Item 9B.
|
Other
Information.
|
Entry
into
Rule 10b5-1
Trading Plans
Our policy governing transactions in our securities by our
directors, officers, and employees permits our officers,
directors, and certain other persons to enter into trading plans
complying with
Rule 10b5-1
under the Securities Exchange Act of 1934, as amended. We have
been advised that a number of our employees, including members
of our senior management team, have entered into trading plans
in accordance with
Rule 10b5-1
and our policy governing transactions in our securities. We
undertake no obligation to update or revise the information
provided herein, including for revision or termination of an
established trading plan.
PART III
Certain information required by Part III of
Form 10-K
is omitted from this report because we expect to file a
definitive proxy statement for our 2010 Annual Meeting of
Stockholders (2010 Proxy Statement) within
120 days after the end of our fiscal year pursuant to
Regulation 14A promulgated under the Securities Exchange
Act of 1934, as amended, and the information included in our
2010 Proxy Statement is incorporated herein by reference to the
extent provided below.
|
|
Item 10.
|
Directors,
Executive Officers and Corporate Governance.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2010 Proxy
Statement.
We have adopted a code of ethics that applies to all of our
directors, officers, and employees. This code is publicly
available on our website at www.athenahealth.com.
Amendments to the code of ethics or any grant of a waiver
from a provision of the code requiring disclosure under
applicable SEC and NASDAQ Global Select Market rules will be
disclosed on our website or, if so required, disclosed in a
Current Report on
Form 8-K.
|
|
Item 11.
|
Executive
Compensation.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2010 Proxy
Statement.
|
|
Item 12.
|
Security
Ownership of Certain Beneficial Owners and Management and
Related Stockholder Matters.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2010 Proxy
Statement.
|
|
Item 13.
|
Certain
Relationships and Related Transactions, and Director
Independence.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2010 Proxy
Statement.
|
|
Item 14.
|
Principal
Accounting Fees and Services.
|
The information required by this Item is incorporated by
reference to the information to be contained in our 2010 Proxy
Statement.
72
PART IV
|
|
Item 15.
|
Exhibits,
Financial Statement Schedules.
|
a) Documents filed as part of this Report.
(1) The following consolidated financial statements are
filed herewith in Item 8 of Part II above.
(i) Report of Independent Registered Public Accounting Firm
(ii) Consolidated Balance Sheets
(iii) Consolidated Statements of Operations
(iv) Consolidated Statements of Changes in
Stockholders Equity (Deficit)
(v) Consolidated Statements of Cash Flows
(vi) Notes to Consolidated Financial Statements
(2) Financial Statement Schedules
All other supplemental schedules are omitted because of the
absence of conditions under which they are required or because
the required information is given in the financial statements or
notes thereto.
(3) Exhibits
|
|
|
Exhibit
|
|
|
No.
|
|
Exhibit Index
|
|
2.1(x)
|
|
Agreement and Plan of Merger by and among athenahealth, Inc.,
Aries Acquisition Corporation, Anodyne Health Partners, Inc.,
and the Securityholders Representatives named therein,
dated October 5, 2009
|
3.1(i)
|
|
Amended and Restated Certificate of Incorporation of the
Registrant
|
3.2(i)
|
|
Amended and Restated Bylaws of the Registrant
|
4.1(i)
|
|
Specimen Certificate evidencing shares of common stock
|
10.1(i)
|
|
Form of Indemnification Agreement, to be entered into between
the Registrant and each of its directors and officers
|
10.2(i)
|
|
1997 Stock Plan of the Registrant and form of agreements
thereunder
|
10.3(i)
|
|
2000 Stock Option and Incentive Plan of the Registrant, as
amended, and form of agreements thereunder
|
10.4(i)(xi)
|
|
2007 Stock Option and Incentive Plan of the Registrant, and form
of agreements thereunder
|
10.5(viii)
|
|
2007 Employee Stock Purchase Plan, as amended
|
10.6(viii)
|
|
Employment Agreement by and between the Registrant and Nancy G.
Brown, dated August 2, 2004, as amended
|
10.7(i)
|
|
Employment Agreement by and between the Registrant and Jonathan
Bush, dated November 1, 1999, as amended
|
10.8(iv)
|
|
Employment Agreement by and between the Registrant and Robert L.
Cosinuke, dated December 3, 2007
|
10.9(xi)
|
|
Employment Agreement by and between the Registrant and Dawn
Griffiths, dated May 30, 2008
|
10.10(viii)
|
|
Employment Agreement by and between the Registrant and Robert M.
Hueber, dated September 16, 2002, as amended
|
10.11(viii)
|
|
Employment Agreement by and between the Registrant and David
Robinson, dated February 24, 2009
|
10.12(iii)
|
|
Management Incentive Compensation Plan of the Registrant,
adopted April 11, 2008
|
10.13(vii)
|
|
Director Compensation Plan of the Registrant, dated December 17,
2008
|
10.14(i)
|
|
Warrant to Purchase 32,468 Shares of the Registrants
Series D Convertible Preferred Stock, issued to GATX Ventures,
Inc. on May 31, 2001
|
73
|
|
|
Exhibit
|
|
|
No.
|
|
Exhibit Index
|
|
#10.15(i)
|
|
Lease between President and Fellows of Harvard College and the
Registrant, dated November 8, 2004, for space at the premises
located at 300 North Beacon Street, Watertown, MA 02472 and 311
Arsenal Street, Watertown, MA 02472
|
10.16(ix)
|
|
Deed of Lease by and between RMZ Infotech Private Limited and
Athena Net India Private Limited, dated April 28, 2009, for
space at the premises located at Unit No. 701, Campus 3B, RMZ
Millenia Tech Park, 143, Dr.MGR Road, Perungudi, Chennai 600 113
|
#10.17(i)
|
|
Agreement of Lease by and between Sentinel Properties --
Bedford, LLC and the Registrant, dated May 8, 2007
|
10.18(vi)(xi)
|
|
Credit Agreement by and between the Registrant and Bank of
America, N.A., as Administrative Agent, Swing Line Lender and
L/C Issuer, dated September 30, 2008, and exhibits and schedules
thereunder
|
10.19(vi)
|
|
Security Agreement by and between the Registrant and Bank of
America, N.A., as Administrative Agent, dated September 30, 2008
|
10.20(vi)
|
|
Term Note by and between the Registrant and Bank of America,
N.A., dated September 30, 2008
|
10.21(xi)
|
|
First Amendment to Credit Agreement by and between the
Registrant and Bank of America, N.A., as Administrative Agent,
Swing Line Lender and L/C Issuer, dated December 12, 2008
|
10.22(x)
|
|
Second Amendment to Credit Agreement and Limited Waiver by and
between the Registrant and Bank of America, N.A., as
Administrative Agent, Swing Line Lender and L/C Issuer, dated
October 5, 2009
|
#10.23(i)
|
|
Amended and Restated Marketing and Sales Agreement by and
between the Registrant and WorldMed Shared Services, Inc. (d/b/a
PSS World Medical Shared Services, Inc.) dated May 24, 2007
|
10.24**
|
|
Master Equipment Lease Agreement by and between CIT Technologies
Corporation and the Registrant, dated June 1, 2007
|
10.25(ii)
|
|
Purchase Agreement dated November 28, 2007, between the
Registrant and Bracebridge Corporation
|
#10.26(v)
|
|
Master Agreement by and between the Registrant and Vision
Business Process Solutions Inc., dated June 30, 2008
|
#10.27**
|
|
Professional Services Agreement by and between the Registrant
and International Business Machines Corporation dated as of
October 2, 2009
|
#10.28**
|
|
Master Agreement for U.S. Availability Services between SunGard
Availability Services LP and the Registrant, dated December 1,
2009, as amended
|
21.1**
|
|
Subsidiaries of the Registrant
|
23.1**
|
|
Consent of Independent Registered Public Accounting Firm
|
31.1**
|
|
Rule 13a-14(a) or 15d-14 Certification of Chief Executive Officer
|
31.2**
|
|
Rule 13a-14(a) or 15d-14 Certification of Chief Financial Officer
|
32.1**
|
|
Certifications of Chief Executive Officer and Chief Financial
Officer pursuant to Exchange Act rules 13a-14(b) or 15d-14(b)
and 18 U.S.C. Section 1350
|
|
|
|
Indicates a management contract or any compensatory plan,
contract, or arrangement.
|
|
#
|
Application has been made to the Securities and Exchange
Commission for confidential treatment of certain provisions.
Omitted material for which confidential treatment has been
requested has been filed separately with the Securities and
Exchange Commission.
|
|
(i)
|
Incorporated by reference to the Registrants registration
statement on
Form S-1
(File
No. 333-143998)
|
|
(ii)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed November 29, 2007.
|
|
(iii)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed April 17, 2008.
|
74
|
|
(iv)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed May 6, 2008.
|
|
(v)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed August 5, 2008.
|
|
(vi)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed November 7, 2008.
|
|
(vii)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed December 23, 2008.
|
|
(viii)
|
Incorporated by reference to the Registrants annual report
on
Form 10-K,
filed March 2, 2009.
|
|
(ix)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed August 6, 2009.
|
|
(x)
|
Incorporated by reference to the Registrants current
report on
Form 8-K,
filed October 5, 2009.
|
|
(xi)
|
Incorporated by reference to the Registrants quarterly
report on
Form 10-Q,
filed October 30, 2009.
|
|
**
|
Filed herewith
|
75
SIGNATURES
Pursuant to the requirements of Section 13 or 15(d) of the
Securities Exchange Act of 1934, the registrant has duly caused
this report to be signed on its behalf by the undersigned,
thereunto duly authorized.
ATHENAHEALTH, INC.
Jonathan Bush
Chief Executive Officer, President, and Chairman
Timothy M. Adams
Chief Financial Officer and Senior Vice President
Dawn Griffiths
Principal Accounting Officer,
Treasurer, and Vice President
Date: March 15, 2010
Pursuant to the requirements of the Securities Exchange Act of
1934, this report has been signed below by the following persons
on behalf of the registrant and in the capacities and on the
dates indicated.
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Jonathan
Bush
(Jonathan
Bush)
|
|
Chief Executive Officer, President, and Chairman (Principal
Executive Officer)
|
|
March 15, 2010
|
|
|
|
|
|
/s/ Timothy
M. Adams
(Timothy
M. Adams)
|
|
Chief Financial Officer and Senior Vice President (Principal
Financial Officer)
|
|
March 15, 2010
|
|
|
|
|
|
/s/ Dawn
Griffiths
(Dawn
Griffiths)
|
|
Treasurer and Vice President (Principal Accounting Officer)
|
|
March 15, 2010
|
|
|
|
|
|
/s/ Ruben
J. King-Shaw, Jr.
(Ruben
J. King-Shaw, Jr.)
|
|
Lead Director
|
|
March 15, 2010
|
|
|
|
|
|
/s/ Richard
N. Foster
(Richard
N. Foster)
|
|
Director
|
|
March 15, 2010
|
|
|
|
|
|
/s/ Brandon
H. Hull
(Brandon
H. Hull)
|
|
Director
|
|
March 15, 2010
|
|
|
|
|
|
/s/ John
A. Kane
(John
A. Kane)
|
|
Director
|
|
March 15, 2010
|
76
|
|
|
|
|
|
|
Signature
|
|
Title
|
|
Date
|
|
|
|
|
|
|
/s/ Ann
H. Lamont
(Ann
H. Lamont)
|
|
Director
|
|
March 15, 2010
|
|
|
|
|
|
/s/ James
L. Mann
(James
L. Mann)
|
|
Director
|
|
March 15, 2010
|
|
|
|
|
|
/s/ William
Winkenwerder, Jr., M.D.
(William
Winkenwerder, Jr., M.D.)
|
|
Director
|
|
March 15, 2010
|
77
Financial
Statements and Supplementary Data
athenahealth,
Inc.
INDEX TO
CONSOLIDATED FINANCIAL STATEMENTS
Contents
|
|
|
|
|
|
|
|
F-2
|
|
Financial Statements
|
|
|
|
|
|
|
|
F-3
|
|
|
|
|
F-4
|
|
|
|
|
F-5
|
|
|
|
|
F-6
|
|
|
|
|
F-7
|
|
F-1
REPORT OF
INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
To the Board of Directors and Stockholders of
athenahealth, Inc.
Watertown, Massachusetts
We have audited the accompanying consolidated balance sheets of
athenahealth, Inc. and subsidiaries (the Company) as
of December 31, 2009 and 2008, and the related consolidated
statements of operations, stockholders equity (deficit),
and cash flows for each of the three years in the period ended
December 31, 2009. These consolidated financial statements
are the responsibility of the Companys management. Our
responsibility is to express an opinion on these consolidated
financial statements based on our audits.
We conducted our audits in accordance with the standards of the
Public Company Accounting Oversight Board (United States). Those
standards require that we plan and perform the audit to obtain
reasonable assurance about whether the consolidated financial
statements are free of material misstatement. An audit includes
examining, on a test basis, evidence supporting the amounts and
disclosures in the consolidated financial statements. An audit
also includes assessing the accounting principles used and
significant estimates made by management, as well as evaluating
the overall financial statement presentation. We believe that
our audits provide a reasonable basis for our opinion.
In our opinion, such consolidated financial statements present
fairly, in all material respects, the financial position of
athenahealth, Inc. and its subsidiaries as of December 31,
2009 and 2008, and the results of their operations and their
cash flows for each of the three years in the period ended
December 31, 2009, in conformity with accounting principles
generally accepted in the United States of America.
As discussed in Note 3 to the consolidated financial
statements, the company changed its method of accounting for
business combinations on January 1, 2009.
As discussed in Note 2 to the consolidated financial
statements, the accompanying 2008 and 2007 consolidated
financial statement have been restated.
We have also audited, in accordance with the standards of the
Public Company Accounting Oversight Board (United States), the
Companys internal control over financial reporting as of
December 31, 2009, based on the criteria established in
Internal Control Integrated Framework issued
by the Committee of Sponsoring Organizations of the Treadway
Commission and our report dated March 15, 2010, expressed
an adverse opinion on the Companys internal control over
financial reporting because of a material weakness.
/s/ Deloitte &
Touche LLP
Boston, Massachusetts
March 15, 2010
F-2
|
|
|
|
|
|
|
|
|
|
|
December 31
|
|
|
December 31
|
|
|
|
2009
|
|
|
2008
|
|
|
|
|
|
|
(As restated)(1)
|
|
|
|
(In thousands)
|
|
|
ASSETS
|
Current assets:
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
30,526
|
|
|
$
|
28,933
|
|
Short-term investments
|
|
|
52,323
|
|
|
|
58,061
|
|
Accounts receivable net
|
|
|
33,323
|
|
|
|
23,236
|
|
Deferred tax assets
|
|
|
5,544
|
|
|
|
9,962
|
|
Prepaid expenses and other current assets
|
|
|
4,663
|
|
|
|
3,624
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
126,379
|
|
|
|
123,816
|
|
Property and equipment net
|
|
|
24,871
|
|
|
|
20,871
|
|
Restricted cash
|
|
|
9,216
|
|
|
|
1,848
|
|
Software development costs net
|
|
|
2,324
|
|
|
|
1,879
|
|
Purchased intangibles net
|
|
|
14,490
|
|
|
|
1,925
|
|
Goodwill
|
|
|
22,120
|
|
|
|
4,887
|
|
Deferred tax assets
|
|
|
10,284
|
|
|
|
13,683
|
|
Other assets
|
|
|
1,393
|
|
|
|
662
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
211,077
|
|
|
$
|
169,571
|
|
|
|
|
|
|
|
|
|
|
|
LIABILITIES AND STOCKHOLDERS EQUITY
|
Current liabilities:
|
|
|
|
|
|
|
|
|
Current portion of long-term debt and capital lease obligations
|
|
$
|
3,437
|
|
|
$
|
2,038
|
|
Accounts payable
|
|
|
1,880
|
|
|
|
803
|
|
Accrued compensation
|
|
|
15,774
|
|
|
|
10,154
|
|
Accrued expenses
|
|
|
10,781
|
|
|
|
7,442
|
|
Current portion of deferred revenue
|
|
|
4,038
|
|
|
|
2,848
|
|
Interest rate derivative liability
|
|
|
291
|
|
|
|
881
|
|
Current portion of deferred rent
|
|
|
1,288
|
|
|
|
1,144
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
37,489
|
|
|
|
25,310
|
|
Deferred rent, net of current portion
|
|
|
7,444
|
|
|
|
8,662
|
|
Deferred revenue, net of current portion
|
|
|
28,684
|
|
|
|
22,186
|
|
Other long-term liabilities
|
|
|
1,191
|
|
|
|
|
|
Debt and capital lease obligations, net of current portion
|
|
|
8,951
|
|
|
|
8,378
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
83,759
|
|
|
|
64,536
|
|
|
|
|
|
|
|
|
|
|
Commitments and contingencies (see notes to financial statements)
|
|
|
|
|
|
|
|
|
Preferred stock; $0.01 par value: 5,000 shares
authorized and no shares issued and outstanding at
December 31, 2009 and 2008, respectively
|
|
|
|
|
|
|
|
|
Common stock; $0.01 par value per share;
125,000 shares authorized;
|
|
|
|
|
|
|
|
|
35,166 shares issued and 33,888 shares outstanding at
December 31, 2009
|
|
|
|
|
|
|
|
|
34,645 shares issued and 33,367 shares outstanding at
December 31, 2008
|
|
|
352
|
|
|
|
346
|
|
Additional paid-in capital
|
|
|
169,715
|
|
|
|
156,303
|
|
Treasury stock, at cost, 1,278 shares
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
Accumulated other comprehensive (loss) income
|
|
|
(73
|
)
|
|
|
338
|
|
Accumulated deficit
|
|
|
(41,476
|
)
|
|
|
(50,752
|
)
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
127,318
|
|
|
|
105,035
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
211,077
|
|
|
$
|
169,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2 Restatement and Reclassifications of
Previously Issued Consolidated Financial Statements of
Notes to Consolidated Financial Statements. |
See notes to consolidated financial statements.
F-3
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(As restated)(1)
|
|
|
(As restated)(1)
|
|
|
|
(In thousands, except per share amounts)
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
183,230
|
|
|
$
|
131,879
|
|
|
$
|
94,182
|
|
Implementation and other
|
|
|
5,297
|
|
|
|
4,403
|
|
|
|
3,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
188,527
|
|
|
|
136,282
|
|
|
|
97,618
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
79,017
|
|
|
|
59,947
|
|
|
|
46,978
|
|
Selling and marketing
|
|
|
34,072
|
|
|
|
22,827
|
|
|
|
17,212
|
|
Research and development
|
|
|
14,348
|
|
|
|
10,600
|
|
|
|
7,476
|
|
General and administrative
|
|
|
36,111
|
|
|
|
29,330
|
|
|
|
19,922
|
|
Depreciation and amortization
|
|
|
7,767
|
|
|
|
5,993
|
|
|
|
5,541
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
171,315
|
|
|
|
128,697
|
|
|
|
97,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
17,212
|
|
|
|
7,585
|
|
|
|
489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
1,016
|
|
|
|
1,942
|
|
|
|
1,415
|
|
Interest expense
|
|
|
(968
|
)
|
|
|
(428
|
)
|
|
|
(3,682
|
)
|
Gain (loss) on interest rate derivative contract
|
|
|
590
|
|
|
|
(881
|
)
|
|
|
|
|
Other income (expense)
|
|
|
255
|
|
|
|
182
|
|
|
|
(5,689
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
893
|
|
|
|
815
|
|
|
|
(7,956
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax (provision) benefit
|
|
|
18,105
|
|
|
|
8,400
|
|
|
|
(7,467
|
)
|
Income tax (provision) benefit
|
|
|
(8,829
|
)
|
|
|
23,202
|
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
|
9,276
|
|
|
|
31,602
|
|
|
|
(7,501
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income (loss) per
share:
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
12,568
|
|
Diluted
|
|
|
34,917
|
|
|
|
34,777
|
|
|
|
12,568
|
|
|
|
|
(1) |
|
See Note 2 Restatement and Reclassifications of
Previously Issued Consolidated Financial Statements of
Notes to Consolidated Financial Statements |
See notes to consolidated financial statements.
F-4
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Additional
|
|
|
|
|
|
|
|
|
Other
|
|
|
|
|
|
Total
|
|
|
Total
|
|
|
|
Common Stock
|
|
|
Paid-In
|
|
|
Treasury Stock
|
|
|
Comprehensive
|
|
|
Accumulated
|
|
|
Stockholders
|
|
|
Comprehensive
|
|
|
|
Shares
|
|
|
Amount
|
|
|
Capital
|
|
|
Shares
|
|
|
Amount
|
|
|
Income (Loss)
|
|
|
Deficit
|
|
|
Equity (Deficit)
|
|
|
Income (Loss)
|
|
|
BALANCE January 1, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As previously reported
|
|
|
5,281
|
|
|
$
|
53
|
|
|
$
|
2,090
|
|
|
|
(1,278
|
)
|
|
$
|
(1,200
|
)
|
|
$
|
(34
|
)
|
|
$
|
(65,180
|
)
|
|
$
|
(64,271
|
)
|
|
|
|
|
Prior period adjustments(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
(9,673
|
)
|
|
$
|
(9,673
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE January 1, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As restated(1)
|
|
|
5,281
|
|
|
|
53
|
|
|
|
2,090
|
|
|
|
(1,278
|
)
|
|
|
(1,200
|
)
|
|
|
(34
|
)
|
|
|
(74,853
|
)
|
|
|
(73,944
|
)
|
|
|
|
|
Stock compensation expense
|
|
|
|
|
|
|
|
|
|
|
1,311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,311
|
|
|
|
|
|
Stock options and warrants exercised
|
|
|
1,000
|
|
|
|
10
|
|
|
|
2,442
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,452
|
|
|
|
|
|
Shareholder contribution of capital
|
|
|
|
|
|
|
|
|
|
|
592
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
592
|
|
|
|
|
|
Shares issued in initial public offering, net of expenses
|
|
|
5,000
|
|
|
|
50
|
|
|
|
81,237
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
81,287
|
|
|
|
|
|
Conversion of convertible preferred stock to common stock
|
|
|
22,332
|
|
|
|
223
|
|
|
|
49,871
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
50,094
|
|
|
|
|
|
Reclassification of warrant liability to additional paid-in
capital
|
|
|
|
|
|
|
|
|
|
|
7,451
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,451
|
|
|
|
|
|
Net loss(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,501
|
)
|
|
|
(7,501
|
)
|
|
$
|
(7,501
|
)
|
Unrealized holding gain on available-for-sale-investments, net
of tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
34
|
|
|
|
|
|
|
|
34
|
|
|
|
34
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
72
|
|
|
|
|
|
|
|
72
|
|
|
|
72
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Loss(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,395
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2007(1)
|
|
|
33,613
|
|
|
|
336
|
|
|
|
144,994
|
|
|
|
(1,278
|
)
|
|
|
(1,200
|
)
|
|
|
72
|
|
|
|
(82,354
|
)
|
|
|
61,848
|
|
|
|
|
|
Stock compensation expense
|
|
|
|
|
|
|
|
|
|
|
5,558
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,558
|
|
|
|
|
|
Stock options and warrants exercised
|
|
|
1,021
|
|
|
|
10
|
|
|
|
4,908
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
4,918
|
|
|
|
|
|
Common stock issued under employee stock purchase plan
|
|
|
11
|
|
|
|
|
|
|
|
317
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
317
|
|
|
|
|
|
Tax benefit realized from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
526
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
526
|
|
|
|
|
|
Net income(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,602
|
|
|
|
31,602
|
|
|
|
31,602
|
|
Unrealized holding gain on available-for-sale-investments, net
of $188 tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
288
|
|
|
|
|
|
|
|
288
|
|
|
|
288
|
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(22
|
)
|
|
|
|
|
|
|
(22
|
)
|
|
|
(22
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income(1)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
31,868
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2008(1)
|
|
|
34,645
|
|
|
|
346
|
|
|
|
156,303
|
|
|
|
(1,278
|
)
|
|
|
(1,200
|
)
|
|
|
338
|
|
|
|
(50,752
|
)
|
|
|
105,035
|
|
|
|
|
|
Stock compensation expense
|
|
|
|
|
|
|
|
|
|
|
8,314
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
8,314
|
|
|
|
|
|
Stock options exercised
|
|
|
488
|
|
|
|
5
|
|
|
|
1,890
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,895
|
|
|
|
|
|
Common stock issued under employee stock purchase plan
|
|
|
33
|
|
|
|
1
|
|
|
|
780
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
781
|
|
|
|
|
|
Tax benefit realized from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
2,428
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,428
|
|
|
|
|
|
Net income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
9,276
|
|
|
|
9,276
|
|
|
|
9,276
|
|
Unrealized holding gain on available-for-sale-investments, net
of $17 tax
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(262
|
)
|
|
|
|
|
|
|
(262
|
)
|
|
|
(262
|
)
|
Foreign currency translation adjustment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(149
|
)
|
|
|
|
|
|
|
(149
|
)
|
|
|
(149
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total Comprehensive Income
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
8,865
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
BALANCE December 31, 2009
|
|
|
35,166
|
|
|
$
|
352
|
|
|
$
|
169,715
|
|
|
|
(1,278
|
)
|
|
$
|
(1,200
|
)
|
|
$
|
(73
|
)
|
|
$
|
(41,476
|
)
|
|
$
|
127,318
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2 Restatement and Reclassifications of
Previously Issued Consolidated Financial Statements of
Notes to Consolidated Financial Statements |
See notes to consolidated financial statements.
F-5
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(As restated)(1)
|
|
|
(As restated)(1)
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
Adjustments to reconcile net income (loss) to net cash provided
by operating activities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Depreciation and amortization
|
|
|
8,403
|
|
|
|
6,095
|
|
|
|
5,541
|
|
Accretion of debt discount
|
|
|
|
|
|
|
|
|
|
|
413
|
|
Amortization of discounts on investments
|
|
|
(113
|
)
|
|
|
(899
|
)
|
|
|
(74
|
)
|
Financial advisor fee paid by investor
|
|
|
|
|
|
|
|
|
|
|
592
|
|
Provision for uncollectible accounts
|
|
|
999
|
|
|
|
405
|
|
|
|
524
|
|
Non-cash warrant expense
|
|
|
|
|
|
|
|
|
|
|
4,995
|
|
(Gain) loss on interest rate derivative contract
|
|
|
(590
|
)
|
|
|
881
|
|
|
|
|
|
Deferred income taxes
|
|
|
5,918
|
|
|
|
(23,833
|
)
|
|
|
|
|
Excess tax benefit from stock-based awards
|
|
|
(2,505
|
)
|
|
|
(526
|
)
|
|
|
|
|
Stock-based compensation expense
|
|
|
8,314
|
|
|
|
5,558
|
|
|
|
1,311
|
|
(Gain) loss on disposal of property and equipment
|
|
|
276
|
|
|
|
(47
|
)
|
|
|
102
|
|
Changes in operating assets and liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Accounts receivable
|
|
|
(10,489
|
)
|
|
|
(9,254
|
)
|
|
|
(4,670
|
)
|
Prepaid expenses and other current assets
|
|
|
(887
|
)
|
|
|
(912
|
)
|
|
|
(1,033
|
)
|
Accounts payable
|
|
|
1,379
|
|
|
|
(1,195
|
)
|
|
|
52
|
|
Other assets
|
|
|
(173
|
)
|
|
|
86
|
|
|
|
162
|
|
Accrued expenses
|
|
|
6,201
|
|
|
|
7,424
|
|
|
|
2,587
|
|
Deferred revenue
|
|
|
7,438
|
|
|
|
7,120
|
|
|
|
4,626
|
|
Deferred rent
|
|
|
(1,118
|
)
|
|
|
(1,446
|
)
|
|
|
(804
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
32,329
|
|
|
|
21,059
|
|
|
|
6,823
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Capitalized software development costs
|
|
|
(2,555
|
)
|
|
|
(1,393
|
)
|
|
|
(1,090
|
)
|
Purchases of property and equipment
|
|
|
(10,277
|
)
|
|
|
(13,452
|
)
|
|
|
(2,693
|
)
|
Proceeds from sales and disposals of property and equipment
|
|
|
4,538
|
|
|
|
4,112
|
|
|
|
1,456
|
|
Purchase in long-term investment
|
|
|
(550
|
)
|
|
|
(550
|
)
|
|
|
|
|
Proceeds from sales and maturities of short-term investments
|
|
|
84,014
|
|
|
|
73,250
|
|
|
|
7,603
|
|
Purchases of short term investments
|
|
|
(78,588
|
)
|
|
|
(129,935
|
)
|
|
|
(1,949
|
)
|
Payments for acquisitions net of cash acquired
|
|
|
(22,391
|
)
|
|
|
(6,680
|
)
|
|
|
|
|
(Increase) decrease in restricted cash
|
|
|
(7,368
|
)
|
|
|
(136
|
)
|
|
|
1,457
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) provided by investing activities
|
|
|
(33,177
|
)
|
|
|
(74,784
|
)
|
|
|
4,784
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options and warrants
|
|
|
2,676
|
|
|
|
5,235
|
|
|
|
2,452
|
|
Proceeds of initial public offering, net of issuance costs
|
|
|
|
|
|
|
|
|
|
|
81,287
|
|
Debt issuance costs
|
|
|
|
|
|
|
(177
|
)
|
|
|
|
|
Excess tax benefit from stock-based awards
|
|
|
2,505
|
|
|
|
526
|
|
|
|
|
|
Proceeds from long-term debt
|
|
|
|
|
|
|
6,000
|
|
|
|
4,249
|
|
Proceeds from line of credit
|
|
|
|
|
|
|
|
|
|
|
5,914
|
|
Payments on long term debt and capital lease obligations
|
|
|
(2,514
|
)
|
|
|
(777
|
)
|
|
|
(24,776
|
)
|
Payments on line of credit
|
|
|
|
|
|
|
|
|
|
|
(13,118
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by financing activities
|
|
|
2,667
|
|
|
|
10,807
|
|
|
|
56,008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects of exchange rate changes on cash and cash equivalents
|
|
|
(226
|
)
|
|
|
(40
|
)
|
|
|
85
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net increase (decrease) in cash and cash equivalents
|
|
|
1,593
|
|
|
|
(42,958
|
)
|
|
|
67,700
|
|
Cash and cash equivalents at beginning of year
|
|
|
28,933
|
|
|
|
71,891
|
|
|
|
4,191
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of year
|
|
$
|
30,526
|
|
|
$
|
28,933
|
|
|
$
|
71,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosures of non-cash investing
activities Property and equipment recorded in
accounts payable and accrued expenses
|
|
$
|
510
|
|
|
$
|
998
|
|
|
$
|
48
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Cash paid for interest
|
|
$
|
836
|
|
|
$
|
324
|
|
|
$
|
3,666
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Non-cash investing
activities Contingent Consideration
|
|
$
|
5,100
|
|
|
$
|
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Supplemental disclosure Cash paid for taxes
|
|
$
|
514
|
|
|
$
|
403
|
|
|
$
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Property and equipment acquired under capital leases
|
|
$
|
4,538
|
|
|
$
|
3,795
|
|
|
$
|
1,456
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
See Note 2 Restatement and Reclassifications of
Previously Issued Consolidated Financial Statements of
Notes to Consolidated Financial Statements |
See notes to consolidated financial statements.
F-6
athenahealth,
Inc.
(Amounts in thousands, except per-share amounts)
|
|
1.
|
BUSINESS
AND ORGANIZATION
|
General athenahealth, Inc. (the
Company, we, us, or
our) is a business services company that provides
ongoing billing, clinical-related, and other related services to
its customers. The Company provides these services with the use
of athenaNet, a proprietary Internet-based practice management
application. The Companys customers consist of medical
group practices ranging in size throughout the United States of
America.
In August 2005, the Company established a subsidiary in Chennai,
India, athenahealth Technology Private Limited, to conduct
research and development activities. On April 10, 2009, the
Company established a Massachusetts corporation, athenahealth
MA, Inc., to hold a share of common stock of athenahealth
Technology Private Limited.
On October 16, 2009, the Company acquired Anodyne Health
Partners, Inc. (Anodyne). The Company paid cash for
Anodyne. For financial reporting purposes, the acquisition was
accounted for using the acquisition method of accounting in
accordance with the guidance on business combinations.
Initial Public Offering On September 25,
2007, the Company raised $90,000 in gross proceeds from the sale
of 5,000 shares of its common stock in an initial public
offering (IPO) at $18.00 per share. The net offering
proceeds after deducting approximately $8,713 in
offering-related expenses and underwriters discount were
approximately $81,287. All outstanding shares of the
Companys convertible preferred stock were converted into
21,531 shares of common stock upon completion of the IPO.
Risks and Uncertainties The Company is
subject to risks common to companies in similar industries and
stages of development, including, but not limited to,
competition from larger companies, a volatile market for its
services, new technological innovations, dependence on key
personnel, third-party service providers and vendors, protection
of proprietary technology, fluctuations in operating results,
dependence on market acceptance of its products, and compliance
with government regulations.
|
|
2.
|
RESTATEMENT
AND RECLASSIFICATION OF PREVIOUSLY ISSUED CONSOLIDATED FINANCIAL
STATEMENTS
|
On March 9, 2010, we concluded that we needed to restate
our previously issued consolidated financial statements for the
years ended December 31, 2008 and 2007. We have also
concluded to restate our previously issued condensed
consolidated financial statements for the first, second, and
third quarters of 2009 and each of the quarters in 2008. (See
Note 20, Summarized Quarterly Unaudited Financial
Data, for information related to each of the restated
quarters.) The restatements resulted primarily from a correction
in the timing of revenue recognition of deferred implementation
fees.
As part of the process to finalize our financial results for the
year ended December 31, 2009, we undertook a comprehensive
review of our significant accounting policies. As a result of
our review, we concluded that, in prior and future periods, we
will amortize deferred implementation revenue over a longer
expected performance period of twelve years in order to reflect
the estimated expected customer life. Previously, the expected
performance period was estimated based upon the initial customer
contract term, which, for the vast majority of contracts, was
one year in duration. As a result of these adjustments, we also
revised our previously calculated income tax expense for each
quarter in 2009 and 2008. The pretax effect of the restatement
adjustments on years and quarters prior to December 31,
2008, had the effect of increasing pretax losses and deferred
tax assets. Because sufficient positive evidence that such
deferred tax assets would be realized did not exist until
December 31, 2008, no tax benefits for the additional
deferred tax assets resulting from the restatement adjustments
were recognized in periods prior to December 31, 2008. At
December 31, 2008, the entire valuation allowance relating
to deferred tax assets was reversed and, therefore, the effect
of the 2008 restatement adjustment includes a $7,149 tax benefit
relating to the recognition of deferred tax assets arising from
the restatement that were generated in prior years. The
restatement adjustments result in a cumulative net reduction to
previously reported shareholders equity of approximately
$10,940 and $13,671 as of December 31, 2008 and 2007,
respectively, and an increase in previously reported net income
F-7
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
by $2,731 for the year ended December 31, 2008 and a
reduction in previously reported net income by $3,998 for the
year ended December 31, 2007. We have also restated the
January 1, 2007 opening retained earnings balance to
recognize the impact of the restatement adjustments that relate
to prior periods. Except as otherwise specified, all information
presented in the consolidated financial statements and the
related notes include all such restatement adjustments.
In addition, in connection with the restatement, we have
corrected previously issued financial statements for the
following reclassification items none of which had any effect on
net income or shareholders equity for any period:
a) Reimbursements of out of pocket (pass
through) expenses which were previously netted against
operating expense have been grossed up and included in
Implementation and other revenue in the consolidated statements
of operations, b) Certain deferred tax liabilities have
been reclassified from non-current to current in the
consolidated statements of financial position, c) Draw
downs of the capital leased lines which were previously
presented as sources of cash within the financing
activities section of the consolidated statements of cash
flows have been reclassified as investing activities
and d) the excess tax benefit from stock-based awards which
were previously presented as sources of cash within the
operating activities section of the consolidated
statements of cash flows in the accrued expense line have been
reclassified as operating activities in the excess
tax benefit from stock-based awards line item.
The following tables summarize the effects of the restatement
and presentation reclassifications on our previously issued
consolidated financial statements:
Summary
of increases (decreases) in Net Income (Loss) for the years
ended December 31, 2008 and 2007
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
|
(In thousands, except per share amounts)
|
|
|
Net income (loss), as previously reported
|
|
$
|
28,871
|
|
|
$
|
(3,503
|
)
|
Net adjustments
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(4,418
|
)
|
|
|
(3,998
|
)
|
Income tax provision
|
|
|
7,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), restated
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
|
|
|
|
|
|
|
|
|
Basic earning (loss) per common share:
|
|
|
|
|
|
|
|
|
Net income (loss), as previously reported
|
|
$
|
0.88
|
|
|
$
|
(0.28
|
)
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(0.13
|
)
|
|
|
(0.32
|
)
|
Income tax provision
|
|
|
0.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), restated
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
Diluted earning (loss) per common share:
|
|
|
|
|
|
|
|
|
Net income (loss), as previously reported
|
|
$
|
0.83
|
|
|
$
|
(0.28
|
)
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(0.13
|
)
|
|
|
(0.32
|
)
|
Income tax provision
|
|
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), restated
|
|
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income (loss) per
share:
|
|
|
|
|
|
|
|
|
Basic
|
|
|
32,746
|
|
|
|
12,568
|
|
Diluted
|
|
|
34,777
|
|
|
|
12,568
|
|
F-8
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table sets forth the effects of the restatement
adjustments on our Accumulated deficit as of
January 1, 2007.
|
|
|
|
|
|
|
Amount
|
|
|
Accumulated deficit, January 1, 2007, as previously reported
|
|
$
|
(65,180
|
)
|
Restatement adjustments:
|
|
|
|
|
Implementation revenue
|
|
|
(9,673
|
)
|
|
|
|
|
|
Accumulated deficit, January 1, 2007, as restated
|
|
$
|
(74,853
|
)
|
|
|
|
|
|
Consolidated
Balance Sheet impact as of December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008
|
|
|
|
As Previously
|
|
|
|
|
|
As
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
Restated
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
28,933
|
|
|
$
|
|
|
|
$
|
28,933
|
|
Short-term investments
|
|
|
58,061
|
|
|
|
|
|
|
|
58,061
|
|
Accounts receivable net
|
|
|
23,236
|
|
|
|
|
|
|
|
23,236
|
|
Deferred tax assets
|
|
|
8,499
|
|
|
|
1,463
|
|
|
|
9,962
|
|
Prepaid expenses and other current assets
|
|
|
3,624
|
|
|
|
|
|
|
|
3,624
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
122,353
|
|
|
|
1,463
|
|
|
|
123,816
|
|
Property and equipment net
|
|
|
20,871
|
|
|
|
|
|
|
|
20,871
|
|
Restricted cash
|
|
|
1,848
|
|
|
|
|
|
|
|
1,848
|
|
Software development costs net
|
|
|
1,879
|
|
|
|
|
|
|
|
1,879
|
|
Purchased intangibles net
|
|
|
1,925
|
|
|
|
|
|
|
|
1,925
|
|
Goodwill
|
|
|
4,887
|
|
|
|
|
|
|
|
4,887
|
|
Deferred tax assets
|
|
|
7,997
|
|
|
|
5,686
|
|
|
|
13,683
|
|
Other assets
|
|
|
662
|
|
|
|
|
|
|
|
662
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
162,422
|
|
|
$
|
7,149
|
|
|
$
|
169,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt and capital lease obligations
|
|
$
|
2,038
|
|
|
$
|
|
|
|
$
|
2,038
|
|
Accounts payable
|
|
|
803
|
|
|
|
|
|
|
|
803
|
|
Accrued compensation
|
|
|
10,154
|
|
|
|
|
|
|
|
10,154
|
|
Accrued expenses
|
|
|
7,442
|
|
|
|
|
|
|
|
7,442
|
|
Current portion of deferred revenue
|
|
|
6,945
|
|
|
|
(4,097
|
)
|
|
|
2,848
|
|
Interest rate derivative liability
|
|
|
881
|
|
|
|
|
|
|
|
881
|
|
Current portion of deferred rent
|
|
|
1,144
|
|
|
|
|
|
|
|
1,144
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
29,407
|
|
|
|
(4,097
|
)
|
|
|
25,310
|
|
Deferred rent, net of current portion
|
|
|
8,662
|
|
|
|
|
|
|
|
8,662
|
|
Deferred revenue, net of current portion
|
|
|
|
|
|
|
22,186
|
|
|
|
22,186
|
|
Debt and capital lease obligations, net of current portion
|
|
|
8,378
|
|
|
|
|
|
|
|
8,378
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
46,447
|
|
|
|
18,089
|
|
|
|
64,536
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-9
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of December 31, 2008
|
|
|
|
As Previously
|
|
|
|
|
|
As
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
Restated
|
|
|
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
346
|
|
|
|
|
|
|
|
346
|
|
Additional paid-in capital
|
|
|
156,303
|
|
|
|
|
|
|
|
156,303
|
|
Treasury stock
|
|
|
(1,200
|
)
|
|
|
|
|
|
|
(1,200
|
)
|
Accumulated other comprehensive income
|
|
|
338
|
|
|
|
|
|
|
|
338
|
|
Accumulated deficit
|
|
|
(39,812
|
)
|
|
|
(10,940
|
)
|
|
|
(50,752
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
115,975
|
|
|
|
(10,940
|
)
|
|
|
105,035
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
162,422
|
|
|
$
|
7,149
|
|
|
$
|
169,571
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Consolidated
Statement of Operations impact for the year ended
December 31, 2008
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2008
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
As
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
Reclassifications
|
|
|
Restated
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
131,879
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
131,879
|
|
Implementation and other
|
|
|
7,673
|
|
|
|
(4,418
|
)
|
|
|
1,148
|
|
|
|
4,403
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
139,552
|
|
|
|
(4,418
|
)
|
|
|
1,148
|
|
|
|
136,282
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
58,799
|
|
|
|
|
|
|
|
1,148
|
|
|
|
59,947
|
|
Selling and marketing
|
|
|
22,827
|
|
|
|
|
|
|
|
|
|
|
|
22,827
|
|
Research and development
|
|
|
10,600
|
|
|
|
|
|
|
|
|
|
|
|
10,600
|
|
General and administrative
|
|
|
29,330
|
|
|
|
|
|
|
|
|
|
|
|
29,330
|
|
Depreciation and amortization
|
|
|
5,993
|
|
|
|
|
|
|
|
|
|
|
|
5,993
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
127,549
|
|
|
|
|
|
|
|
1,148
|
|
|
|
128,697
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
12,003
|
|
|
|
(4,418
|
)
|
|
|
|
|
|
|
7,585
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
1,942
|
|
|
|
|
|
|
|
|
|
|
|
1,942
|
|
Interest expense
|
|
|
(428
|
)
|
|
|
|
|
|
|
|
|
|
|
(428
|
)
|
Loss on interest rate derivative contract
|
|
|
(881
|
)
|
|
|
|
|
|
|
|
|
|
|
(881
|
)
|
Other income
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
182
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
815
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income (loss) before income tax benefit
|
|
|
12,818
|
|
|
|
(4,418
|
)
|
|
|
|
|
|
|
8,400
|
|
Income tax benefit
|
|
|
16,053
|
|
|
|
7,149
|
|
|
|
|
|
|
|
23,202
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
28,871
|
|
|
|
2,731
|
|
|
|
|
|
|
|
31,602
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.88
|
|
|
$
|
0.08
|
|
|
$
|
|
|
|
$
|
0.97
|
|
Net income per share diluted
|
|
$
|
0.83
|
|
|
$
|
0.08
|
|
|
$
|
|
|
|
$
|
0.91
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
32,746
|
|
|
|
32,746
|
|
|
|
32,746
|
|
|
|
32,746
|
|
Diluted
|
|
|
34,777
|
|
|
|
34,777
|
|
|
|
34,777
|
|
|
|
34,777
|
|
F-10
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Consolidated
Statement of Operations impact for the year ended
December 31, 2007
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31, 2007
|
|
|
|
As Previously
|
|
|
|
|
|
|
|
|
|
|
|
|
Reported
|
|
|
Adjustments
|
|
|
Reclassifications
|
|
|
As Restated
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
94,182
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
94,182
|
|
Implementation and other
|
|
|
6,591
|
|
|
|
(3,998
|
)
|
|
|
843
|
|
|
|
3,436
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
100,773
|
|
|
|
(3,998
|
)
|
|
|
843
|
|
|
|
97,618
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
46,135
|
|
|
|
|
|
|
|
843
|
|
|
|
46,978
|
|
Selling and marketing
|
|
|
17,212
|
|
|
|
|
|
|
|
|
|
|
|
17,212
|
|
Research and development
|
|
|
7,476
|
|
|
|
|
|
|
|
|
|
|
|
7,476
|
|
General and administrative
|
|
|
19,922
|
|
|
|
|
|
|
|
|
|
|
|
19,922
|
|
Depreciation and amortization
|
|
|
5,541
|
|
|
|
|
|
|
|
|
|
|
|
5,541
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
96,286
|
|
|
|
|
|
|
|
843
|
|
|
|
97,129
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income (loss)
|
|
|
4,487
|
|
|
|
(3,998
|
)
|
|
|
|
|
|
|
489
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
1,415
|
|
|
|
|
|
|
|
|
|
|
|
1,415
|
|
Interest expense
|
|
|
(3,682
|
)
|
|
|
|
|
|
|
|
|
|
|
(3,682
|
)
|
Other income (expense)
|
|
|
(5,689
|
)
|
|
|
|
|
|
|
|
|
|
|
(5,689
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other expense
|
|
|
(7,956
|
)
|
|
|
|
|
|
|
|
|
|
|
(7,956
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Loss before income tax provision
|
|
|
(3,469
|
)
|
|
|
(3,998
|
)
|
|
|
|
|
|
|
(7,467
|
)
|
Income tax provision
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
|
(34
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss
|
|
|
(3,503
|
)
|
|
|
(3,998
|
)
|
|
|
|
|
|
|
(7,501
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share basic
|
|
$
|
(0.28
|
)
|
|
$
|
(0.32
|
)
|
|
$
|
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net loss per share diluted
|
|
$
|
(0.28
|
)
|
|
$
|
(0.32
|
)
|
|
$
|
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net loss per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
12,568
|
|
|
|
12,568
|
|
|
|
12,568
|
|
|
|
12,568
|
|
Diluted
|
|
|
12,568
|
|
|
|
12,568
|
|
|
|
12,568
|
|
|
|
12,568
|
|
F-11
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Consolidated
Statement of Stockholders Equity Impact
In addition to the effects on the consolidated balance sheets as
of December 31, 2008, and consolidated statements of
operations for the years ended December 31, 2008 and 2007,
discussed above, the restatement affected the consolidated
statements of stockholders equity as of December 31,
2008 and 2007. Stockholders equity as of January 1,
2007, is approximately $73,944 as restated, compared to
approximately $64,271 as previously reported. The following
table sets forth the effects of the restatement on our
consolidated stockholders equity as of December 31,
2008 and 2007:
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended
|
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2007
|
|
|
Stockholders equity, as previously reported
|
|
$
|
115,975
|
|
|
$
|
75,519
|
|
Effect of restatement adjustment on net (loss) for the current
period
|
|
|
2,731
|
|
|
|
(3,998
|
)
|
Cumulative adjustment to accumulated deficit
|
|
|
(13,671
|
)
|
|
|
(9,673
|
)
|
|
|
|
|
|
|
|
|
|
Total restatement adjustments
|
|
|
(10,940
|
)
|
|
|
(13,671
|
)
|
|
|
|
|
|
|
|
|
|
Stockholders equity, as restated
|
|
$
|
105,035
|
|
|
$
|
61,848
|
|
|
|
|
|
|
|
|
|
|
Consolidated
Statement of Cash Flows Impact
The following table includes selected information from our
consolidated statements of cash flows presenting previously
reported and restated cash flows, for the years ended
December 31, 2008 and 2007:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Year Ended December 31,
|
|
|
2008
|
|
2007
|
|
|
As Previously
|
|
As
|
|
As Previously
|
|
As
|
|
|
Reported
|
|
Restated
|
|
Reported
|
|
Restated
|
|
Net income (loss)
|
|
$
|
28,871
|
|
|
$
|
31,602
|
|
|
$
|
(3,503
|
)
|
|
$
|
(7,501
|
)
|
Deferred income taxes(1)
|
|
|
(16,684
|
)
|
|
|
(23,833
|
)
|
|
|
|
|
|
|
|
|
Excess tax benefit from stock-based awards(2)
|
|
|
|
|
|
|
(526
|
)
|
|
|
|
|
|
|
|
|
Accrued expenses(2)
|
|
|
6,898
|
|
|
|
7,424
|
|
|
|
2,587
|
|
|
|
2,587
|
|
Deferred revenue(1)
|
|
|
2,702
|
|
|
|
7,120
|
|
|
|
628
|
|
|
|
4,626
|
|
Proceeds from the sales and disposals of property and
equipment(3)
|
|
|
317
|
|
|
|
4,112
|
|
|
|
|
|
|
|
1,456
|
|
Net cash provided by (used in) investing activities
|
|
|
(78,579
|
)
|
|
|
(74,784
|
)
|
|
|
3,328
|
|
|
|
4,784
|
|
Proceeds from long-term debt and capital lease obligations(3)
|
|
|
9,795
|
|
|
|
6,000
|
|
|
|
5,705
|
|
|
|
4,249
|
|
Net cash provided by financing activities
|
|
|
14,602
|
|
|
|
10,807
|
|
|
|
57,464
|
|
|
|
56,008
|
|
|
|
|
(1) |
|
Revenue and related tax effect due to the correction of the
accounting for implementation fees. |
|
(2) |
|
To separately present the excess tax benefit from stock-based
awards previously presented as a component of the change in
accrued expenses. |
|
(3) |
|
To correct the presentation of draw downs of capital lease
obligations. |
|
|
3.
|
SUMMARY
OF SIGNIFICANT ACCOUNTING POLICIES
|
Principles of Consolidation The accompanying
consolidated financial statements include the results of
operations of the Company and its wholly owned subsidiaries. All
intercompany balances and transactions have been eliminated in
consolidation.
F-12
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Comprehensive Income (Loss) Comprehensive
income (loss) includes net income (loss), foreign currency
translation adjustments, and unrealized holding gains (losses)
on
available-for-sale
securities.
Use of Estimates The preparation of financial
statements in conformity with accounting principles generally
accepted in the United States of America requires management to
make estimates and assumptions that affect the reported amounts
of assets and liabilities and the disclosure of contingent
assets and liabilities at the date of the financial statements,
as well as the reported amounts of revenues and expenses during
the reporting period. Significant estimates and assumptions are
used for, but are not limited to: (1) revenue recognition;
including the estimated expected performance period;
(2) allowance for doubtful accounts; (3) asset
impairments; (4) depreciable lives of assets;
(5) economic lives and fair value of leased assets;
(6) income tax reserves and valuation allowances;
(7) fair value of stock options; (8) allocation of
direct and indirect cost of sales; and (9) litigation
reserves. Actual results could significantly differ from those
estimates.
Revenue Recognition The Company recognizes
revenue when there is evidence of an arrangement, the service
has been provided to the customer, the collection of the fees is
reasonably assured, and the amount of fees to be paid by the
customer are fixed or determinable.
The Company derives its revenue from business services fees,
implementation fees, and other services. Business services fees
include amounts charged for ongoing billing, clinical-related,
and other related services and are generally billed to the
customer as a percentage of total collections. The Company does
not recognize revenue for business services fees until these
collections are made, as the services fees are not fixed and
determinable until such time. Business services fees also
include amounts charged to customers for generating and mailing
patient statements and are recognized as the related services
are performed.
Implementation revenue consists primarily of professional
services fees related to assisting customers with the
implementation of the Companys services and are generally
billed upfront and recorded as deferred revenue until the
implementation is complete and then recognized ratably over the
longer of the life of the agreement or the estimated expected
customer life, which is currently estimated to be twelve years.
The Company evaluates the length of the amortization period of
the implementation fees based on our experience with customer
contract renewals and consideration of the period over which
those customers will receive benefits from our current portfolio
of services. Certain expenses related to the implementation of a
customer, such as
out-of-pocket
travel, are typically reimbursed by the customer. This is
accounted for as both revenue and expense in the period the cost
is incurred. Other services consist primarily of training and
interface fees and are recognized as the services are performed.
The Company utilizes the authoritative revenue recognition
guidance to determine whether its arrangements containing
multiple deliverables contain more than one unit of accounting.
Multiple element arrangements require the delivery or
performance of multiple products, services
and/or
rights to use assets. To qualify as a separate unit of
accounting, the delivered item must have value to the customer
on a standalone basis and there must be objective and reliable
evidence of fair value of the undelivered element.
Direct Operating Expenses Direct operating
expenses consist primarily of salaries, benefits, and
stock-based compensation related to personnel who provide
services to clients; claims processing costs; implementing new
clients; and other direct costs related to collection and
business services. Costs associated with the implementation of
new clients are expensed as incurred. The reported amounts of
direct operating expenses do not include allocated amounts for
rent, depreciation, amortization, or other overhead costs,
except for the amortization of certain intangible assets.
Research and Development Expenses Research
and development expenses consist primarily of personnel-related
costs and consulting fees for third-party developers. All such
costs are expensed as incurred.
Cash and Cash Equivalents Cash and cash
equivalents consist of deposits, money market funds, commercial
paper, and other liquid securities with remaining maturities of
three months or less at the date of purchase.
F-13
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Investments Management determines the
appropriate classification of investments at the time of
purchase based upon managements intent with regard to such
investments. All investments are classified as
available-for-sale
and are recorded at fair value with unrealized holding gains and
losses included in accumulated other comprehensive income
(loss). The Company classifies its investments based on the
maturity of the instrument. The Company determines realized
gains and losses based on the specific identification method.
Accounts Receivable Accounts receivable
represents amounts due from customers for subscription and
implementation services. Accounts receivable are stated net of
an allowance for uncollectible accounts, which are determined by
establishing reserves for specific accounts and consideration of
historical and estimated probable losses.
Activity in the allowance for doubtful accounts is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Beginning balance
|
|
$
|
726
|
|
|
$
|
437
|
|
|
$
|
211
|
|
Provision
|
|
|
999
|
|
|
|
405
|
|
|
|
524
|
|
Write-offs and adjustments
|
|
|
(454
|
)
|
|
|
(116
|
)
|
|
|
(298
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Ending balance
|
|
$
|
1,271
|
|
|
$
|
726
|
|
|
$
|
437
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Financial Instruments Certain financial
instruments are required to be recorded at fair value. The other
financial instruments approximate their fair value, primarily
because of their short-term nature which include cash
equivalents, accounts receivable, accounts payable, and accrued
expenses. The carrying amounts of the Companys debt
obligations approximate fair value based upon our best estimate
of interest rates that would be available to the Company for
similar debt obligations. All highly liquid debt instruments
purchased with a maturity of three months or less at the date of
acquisition are included in cash and cash equivalents.
Derivative financial instruments are used to manage certain of
the Companys interest rate exposures. The Company does not
enter into derivatives for speculative purposes, nor does the
Company hold or issue any financial instruments for trading
purposes. In October 2008, the Company entered into a derivative
instrument that is not designated as a hedge. The Company
entered into the derivative instrument to offset the cash flow
exposure associated with its interest payments on certain
outstanding debt. Derivatives are carried at fair value, as
determined using standard valuation models and adjusted, when
necessary, for credit risk and are separately presented on the
balance sheet. The gains or losses from changes in the fair
value of derivative instruments that are not accounted for as
hedges are recognized in earnings and are separately presented.
Property and Equipment Property and equipment
are stated at cost. Equipment, furniture and, fixtures are
depreciated using the straight-line method over their estimated
useful lives, generally ranging from three to five years.
Leasehold improvements are depreciated using the straight-line
method over the lesser of the useful life of the improvements or
the applicable lease terms, excluding renewal periods. Buildings
are depreciated using the straight-line method over
30 years. Building improvements are depreciated using the
straight-line method over the lesser of the useful life of the
improvement or the remaining life of the building. Costs
associated with maintenance and repairs are expensed as incurred.
Long-Lived Assets Long-lived assets to be
held and used are reviewed for impairment whenever events or
changes in circumstances indicate that the carrying amount of
such assets may not be recoverable. Determination of
recoverability of long-lived assets is based on an estimate of
undiscounted future cash flows resulting from the use of the
asset and its eventual disposition, as compared with the asset
carrying value. Measurement of an impairment loss for long-lived
assets that management expects to hold and use is based on the
fair value of the asset. Long-lived assets to be disposed of are
reported at the lower of carrying amount or fair value, less
costs to sell. No impairment losses have been recognized in the
years ended December 31, 2009, 2008, or 2007.
F-14
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Restricted Cash Restricted cash consists of
funds held under a letter of credit as a condition of the
Companys operating lease for its corporate headquarters
(see Note 10). The letter of credit was reduced in 2008 to
$856. The letter of credit will remain in effect during the term
of the lease agreement. The remaining restricted cash balance as
of December 31, 2009, consists of escrowed amounts relating
to the purchase of MedicalMessaging and Anodyne (see
Note 8). Of the remaining balance, $660 relates to
MedicalMessaging and will be paid over a three-year period
starting in 2008 if MedicalMessaging achieves certain financial
milestones. Restricted cash relating to the purchase of Anodyne
at December 31, 2009, was $7,700 and may be paid over a
three-year period starting in 2010 if Anodyne achieves certain
business and financial milestones or released to the Company to
cover indemnification claims.
Software Development Costs The Company
accounts for software development costs based on required
criteria and timing. Costs related to the preliminary project
stage of subsequent versions of athenaNet or other technologies
are expensed as incurred. Costs incurred in the application
development stage are capitalized, and such costs are amortized
over the softwares estimated economic life. The estimated
useful life of the software is two years. Amortization expense
was $2,110, $1,395, and $958 for the years ended
December 31, 2009, 2008, and 2007, respectively. Future
amortization expense for all software development costs
capitalized as of December 31, 2009, is estimated to be
$1,647 and $677 for the years ending December 31, 2010, and
2011, respectively.
Goodwill Goodwill is recorded as the
difference, if any, between the aggregate consideration paid for
an acquisition and the fair value of the net tangible and
intangible assets acquired. Goodwill is not amortized but is
evaluated for impairment annually or more frequently if
indicators of impairment are present or changes in circumstances
suggest that impairment may exist. The Company evaluates the
carrying value of its goodwill annually on November 30. The
first step of the goodwill impairment test compares the fair
value of the reporting unit with its carrying amount, including
goodwill. If the fair value of the Companys reporting unit
exceeds its carrying amount, the goodwill of the reporting unit
is considered not impaired. If the carrying amount of the
Companys reporting unit exceeds its fair value, the second
step of the goodwill impairment test is performed to measure the
amount of impairment loss, if any. The second step of the
goodwill impairment test, used to measure the amount of
impairment loss, compares the implied fair value of the affected
reporting units goodwill with the carrying value of that
goodwill. No impairment losses have been recognized in the years
ended December 31, 2009, 2008, and 2007.
Other Intangible Assets Other intangible
assets consist of technology and customer relationships acquired
in connection with business acquisitions and are amortized over
their estimated useful lives on a straight-line basis.
Accrued expenses and accrued compensation
Accrued expenses consist of the following:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Accrued bonus
|
|
|
8,030
|
|
|
|
5,310
|
|
Accrued vacation
|
|
|
1,884
|
|
|
|
1,169
|
|
Accrued payroll
|
|
|
4,081
|
|
|
|
2,379
|
|
Accrued commissions
|
|
|
1,779
|
|
|
|
1,296
|
|
|
|
|
|
|
|
|
|
|
Accrued compensation expenses
|
|
$
|
15,774
|
|
|
$
|
10,154
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
6,468
|
|
|
$
|
7,442
|
|
Current portion of accrued contingent consideration
|
|
|
4,313
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Accrued expenses
|
|
$
|
10,781
|
|
|
$
|
7,442
|
|
|
|
|
|
|
|
|
|
|
Warrant Liability Prior to our IPO,
freestanding warrants exercisable for shares of the
Companys redeemable convertible preferred stock were
classified as a warrant liability on the Companys balance
sheet.
F-15
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
These warrants were issued for the purchase of the
Companys Series D and Series E Preferred Stock.
During the year ended December 31, 2007, the Company
revalued the warrant liability relating to the preferred stock
warrants and recorded other expense of $4,995, for the increase
in value of the warrants. Upon completion of the IPO and the
conversion of outstanding preferred stock to common stock, the
preferred stock warrants became automatically exercisable into
shares of common stock. Accordingly, the warrant liability of
$7,451 was reclassified to additional paid-in capital.
Deferred Rent Deferred rent consists of step
rent and tenant improvement allowances and other incentives
received from landlords related to the Companys operating
leases for its facilities. Step rent represents the difference
between actual operating lease payments due and straight-line
rent expense, which is recorded by the Company over the term of
the lease, including any construction period. The excess is
recorded as a deferred credit in the early periods of the lease,
when cash payments are generally lower than straight-line rent
expense, and is reduced in the later periods of the lease when
payments begin to exceed the straight-line expense. Tenant
allowances from landlords for tenant improvements are generally
comprised of cash received from the landlord as part of the
negotiated terms of the lease or reimbursements of moving costs.
These cash payments are recorded as deferred rent from landlords
and are amortized as a reduction of periodic rent expense, over
the term of the applicable lease.
Deferred Revenue Deferred revenue primarily
consists of billings or payments received in advance of the
revenue recognition criteria being met. Deferred revenue
includes certain deferred implementation services fees which are
recognized as revenue ratably over the longer of the life of the
agreement or the estimated expected customer life, which is
currently estimated to be twelve years. Deferred revenue that
will be recognized during the succeeding
12-month
period is recorded as current deferred revenue and the remaining
portion is recorded as noncurrent.
Concentrations of Credit Risk Financial
instruments that potentially subject the Company to
concentrations of credit risk are cash equivalents, investments,
derivatives, and accounts receivable. The Company attempts to
limit its credit risk associated with cash equivalents,
investments by investing in highly rated corporate and financial
institutions, and engages with highly rated financial
institutions as a counterparty to its derivative transaction.
With respect to customer accounts receivable, the Company
manages its credit risk by performing ongoing credit evaluations
of its customers. No customer accounted for more than 10% of
revenues or accounts receivable as of or for the years ended
December 31, 2009, 2008, or 2007.
Other Income (Expense) other expense consists
of the following:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Loss on warrants
|
|
$
|
|
|
|
$
|
|
|
|
$
|
(4,995
|
)
|
Financial advisor fee paid by shareholder
|
|
|
|
|
|
|
|
|
|
|
(592
|
)
|
Other income (expense)
|
|
|
255
|
|
|
|
182
|
|
|
|
(102
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
$
|
255
|
|
|
$
|
182
|
|
|
$
|
(5,689
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income Taxes Deferred tax assets and
liabilities relate to temporary differences between the
financial reporting and income tax bases of assets and
liabilities and are measured using enacted tax rates and laws
expected to be in effect at the time of their reversal. A
valuation allowance is established to reduce net deferred tax
assets if, based on the available positive and negative
evidence, it is more likely than not that some or all of the
deferred tax assets will not be realized. In making such
determination, the Company considers all available positive and
negative evidence, including future reversals of existing
taxable temporary differences, projected future taxable income,
tax planning strategies, and recent financial results.
The Company recognizes a tax benefit from an uncertain tax
position when it is more likely than not that the position will
be sustained upon examination, including resolutions of any
related appeals or litigation
F-16
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
processes, based on the technical merits. Our income tax
positions must meet a more-likely-than-not recognition threshold
at the balance sheet date to be recognized in the related period.
The Companys policy is to record interest and penalties
related to unrecognized tax benefits in income tax expense. As
of December 31, 2009, the Company has no accrued interest
or penalties related to uncertain tax positions.
Segment Reporting Operating segments are
identified as components of an enterprise about which separate
discrete financial information is available for evaluation by
the chief decision-maker, or decision-making group, in making
decisions regarding resource allocation and assessing
performance. The Company, which uses consolidated financial
information in determining how to allocate resources and assess
performance, has determined that it operates in one segment.
Stock-Based Compensation The Company accounts
for share-based awards, including shares issued under employee
stock purchase plans, stock options, and share-based awards with
compensation cost measured using the fair value of the awards
issued.
In determining the exercise prices for stock-based awards before
the IPO, the Companys Board of Directors considered the
estimated fair value of the common stock as of each grant date.
The determination of the fair value of the Companys common
stock without an active market involves significant assumptions,
estimates, and complexities that impact the amount of
stock-based compensation. The estimated fair value of the
Companys common stock prior to the Companys IPO was
determined by the Board of Directors after considering a broad
range of factors including, but not limited to, the illiquid
nature of an investment in common stock, the Companys
historical financial performance and financial position, the
Companys significant accomplishments and future prospects,
opportunity for liquidity events, and recent sale and offer
prices of the common and convertible preferred stock in private
transactions negotiated at arms length. Since the IPO, the
exercise prices for stock-based awards have been set at the
closing value of the Companys stock price on the grant
date.
Foreign Currency Translation The financial
position and results of operations of the Companys foreign
subsidiary are measured using local currency as the functional
currency. Assets and liabilities are translated at the rate of
exchange in effect at the end of each reporting period. Revenues
and expenses are translated at the average exchange rate for the
period. Foreign currency translation gains and losses are
recorded within other comprehensive (loss) income.
Recent Accounting Pronouncements In December
2007, the Financial Accounting Standards Board
(FASB) issued authoritative guidance on business
combinations. This guidance establishes principles and
requirements for how an acquirer recognizes and measures in its
financial statements significant aspects of a business
combination. Under this guidance, acquisition costs are
generally expensed as incurred; non-controlling interests are
reflected at fair value at the acquisition date; in-process
research and development (IPR&D) is recorded at
fair value as an intangible asset at the acquisition date;
restructuring costs associated with a business combination are
generally expensed rather than capitalized; contingent
consideration is measured at fair value at the acquisition date,
with changes in the fair value after the acquisition date
affecting earnings; and changes in deferred tax asset valuation
allowances and income tax uncertainties after the measurement
period will affect income tax expense. The Company adopted this
guidance on January 1, 2009 and during the year ended
December 31, 2009, expensed $751 of acquisition costs that,
prior to the change in accounting, would have been included as
part of the purchase price. The potential contingent
consideration of $7,700 was recorded in the initial purchase
price allocation at its estimated fair value of $5,100. A
portion of the contingent consideration relating to the Anodyne
acquisition expected to be paid in 2011 and 2012 totaling $787
and is presented in other long-term liabilities. The contingent
consideration will be accreted to the amount payable when, and
if, earned. The difference between the estimated and earn-out
amount will be charged or credited to expense. The contingent
consideration for acquisitions which occurred prior to this
change will be recorded as additional goodwill when it is
earned. In addition, under the provisions of
F-17
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
guidance, future reversal of the Companys
acquisition-related tax reserves of $680 (excluding interest and
penalties) will be recorded in earnings, rather than as an
adjustment to goodwill or acquisition related other intangible
assets and will affect the Companys annual effective
income tax rate.
In October 2009, the FASB issued authoritative guidance on
revenue recognition that will become effective for the Company
beginning January 1, 2011, with earlier adoption permitted.
Under the new guidance on arrangements that include software
elements, tangible products that have software components that
are essential to the functionality of the tangible product will
no longer be within the scope of the software revenue
recognition guidance, and software-enabled products will now be
subject to other relevant revenue recognition guidance.
Additionally, the FASB issued authoritative guidance on revenue
arrangements with multiple deliverables that are outside the
scope of the software revenue recognition guidance. Under the
new guidance, when vendor specific objective evidence or third
party evidence for deliverables in an arrangement cannot be
determined, a best estimate of the selling price is required to
separate deliverables and allocate arrangement consideration
using the relative selling price method. The new guidance
includes new disclosure requirements on how the application of
the relative selling price method affects the timing and amount
of revenue recognition. The Company is currently evaluating the
impact of adoption of this authoritative guidance might have on
our financial statements, if any.
From time to time, new accounting pronouncements are issued by
FASB and are adopted by us as of the specified effective date.
Unless otherwise discussed, we believe that the impact of other
recently issued accounting pronouncements will not have a
material impact on consolidated financial position, results of
operations, and cash flows, or do not apply to our operations.
|
|
4.
|
NET
INCOME (LOSS) PER SHARE
|
Basic net income (loss) per share is computed by dividing net
income (loss) by the weighted average number of common shares
outstanding during the period. Diluted net income (loss) per
share is computed by dividing net income (loss) by the weighted
average number of common shares outstanding and potentially
dilutive securities outstanding during the period under the
treasury stock method. Potentially dilutive securities include
stock options and warrants. Under the treasury stock method,
dilutive securities are assumed to be exercised at the beginning
of the periods and as if funds obtained thereby were used to
purchase common stock at the average market price during the
period. Securities are excluded from the computations of diluted
net income (loss) per share if their effect would be
antidilutive to earnings per share.
The following table reconciles the weighted average shares
outstanding for basic and diluted net income (loss) per share
for the periods indicated.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
|
|
|
|
(As restated)
|
|
|
(As restated)
|
|
|
Net income (loss)
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
Weighted average shares used in computing basic net income
(loss) per share
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
12,568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share basic
|
|
$
|
0.28
|
|
|
$
|
0.97
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss)
|
|
$
|
9,276
|
|
|
$
|
31,602
|
|
|
$
|
(7,501
|
)
|
Weighted average shares used in computing basic net income
(loss) per share
|
|
|
33,584
|
|
|
|
32,746
|
|
|
|
12,568
|
|
Effect of dilutive securities
|
|
|
1,333
|
|
|
|
2,031
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing diluted net income
(loss) per share
|
|
|
34,917
|
|
|
|
34,777
|
|
|
|
12,568
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss) per share diluted
|
|
$
|
0.27
|
|
|
$
|
0.91
|
|
|
$
|
(0.60
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-18
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Outstanding unvested common stock purchased by employees is
subject to repurchase by the Company and therefore is not
included in the calculation of the weighted-average shares
outstanding for basic earnings per share.
The following potentially dilutive securities were excluded from
the calculation of diluted net income (loss) per share, since to
include them would be anti-dilutive:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Options to purchase common stock
|
|
|
1,021
|
|
|
|
1,088
|
|
|
|
2,889
|
|
Warrants to purchase common stock
|
|
|
|
|
|
|
|
|
|
|
65
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
1,021
|
|
|
|
1,088
|
|
|
|
2,954
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5.
|
FAIR
VALUE OF FINANCIAL INSTRUMENTS
|
As of December 31, 2009 and 2008, the carrying amounts of
cash and cash equivalents, restricted cash, receivables,
accounts payable, and accrued expenses approximated their
estimated fair values because of their short term nature of
these financial instruments. All highly liquid debt instruments
purchased with a maturity of three months or less at the date of
acquisition are included in cash and cash equivalents. Included
in cash and cash equivalents as of December 31, 2009 and
2008, are money market fund investments of $10,081 and $23,610,
respectively, which are reported at fair value. The fair value
of these investments was determined by using quoted prices for
identical investments in active markets which are considered to
be Level 1 inputs.
The carrying amounts of the Companys debt obligations
approximate fair value based upon our best estimate of interest
rates that would be available to the Company for similar debt
obligations. The estimated fair value of our long-term debt was
determined using quoted market prices and other inputs that were
derived from available market information and may not be
representative of actual values that could have been or will be
realized in the future.
The following tables present information about the
Companys financial assets and liabilities that are
measured at fair value on a recurring basis as of
December 31, 2009 and 2008, and indicates the fair value
hierarchy of the valuation techniques the Company utilized to
determine such fair value. In general, fair values determined by
Level 1 inputs utilize quoted prices (unadjusted) in active
markets for identical assets or liabilities and fair values
determined by Level 2 inputs utilize quoted prices
(unadjusted) in inactive markets for identical assets or
liabilities obtained from readily available pricing sources for
comparable instruments. The fair values determined by
Level 3 inputs are unobservable values which are supported
by little or no market activity.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of December 31, 2009 Using
|
|
|
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market securities
|
|
$
|
10,081
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
10,081
|
|
Available-for-sale
investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government backed securities
|
|
|
|
|
|
|
52,323
|
|
|
|
|
|
|
|
52,323
|
|
Accrued contingent consideration
|
|
|
|
|
|
|
|
|
|
|
(5,100
|
)
|
|
|
(5,100
|
)
|
Interest rate swap derivative
|
|
|
|
|
|
|
(291
|
)
|
|
|
|
|
|
|
(291
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
10,081
|
|
|
$
|
52,032
|
|
|
$
|
(5,100
|
)
|
|
$
|
57,013
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-19
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Fair Value Measurements as of
|
|
|
|
|
|
|
December 31, 2008 Using
|
|
|
|
|
|
|
Level 1
|
|
|
Level 2
|
|
|
Level 3
|
|
|
Total
|
|
|
Cash equivalents:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Money market securities
|
|
$
|
23,610
|
|
|
$
|
|
|
|
$
|
|
|
|
$
|
23,610
|
|
Available-for-sale
investments:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Commercial paper
|
|
|
|
|
|
|
16,575
|
|
|
|
|
|
|
|
16,575
|
|
U.S. government backed securities
|
|
|
|
|
|
|
41,486
|
|
|
|
|
|
|
|
41,486
|
|
Interest rate swap derivative
|
|
|
|
|
|
|
(881
|
)
|
|
|
|
|
|
|
(881
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
23,610
|
|
|
$
|
57,180
|
|
|
$
|
|
|
|
$
|
80,790
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
U.S. government backed securities and commercial paper are
valued using a market approach based upon the quoted market
prices of identical instruments when available or other
observable inputs such as trading prices of identical
instruments in inactive markets or similar securities. The
interest rate swap derivative is valued using an interest rate
swap model and observable inputs at the reporting date. The
accrued contingent consideration is valued using a
probability-weighted income approach model at the acquisition
and reporting date.
|
|
|
|
|
Balance as of January 1, 2009
|
|
$
|
|
|
Contingent consideration relating to acquisition valued at
October 16, 2009
|
|
|
5,100
|
|
|
|
|
|
|
Balance as of December 31, 2009
|
|
$
|
5,100
|
|
|
|
|
|
|
|
|
6.
|
SHORT-TERM
INVESTMENTS
|
The summary of
available-for-sale
securities as of December 31, 2009, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
|
|
Amortized
|
|
Unrealized
|
|
|
|
|
Cost
|
|
Gains
|
|
Fair Value
|
|
U.S. government backed securities
|
|
$
|
52,280
|
|
|
$
|
43
|
|
|
$
|
52,323
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The summary of
available-for-sale
securities as of December 31, 2008, is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gross
|
|
|
|
|
|
|
Amortized
|
|
|
Unrealized
|
|
|
|
|
|
|
Cost
|
|
|
Gains
|
|
|
Fair Value
|
|
|
Commercial paper
|
|
$
|
16,487
|
|
|
$
|
88
|
|
|
$
|
16,575
|
|
U.S. government backed securities
|
|
|
41,098
|
|
|
|
388
|
|
|
|
41,486
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
57,585
|
|
|
$
|
476
|
|
|
$
|
58,061
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Scheduled maturity dates of U.S. government backed
securities and commercial paper as of December 31, 2009 and
2008, was within one year of that date and therefore investments
were classified as short-term. There were no material realized
gains and losses on sales of these investments for the periods
presented. Unrealized gains and losses are included in other
accumulated comprehensive income.
F-20
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
7.
|
PROPERTY
AND EQUIPMENT
|
On February 15, 2008, the Company purchased a complex of
buildings totaling 186,000 square feet, including
approximately 133,000 square feet of office space, on
approximately 53 acres of land located in Belfast, Maine,
for a total price of $6,197. The Company is using the office
space of this facility as a second operational service site, and
are leasing a small portion of the space to commercial tenants.
The building is being depreciated over 30 years. The
Company allocated $800 of the purchase price to land and $5,397
to the buildings. In addition, the gross amount of the Company
assets under capital leases as December 31, 2008, was
$4,169 of equipment, $793 of leasehold and building improvements
and $289 of furniture, the gross amount of the capital leases as
of December 31, 2009 was $8,551 of equipment, $1,249 of
leasehold improvements, and $300 of furniture. Property and
equipment consist of the following:
|
|
|
|
|
|
|
|
|
|
|
Years Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Equipment
|
|
$
|
17,063
|
|
|
$
|
12,921
|
|
Furniture and fixtures
|
|
|
804
|
|
|
|
853
|
|
Leasehold improvements
|
|
|
9,854
|
|
|
|
9,499
|
|
Building and improvements
|
|
|
8,515
|
|
|
|
6,698
|
|
Land
|
|
|
800
|
|
|
|
800
|
|
|
|
|
|
|
|
|
|
|
Total property and equipment, at cost
|
|
|
37,036
|
|
|
|
30,771
|
|
Accumulated depreciation and amortization
|
|
|
(13,897
|
)
|
|
|
(11,783
|
)
|
Construction in progress
|
|
|
1,732
|
|
|
|
1,883
|
|
|
|
|
|
|
|
|
|
|
Property and equipment, net
|
|
$
|
24,871
|
|
|
$
|
20,871
|
|
|
|
|
|
|
|
|
|
|
Depreciation expense on property and equipment was $5,658,
$4,598, and $4,583 for the years ended December 31, 2009,
2008, and 2007, respectively. During the year ended
December 31, 2009 and 2008, the Company wrote off fully
depreciated assets totaling approximately $3,503 and $7,190,
respectively. Since the assets were fully depreciated, there was
no impact on the statement of operations.
Acquisition
of Anodyne Health Partners, Inc.
On October 16, 2009, the Company acquired Anodyne Health
Partners, Inc. (Anodyne), a software enabled service
business intelligence company based in Alpharetta, Georgia. The
Company believes that the acquisition of Anodyne provides the
Company with expanded service offerings that will better enable
it to compete in the large medical group market. The Anodyne
software as a service business intelligence tool enhances
customers ability to view all facets of its revenue cycle
information and to access and extract critical operational and
administrative information from various data systems. The
Company used existing cash to fund the acquisition of Anodyne,
following which Anodyne became a
wholly-owned
subsidiary of the Company. The Company has determined that the
presentation of pro forma information is impracticable as the
preexisting business acquired was previously combined with other
operations that were not part of the business combination.
The Company has accounted for the acquisition as a business
combination using the acquisition method. The Company incurred
legal costs and professional fees in connection with the
acquisition of $751 which are included in general and
administrative expenses. The results of Anodynes
operations are included in the statement of operations of the
combined entity since the date of acquisition.
F-21
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following table summarizes the total consideration
transferred on the acquisition date:
|
|
|
|
|
Cash payments
|
|
$
|
22,300
|
|
Contingent consideration
|
|
|
5,100
|
|
Cash acquired
|
|
|
(50
|
)
|
|
|
|
|
|
Fair value of total consideration
|
|
$
|
27,350
|
|
|
|
|
|
|
The fair values assigned to tangible and intangible assets
acquired and liabilities assumed are based on managements
estimates and assumptions, as well as other information compiled
by management, including valuations that utilize customary
valuation procedures and techniques.
The following table summarizes the recognized amounts of
identifiable assets acquired and liabilities assumed:
|
|
|
|
|
Current assets and other assets
|
|
$
|
757
|
|
Property and equipment
|
|
|
128
|
|
Intangible assets:
|
|
|
|
|
Technology
|
|
|
2,000
|
|
Customer relationships
|
|
|
11,200
|
|
Deferred tax asset
|
|
|
(2,206
|
)
|
Accrued expenses and other liabilities
|
|
|
(1,041
|
)
|
Deferred revenue
|
|
|
(250
|
)
|
|
|
|
|
|
Total identifiable net assets
|
|
|
10,588
|
|
Goodwill
|
|
|
16,762
|
|
|
|
|
|
|
|
|
$
|
27,350
|
|
|
|
|
|
|
Revenue from the date of acquisition of Anodyne,
October 16, 2009, to December 31, 2009, was $906. The
Company has determined that the presentation of Anodynes
net income is impracticable for the period ended
December 31, 2009, due to the integration of Anodyne
operations into the Company upon acquisition.
Contingent consideration is recorded at fair value as an element
of purchase price with subsequent adjustments recognized in the
consolidated statement of operations. The Company accrued a
liability of $5,100 for the estimated fair value of contingent
considerations expected to be payable based upon one of the
acquired companies reaching specific performance metrics over
the next three years of operation. There are two separate
elements that make up the contingent consideration. The first
potential contingent consideration ranges from zero to $4,800
and is payable in one installment based upon operational
performance for the year ending December 31, 2010. The
second potential contingent consideration ranges from zero to
$2,900 and is payable in quarterly installments based upon the
selling of the Companys product base into the Anodyne
customer base for the year ending December 31, 2010 and
2011, and the six-month period ended June 30, 2012.
The fair value was determined using a probability-weighted
income approach. That approach is based on significant inputs
that are not observable in the market, which are referred to as
level 3 inputs. Key assumptions include a discount rate of
21%, a probability adjusted level of 60%. As of
December 31, 2009, the amount recognized for the contingent
consideration, the range of outcomes and assumptions has not
changed.
The intangibles are being amortized over 5-10 years, with
customer lists being amortized over 10 years. The goodwill
of $16,762 resulting from the acquisition arises largely from
the synergies expected from combining the operations of the
acquisitions with our existing services operations, as well as
from the benefits
F-22
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
derived from the assembled workforce of the acquisitions. The
goodwill recognized is not expected to be deductible for tax
purposes.
Acquisition
of Crest Line Technologies, Inc. (d.b.a.
MedicalMessaging.net)
On September 5, 2008, the Company acquired specified assets
and assumed specified liabilities of Crest Line Technologies,
LLC (d.b.a. MedicalMessaging.net)
(MedicalMessaging). MedicalMessaging is a provider
of live and automated calling services for healthcare
professionals. The purpose of the acquisition is to augment the
Companys core business service offering with
MedicalMessagings automated and live communication
services. The Company believes the purchase of MedicalMessaging
gave access to a developed technology that could speed the time
to market versus internal development of our own similar
product. In addition, the Company plans to leverage its existing
customer base to increase revenues of the MedicalMessaging
services.
Consideration for this transaction was approximately $7,100,
plus potential additional consideration of $992 which was to be
paid over a three-year period if MedicalMessaging achieves
certain financial milestones. If the contingent consideration is
paid, it will result in an increase in the goodwill. The final
payment will include accrued interest on the escrowed amounts.
At the date of acquisition, the Company determined that $241 of
the $992 potential contingent consideration was met and recorded
the obligation. At December 31, 2008, the Company
determined that $331 of the potential consideration was met and
recorded to the obligation. This amount was paid out in March
2009 from a restricted cash account. During 2009, the Company
paid a working capital adjustment of $141. As of
December 31, 2009, the Company determined that an
additional $331 of the potential consideration was met and
recorded to the obligation. The excess of the purchase price
over the fair value of the acquired net assets has been
allocated to goodwill, all of which is tax deductible.
Allocation of the purchase price for the acquisition was based
on estimates of the fair value of the net assets acquired, and
is subject to adjustment upon finalization of the contingent
consideration. The fair values assigned to tangible and
intangible assets acquired and liabilities assumed are based on
managements estimates and assumptions, as well as other
information compiled by management, including valuations that
utilize customary valuation procedures and techniques.
|
|
9.
|
GOODWILL
AND OTHER PURCHASED INTANGABLE ASSETS
|
The following table summarizes the activity relating to the
carrying value of the Companys goodwill during the years
ended December 31, 2009 and 2008:
|
|
|
|
|
Gross balance as of January 1, 2008
|
|
$
|
|
|
Goodwill recorded in connection with Medical Messaging
|
|
|
4,887
|
|
|
|
|
|
|
Gross balance as of December 31, 2008
|
|
$
|
4,887
|
|
|
|
|
|
|
Contingent consideration recorded in connection with Medical
Messaging
|
|
|
330
|
|
Net working capital adjustment recorded in connection with
Medical Messaging
|
|
|
141
|
|
Goodwill recorded in connection with Anodyne
|
|
|
16,762
|
|
|
|
|
|
|
Gross balance as of December 31, 2009
|
|
$
|
22,120
|
|
|
|
|
|
|
F-23
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Other
Intangible Assets
Intangible assets acquired as of December 31, 2009 and
2008, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2009
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Weighted Averge Remaining
|
|
|
|
Gross
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (years)
|
|
|
Developed technology
|
|
$
|
3,161
|
|
|
$
|
(390
|
)
|
|
$
|
2,771
|
|
|
|
4.4
|
|
Customer relationships
|
|
|
12,066
|
|
|
|
(347
|
)
|
|
|
11,719
|
|
|
|
9.7
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
15,227
|
|
|
$
|
(737
|
)
|
|
$
|
14,490
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
December 31, 2008
|
|
|
|
|
|
|
|
|
|
Accumulated
|
|
|
|
|
|
Weighted Averge Remaining
|
|
|
|
Gross
|
|
|
Amortization
|
|
|
Net
|
|
|
Useful Life (years)
|
|
|
Developed technology
|
|
$
|
1,161
|
|
|
$
|
(74
|
)
|
|
$
|
1,087
|
|
|
|
5
|
|
Customer relationships
|
|
|
866
|
|
|
|
(28
|
)
|
|
|
838
|
|
|
|
10
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
2,027
|
|
|
$
|
(102
|
)
|
|
$
|
1,925
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Amortization expense for the years ended December 31, 2009,
2008, and 2007, was $635, $102 and $0, respectively, and is
included in direct operating expenses. Estimated amortization
expense, based upon the Companys intangible assets at
December 31, 2009, is as follows:
|
|
|
|
|
Year Ending December 31,
|
|
Amount
|
|
|
2010
|
|
$
|
1,839
|
|
2011
|
|
|
1,839
|
|
2012
|
|
|
1,839
|
|
2013
|
|
|
1,765
|
|
2014
|
|
|
1,523
|
|
Thereafter
|
|
|
5,685
|
|
|
|
|
|
|
Total
|
|
$
|
14,490
|
|
|
|
|
|
|
|
|
10.
|
OPERATING
LEASES AND OTHER COMMITMENTS
|
The Company maintains operating leases for facilities and
certain office equipment. The facility leases contain renewal
options and require payments of certain utilities, taxes, and
shared operating costs of each leased facility. The Company also
rents certain of its leased facilities to third-party tenants.
The rental agreements expire at various dates from 2010 to 2015.
The Company entered into a lease agreement with a new landlord
in connection with the relocation of its corporate offices in
June 2005. The Company assumed possession of the leased space in
January of 2005, with a rent commencement date of June 2005 and
expiration date of June 2015. The Company was not required to
pay rent from January 2005 through June 2005. The Company
recognizes rent escalations and lease incentives for this lease
on a straight-line basis over the lease period from January 2005
(date of possession) to June 2015.
Under the terms of such lease agreement, the landlord provided
approximately $9,400 in allowances to the Company for the
leasehold improvements for the office space and reimbursement of
moving costs. These lease incentives are being recorded as a
reduction of rent expense on a straight-line basis over the term
of the new lease. The Company has recorded the leasehold
improvements in property and equipment in the accompanying
balance sheets. Moving costs were expensed as incurred.
F-24
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Additionally, the landlord agreed to make all payments under the
Companys lease agreement relating to its previous office
space, amounting to approximately $2,100. The Company recognized
the lease costs when the Company ceased to use the previous
office space. The payments and incentives received from the new
landlord are being recognized over the new lease term.
The lease agreement contains certain financial and operational
covenants. These covenants provide for restrictions on, among
other things, a change in control of the Company and certain
structural additions to the premises, without prior consent from
the landlord.
Rent expense totaled $2,399, $2,121, and $2,901 for the years
ended December 31, 2009, 2008, and 2007, respectively. In
June 2005, the Company entered into a
sub-lease
agreement, which generated rental income of $497, $378, and $286
for the years ended December 31, 2009, 2008, and 2007,
respectively. Rental income is recorded as a reduction in rent
expense. We terminated this
sub-lease
effective February 2010.
The Company entered into a lease agreement with a new landlord
in connection with the relocation of its corporate offices in
India in May 2009. The Company assumed possession of the leased
space in May of 2009, with a rent commencement date of May 2009
and expiration date of April 2012. The Company was not required
to pay rent from May 2009 through August 2009. The Company
recognizes rent escalations for this lease on a straight-line
basis over the lease period from May 2009 (date of possession)
to April 2012. Rent expense totaled $275, $214, and $201 for the
years ended December 31, 2009, 2008, and 2007, respectively.
In March 2007, the Company entered into a noncancelable contract
for data center services in the event of a service interruption
in the Companys primary data center. The term of the
agreement is 36 months, commencing in July 2007, at a
monthly rate of $27, for a total payments of $978 over the term
of the agreement.
In December 2009, the Company entered into a noncancelable
contract for data center services in the event of a service
interruption in the Companys primary data center. The term
of the agreement is 26 months, commencing in December 2009,
at a monthly rate of $20, for a total payments of $480 over the
term of the agreement.
In May 2007, the Company entered into a ten-year, noncancelable
lease agreement with a data center provider in Bedford,
Massachusetts. Under the agreement, the Company took possession
of a portion of the contracted space in June 2007. Minimum
payments under the lease total $6,133 over the life of the
agreement. The Company paid $496, $243 and $119 under this
agreement in 2009, 2008, and 2007, respectively.
Future minimum lease payments under noncancelable operating
leases as of December 31, 2009, are as follows:
|
|
|
|
|
|
|
Future Rent
|
|
Year Ending December 31,
|
|
Payments
|
|
|
2010
|
|
$
|
5,357
|
|
2011
|
|
|
5,439
|
|
2012
|
|
|
5,212
|
|
2013
|
|
|
5,233
|
|
2014
|
|
|
5,396
|
|
Thereafter
|
|
|
4,141
|
|
|
|
|
|
|
Total minimum lease payments
|
|
$
|
30,778
|
|
|
|
|
|
|
F-25
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
11.
|
LONG-TERM
DEBT AND CAPITAL LEASE OBLIGATIONS
|
The summary of outstanding debt and capital lease obligations is
as follows:
|
|
|
|
|
|
|
|
|
|
|
As of December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Term loan
|
|
$
|
5,625
|
|
|
$
|
6,000
|
|
Capital lease obligation
|
|
|
6,763
|
|
|
|
4,416
|
|
|
|
|
|
|
|
|
|
|
|
|
|
12,388
|
|
|
|
10,416
|
|
Less current portion of long-term debt and capital lease
obligations
|
|
|
(3,437
|
)
|
|
|
(2,038
|
)
|
|
|
|
|
|
|
|
|
|
Long-term debt and capital lease obligations, net of current
portion
|
|
$
|
8,951
|
|
|
$
|
8,378
|
|
|
|
|
|
|
|
|
|
|
2008 Term and Revolving Loans On
September 30, 2008, the Company entered into a Credit
Agreement (the Credit Agreement) with a financial
institution. The Credit Agreement consists of a revolving credit
facility in the amount of $15,000 and a term loan facility in
the amount of $6,000 (collectively, the Credit
Facility). The revolving credit facility may be extended
by up to an additional $15,000 on the satisfaction of certain
conditions and includes a $10,000 limit for the issuance of
standby letters of credit. The revolving credit facility matures
on September 30, 2011, and the term facility matures on
September 30, 2013, although either facility may be
voluntarily prepaid in whole or in part at any time without
premium or penalty. On September 30, 2008, the Company
borrowed $6,000 under the term loan facility for general working
capital purposes. The term loan has a
5-year term
which is payable quarterly starting March 31, 2009, for $75
each quarter. The Company has the option to extend the loan at
the end of the
5-year term.
As of December 31, 2009, there were no amounts outstanding
under the revolving credit facility.
The revolving credit loans and term loan bear interest, at the
Companys option, at either (i) the London Interbank
Offered Rate (LIBOR), or (ii) the higher of
(a) the Federal Funds Rate plus 0.50% or (b) the
financial institutions prime rate (the higher of the two
being the Base Rate). For term loans, these rates
are adjusted down 100 basis points for Base Rate loans and
up 100 basis points for LIBOR loans. For revolving credit
loans, a margin is added to the chosen interest rate that is
based on the Companys consolidated leverage ratio, as
defined in the Credit Agreement, which margin can range from 100
to 275 basis points for LIBOR loans and from 0 to
50 basis points for Base Rate loans. A default rate shall
apply on all obligations in the event of a default under the
Credit Agreement at a rate per annum equal to 2% above the
applicable interest rate. The Company was also required to pay
commitment fees and upfront fees for this Credit Facility. The
interest rate as of December 31, 2009 and 2008, for the
term loan was 4.5%.
The obligations of the Company and its subsidiaries under the
Credit Agreement are collateralized by substantially all assets.
The Credit Agreement also contains certain financial and
nonfinancial covenants, including limitations on our
consolidated leverage ratio and capital expenditures, defaults
relating to non-payment, breach of covenants, inaccuracy of
representations and warranties, default under other indebtedness
(including a cross-default with our interest rate swap),
bankruptcy and insolvency, inability to pay debts, attachment of
assets, adverse judgments, ERISA violations, invalidity of loan
and collateral documents, and change of control. Upon an event
of default, the lenders may terminate the commitment to make
loans and the obligation to extend letters of credit, declare
the unpaid principal amount of all outstanding loans and
interest accrued under the Credit Agreement to be immediately
due and payable, require us to provide cash and deposit account
collateral for our letter of credit obligations, and exercise
their security interests and other rights under the Credit
Agreement.
Capital Lease Obligation In June 2007, the
Company entered into a master lease and security agreement (the
Equipment Line) with a financing company. The
Equipment Line allows for the Company to lease from the
financing company eligible equipment purchases, submitted within
90 days of the applicable
F-26
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
equipments invoice date. Each lease has a 36 month
term which are payable in equal monthly installments, commencing
on the first day of the fourth month after the date of the
disbursements of such loan and continuing on the first day of
each month thereafter until paid in full. The Company has
accounted for these as capital leases. As of December 31,
2009 and 2008, the Company had $6,763 and $4,416, respectively,
of outstanding capital leases. The interest rate as of
December 31, 2009 and 2008, was 3.5% and 5.8%, respectively.
Future principal payments on debt and outstanding capital leases
as of December 31, 2009, are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capital Lease
|
|
Year Ending December 31,
|
|
Debt
|
|
|
Obligations
|
|
|
2010
|
|
$
|
300
|
|
|
$
|
3,269
|
|
2011
|
|
|
300
|
|
|
|
2,904
|
|
2012
|
|
|
300
|
|
|
|
956
|
|
2013
|
|
|
300
|
|
|
|
|
|
Thereafter
|
|
|
4,425
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
5,625
|
|
|
|
7,129
|
|
Less: imputed interest
|
|
|
|
|
|
|
(366
|
)
|
|
|
|
|
|
|
|
|
|
Present value of future minimum lease payments
|
|
|
|
|
|
|
6,763
|
|
Less current portion
|
|
|
(300
|
)
|
|
|
(3,137
|
)
|
|
|
|
|
|
|
|
|
|
Long-term portion
|
|
$
|
5,325
|
|
|
$
|
3,626
|
|
|
|
|
|
|
|
|
|
|
The Companys borrowings are collateralized by
substantially all assets.
Interest paid was $836, $324, and $3,666 for the years ended
December 31, 2009, 2008, and 2007, respectively.
|
|
12.
|
INTEREST
RATE SWAP DERIVATIVE
|
The Company entered into a derivative instrument which has a
decreasing notional value over the term to offset the cash flow
exposure associated with its interest payments on certain
outstanding debt. In October 2008, we entered into an interest
rate swap to mitigate the cash flow exposure associated with our
interest payments on certain outstanding debt. Our interest rate
swap is not designated as a hedging instrument. The derivative
is accounted for at fair value with gains or losses reported in
earnings.
The swap had a notional amount of $5,850 to hedge changes in
cash flows attributable to changes in the LIBOR rate associated
with the September 30, 2008, issuance of the Term Loan due
September 30, 2028. We pay a fixed rate of 4.55% and
receive a variable rate based on one month LIBOR. The fair value
of derivatives as of December 31, 2009, is summarized in
the following table.
|
|
|
|
|
|
|
|
|
|
|
Liability Derivatives
|
|
|
|
|
Balance Sheet Location
|
|
Fair Value
|
|
Interest rate contracts
|
|
|
Interest rate derivative liability
|
|
|
$
|
291
|
|
|
|
|
|
|
|
|
|
|
Total derivatives
|
|
|
|
|
|
$
|
291
|
|
|
|
|
|
|
|
|
|
|
F-27
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The effect of derivative instruments on the consolidated
statements of operations is summarized in the following table.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Gain Recognized in
|
|
Loss Recognized in
|
|
|
|
|
Earnings for the
|
|
Earnings for the
|
|
|
Location of Gain (Loss)
|
|
Year Ended December 31,
|
|
Year Ended December 31,
|
|
|
Recognized in Earnings
|
|
2009
|
|
2008
|
|
Interest rate contracts
|
|
Gain (loss) on interest rate derivative contract
|
|
$
|
590
|
|
|
$
|
(881
|
)
|
Derivatives are carried at fair value, as determined using
standard valuation models and adjusted, when necessary, for
credit risk and is separately presented on the balance sheet.
The Company manages its interest rate exposures by maintaining a
fixed rate debt to minimize interest expense and interest rate
volatility. The following is a description/summary of the
derivative financial instrument the Company has entered into to
manage the interest rate exposure:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Maturity
|
|
Fair Value
|
|
|
|
|
Notional
|
|
|
|
|
|
Fiscal Year
|
|
(Fiscal
|
|
as of December 31,
|
Description
|
|
Borrowing
|
|
Amount
|
|
Receive
|
|
Pay
|
|
Entered Into
|
|
Year)
|
|
2009
|
|
Interest rate swap
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
variable to fixed
|
|
Revolving
Credit
Facility
|
|
$5,625
|
|
LIBOR
plus
1.0%
|
|
4.55%
Fixed
|
|
2008
|
|
2028
|
|
$(291)
|
|
|
13.
|
CONVERTIBLE
PREFERRED STOCK
|
All outstanding shares of the Companys convertible
preferred stock were converted into 21,531 shares of common
stock upon completion of the IPO.
After the consummation of the initial public offering in
September 2007 and the filing of the Companys amended and
restated certificate of incorporation, the Companys board
of directors has the authority, without further action by
stockholders, to issue up to 5,000 shares of preferred
stock in one or more series. The Companys board of
directors may designate the rights, preferences, privileges, and
restrictions of the preferred stock, including dividend rights,
conversion rights, voting rights, terms of redemption,
liquidation preference, and number of shares constituting any
series or the designation of any series. The issuance of
preferred stock could have the effect of restricting dividends
on the Companys common stock, diluting the voting power of
its common stock, impairing the liquidation rights of its common
stock, or delaying or preventing a change in control. The
ability to issue preferred stock could delay or impede a change
in control. As of December 31, 2009 and 2008, no shares of
preferred stock were outstanding.
|
|
15.
|
COMMON
STOCK AND WARRANTS
|
Common Stock Common stockholders are entitled
to one vote per share and dividends when declared by the Board
of Directors, subject to any preferential rights of preferred
stockholders.
Warrants In connection with equipment
financing with a finance company and a bank in May 2001, the
Company issued warrants to purchase 65 shares of the
Companys Series D Preferred Stock at an exercise
price of $3.08 per share. The warrants are exercisable through
September 2012.
Upon completion of the IPO, all of the Companys
outstanding preferred stock was automatically converted into
common stock and, accordingly, all warrants to purchase
preferred stock were converted into warrants to purchase common
stock. During the year ended December 31, 2008, warrant
holders exercised using the net issue exercise provision
resulting in 29 shares of common stock issued to the
warrant holder on the exercise of 32 warrants. No warrants were
exercised during the year ended December 31, 2009.
F-28
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Shares Reserved for Future Issuance The
Company has reserved shares of common stock for future issuance
for the following purposes:
|
|
|
|
|
|
|
|
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
Stock award plans
|
|
|
4,583
|
|
|
|
4,003
|
|
Warrants to purchase common stock
|
|
|
32
|
|
|
|
32
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
4,615
|
|
|
|
4,035
|
|
|
|
|
|
|
|
|
|
|
|
|
16.
|
STOCK-BASED
COMPENSATION
|
The Companys stock award plans provide the opportunity for
employees, consultants, and directors to be granted options to
purchase, receive share awards, or make direct purchases of
shares of the Companys common stock, up to
5,238 shares. On January 30, 2007, the Companys board
of directors voted to increase the number of shares eligible for
grant under the Companys stock award plans by 448. On
May 2, 2007, the Companys board of directors voted to
increase the number of shares eligible for grant under the
Companys stock awards plans by 149. Options granted under
the plan may be incentive stock options or non-qualified stock
options under the applicable provisions of the Internal Revenue
Code.
In 2007, the Companys 2007 Employee Stock Purchase Plan
(2007 ESPP) was adopted by the board of directors
and approved by the stockholders. A total of 500 shares of
common stock has been reserved for future issuance to
participating employees under the 2007 ESPP. Employees may
authorize deductions from 1% to 10% of compensation for each
payroll period during the offering period. On February 8,
2008, the board of directors approved an amendment to the
Companys 2007 ESPP. Under the terms of the amendment to
the 2007 ESPP, the purchase price shall be equal to 85% of the
lower of the closing price of the Companys common stock on
(1) the first day of the purchase period or (2) the
last day of the purchase period. On May 1, 2008, the board
of directors approved another amendment to the 2007 ESPP, which
allows employees, officers, and directors of the Companys
majority owned subsidiary, athenahealth Technology Private
Limited, to participate in the 2007 ESPP. The expense for the
years ended December 31, 2009 and 2008 was $388 and $172,
respectively.
In 2007, the board of directors and the Companys
stockholders approved the 2007 Stock Option and Incentive Plan
(the 2007 Stock Option Plan) effective as of the
close of the Companys IPO, which occurred on
September 25, 2007. The board of directors authorized
1,000 shares in addition to the shares forfeited under the
Companys 2007 Stock Option Plan. Options granted under
this plan may be incentive stock options or non-qualified stock
options under the applicable provisions of the Internal Revenue
Code. The 2007 Stock Option Plan includes an evergreen
provision that allows for an annual increase in the number
of shares of common stock available for issuance under the 2007
Stock Option Plan. The annual increase will be added on the
first day of each fiscal year from 2008 through 2013, inclusive,
and will be equal to the lesser of (i) 5.0% of the number
of then-outstanding shares of stock and of the preceding
December 31 and (ii) a number as determined by the board of
directors. On January 1, 2009 and 2008, another 1,105 and
611 options, respectively, became available for grant under this
evergreen provision.
Incentive stock options are granted with exercise prices at or
above the fair value of the Companys common stock at the
grant date as determined by the Board of Directors. Incentive
stock options granted to employees who own more than 10% of the
voting power of all classes of stock are granted with exercise
prices at 110% of the fair value of the Companys common
stock at the date of the grant. Non-qualified stock options may
be granted with exercise prices up to the fair value of the
Companys common stock on the date of the grant, as
determined by the Board of Directors. All options granted vest
over a range of one to four years and have contractual terms of
between five and ten years. Options granted typically vest 25%
per year over a total of four years at each anniversary, with
the exception of options granted to members of the board of
directors, which vest on a quarterly basis.
F-29
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Pursuant to stock option awards granted under the Companys
2000 Stock Option and Incentive Plan, unvested stock options
awarded under these awards shall become accelerated by a period
of one year upon the consummation of an acquisition of the
Company. For purposes of these agreements, an acquisition is
defined as: (i) the sale of the Company by merger in which
its shareholders in their capacity as such no longer own a
majority of the outstanding equity securities of the Company;
(ii) any sale of all or substantially all of the assets or
capital stock of the Company; or (iii) any other
acquisition of the business of the Company, as determined by its
board of directors.
As of December 31, 2009 and 2008, there were approximately
1,151 and 1,052 shares, respectively, available for grant
under the Companys stock award plans.
The following table presents the stock option activity for the
year ended December 31, 2009:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
|
|
|
|
|
|
|
Weighted-
|
|
|
Average
|
|
|
|
|
|
|
|
|
|
Average
|
|
|
Remaining
|
|
|
Aggregate
|
|
|
|
|
|
|
Exercise
|
|
|
Contractual Term
|
|
|
Instrinsic
|
|
|
|
Shares
|
|
|
Price
|
|
|
(in years)
|
|
|
Value
|
|
|
Outstanding January 1, 2009
|
|
|
2,951
|
|
|
$
|
16.02
|
|
|
|
|
|
|
|
|
|
Granted
|
|
|
1,080
|
|
|
|
28.97
|
|
|
|
|
|
|
|
|
|
Exercised
|
|
|
(488
|
)
|
|
|
3.88
|
|
|
|
|
|
|
|
|
|
Forfeited
|
|
|
(111
|
)
|
|
|
22.78
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Outstanding as of December 31, 2009
|
|
|
3,432
|
|
|
$
|
21.62
|
|
|
|
7.6
|
|
|
$
|
81,083
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Exercisable as of December 31, 2009
|
|
|
1,526
|
|
|
$
|
12.73
|
|
|
|
6.3
|
|
|
$
|
49,614
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Vested and expected to vest as of December 31, 2009
|
|
|
3,178
|
|
|
$
|
21.05
|
|
|
|
7.6
|
|
|
$
|
76,875
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted-average fair value of options granted for the year
ended December 31, 2009
|
|
|
|
|
|
$
|
14.56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
The Company recorded compensation expense of $8,314, $5,558, and
$1,311 for the years ended December 31, 2009, 2008, and
2007, respectively. There was an impact of $2,505 and $526 on
the presentation in the consolidated statements of cash flows
relating to excess tax benefits on the state tax level that have
been realized as a reduction in taxes payable for the year ended
December 31, 2009 and 2008, respectively.
Stock-based compensation expense for the years ended
December 31, 2009, 2008, and 2007, are as follows (no
amounts were capitalized):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Stock-based compensation charged to:
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating
|
|
$
|
1,589
|
|
|
$
|
872
|
|
|
$
|
181
|
|
Selling and marketing
|
|
|
2,126
|
|
|
|
1,383
|
|
|
|
97
|
|
Research and development
|
|
|
1,015
|
|
|
|
1,086
|
|
|
|
260
|
|
General and administrative
|
|
|
3,584
|
|
|
|
2,217
|
|
|
|
773
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
8,314
|
|
|
$
|
5,558
|
|
|
$
|
1,311
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-30
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company uses the Black-Scholes option pricing model to value
share-based awards and determine the related compensation
expense. The assumptions used in calculating the fair value of
share-based awards represent managements best estimates.
The following table illustrates the weighted average assumptions
used to compute stock-based compensation expense for awards
granted:
|
|
|
|
|
|
|
|
|
Year Ended December 31,
|
|
|
2009
|
|
2008
|
|
2007
|
|
Risk-free interest rate
|
|
1.9% - 3.0%
|
|
1.9% - 3.5%
|
|
3.5% - 4.9%
|
Expected dividend yield
|
|
0.0%
|
|
0.0%
|
|
0.0%
|
Expected option term (years)
|
|
6.25
|
|
6.25
|
|
6.25
|
Expected stock volatility
|
|
48% - 53%
|
|
48% - 54%
|
|
71.0%
|
The risk-free interest rate estimate was based on the
U.S. Treasury rates for U.S. Treasury zero-coupon
bonds with maturities similar to those of the expected term of
the award being valued.
The expected dividend yield was based on the Companys
expectation of not paying dividends in the foreseeable future.
The weighted average expected option term reflects the
application of the simplified method. The simplified method
defines the life as the average of the contractual term of the
options and the weighted average vesting period for all option
tranches. In December 2007, the SEC issued additional guidance,
which permits entities, under certain circumstances, to continue
to use the simplified method beyond December 31, 2007. We
have continued to utilize this methodology for the year ended
December 31, 2009, due to the short length of time our
common stock has been publicly traded. The resulting fair value
is recorded as compensation cost on a straight-line basis over
the requisite service period, which generally equals the option
vesting period. Since the Company completed its initial public
offering in September 2007, it did not have sufficient history
as a publicly traded company to evaluate its volatility factor
and expected term. As such, the Company analyzed the
volatilities of a group of peer companies to support the
assumptions used in its calculations. The Company averaged the
volatilities of the peer companies with
in-the-money
options, sufficient trading history and similar vesting terms to
generate the assumptions.
As of December 31, 2009 and 2008, there was $25,474 and
$16,435, respectively, of unrecognized stock compensation
expense related to unvested share-based compensation
arrangements granted under the Companys stock award plans.
This expense is expected to be recognized over a
weighted-average period of approximately 2.7 years.
Cash received from stock option exercises during the years ended
December 31, 2009 and 2008, was $1,895 and $4,918,
respectively. The intrinsic value of the shares issued from
option exercises in the years ended December 31, 2009 and
2008, was $16,547 and $25,932, respectively. The Company
generally issues previously unissued shares for the exercise of
stock options, however the Company may reissue previously
acquired treasury shares to satisfy these issuances in the
future.
Summary of Employee Stock Option Exercises
The weighted average fair value of employee stock purchase
shares granted during fiscal 2009, 2008, and 2007,was $14.56,
$16.52, and $6.10, respectively. Employees purchased
488 shares, 991 shares, and 433 shares,
respectively, for fiscal 2009, 2008, and 2007. The intrinsic
value of shares purchased during fiscal 2009, 2008, and 2007,
was $16,547, $25,932, and $3,642, respectively. The intrinsic
value is calculated as the difference between the market value
on the date of purchase and the purchase price of the shares.
F-31
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The components of the Companys income tax (benefit)
provision for the years ended December 31, 2009, 2008, and
2007 are as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Current Provision:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
$
|
174
|
|
|
$
|
(16
|
)
|
|
$
|
24
|
|
State
|
|
|
2,706
|
|
|
|
647
|
|
|
|
10
|
|
Foreign
|
|
|
31
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2,911
|
|
|
|
631
|
|
|
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Deferred Provision:
|
|
|
|
|
|
|
|
|
|
|
|
|
Federal
|
|
|
6,527
|
|
|
|
34
|
|
|
|
|
|
State
|
|
|
(609
|
)
|
|
|
9
|
|
|
|
|
|
Valuation allowance reversal
|
|
|
|
|
|
|
(23,876
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
5,918
|
|
|
|
(23,833
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total income tax provision (benefit)
|
|
$
|
8,829
|
|
|
$
|
(23,202
|
)
|
|
$
|
34
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
During the year ended December 31, 2009, the Company
utilized tax federal and state net operating loss carryforwards
to reduce the current tax provision by $8,246 and $21,
respectively. The Company recognized an alternative minimum tax
expense for the year ended December 31, 2008, and
December 31, 2007. During the year ended December 31,
2008, the Company utilized tax net operating loss carryforwards
to reduce the current tax provision by $7,797.
The components of the Companys deferred income taxes as of
December 31, 2009 and 2008, are as follows:
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
Deferred tax assets:
|
|
|
|
|
|
|
|
|
Federal net operating loss carryforward
|
|
$
|
4,851
|
|
|
$
|
10,468
|
|
State net operating loss carryforward
|
|
|
151
|
|
|
|
58
|
|
Research and development tax credits
|
|
|
881
|
|
|
|
841
|
|
Allowance for doubtful accounts
|
|
|
611
|
|
|
|
377
|
|
Deferred rent obligation
|
|
|
2,346
|
|
|
|
2,570
|
|
Stock compensation
|
|
|
3,197
|
|
|
|
1,529
|
|
Other accrued liabilities
|
|
|
920
|
|
|
|
321
|
|
Deferred revenue
|
|
|
10,395
|
|
|
|
9,893
|
|
Other
|
|
|
422
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
23,774
|
|
|
|
26,057
|
|
Deferred tax liabilities:
|
|
|
|
|
|
|
|
|
Intangibles
|
|
|
(5,527
|
)
|
|
|
|
|
Capitalized software development
|
|
|
(924
|
)
|
|
|
(743
|
)
|
Property and equipment
|
|
|
(1,412
|
)
|
|
|
(1,481
|
)
|
Investments
|
|
|
(17
|
)
|
|
|
(188
|
)
|
Other
|
|
|
(66
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(7,946
|
)
|
|
|
(2,412
|
)
|
|
|
|
|
|
|
|
|
|
Net deferred tax assets
|
|
$
|
15,828
|
|
|
$
|
23,645
|
|
|
|
|
|
|
|
|
|
|
F-32
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The Company classifies its deferred tax assets and liabilities
as current or noncurrent based on the classification of the
related asset or liability for financial reporting giving rise
to the temporary difference. A deferred tax asset that is not
related to an asset or liability for financial reporting,
including deferred tax assets related to NOLs, is classified
according to the expected reversal date.
As of December 31, 2009, the Company had federal and state
NOLs of approximately $55,895 (which includes $41,627 of NOLs
from stock-based compensation) and $16,549 (which includes
$14,717 of NOLs from stock-based compensation), respectively, to
offset future federal and state taxable income. The state NOLs
begin to expire 2010 and the federal NOLs expire at various
times from 2017 through 2028.
The Company has generated NOLs from stock compensation
deductions in excess of expenses recognized for financial
reporting purposes (excess tax benefits). Excess tax benefits
are realized when they reduce taxes payable, as determined using
a with and without method, and are credited to
additional paid-in capital and not as a reduction of income tax
provision. During the years ended December 31, 2009 and
2008, the Company realized excess tax benefits from state tax
deductions of $2,505 and $526, respectively, which was credited
to additional paid-in capital. As of December 31, 2009, the
amount of unrecognized federal and state excess tax benefits is
$14,153 and $872, respectively, which will be credited to
additional paid-in capital when realized.
The Company records a deferred tax asset or liability based on
the difference between the financial statement and tax bases of
assets and liabilities, as measured by enacted tax rates assumed
to be in effect when these differences reverse. In evaluating
the Companys ability to recover its deferred tax assets,
the Company considers all available positive and negative
evidence including its past operating results, the existence of
cumulative income in the most recent fiscal years, changes in
the business in which the Company operates and its forecast of
future taxable income. In determining future taxable income, the
Company is responsible for assumptions utilized including the
amount of state, federal and international pre-tax operating
income, the reversal of temporary differences and the
implementation of feasible and prudent tax planning strategies.
These assumptions require significant judgment about the
forecasts of future taxable income and are consistent with the
plans and estimates that the Company is using to manage the
underlying businesses. Based on the consideration of the weight
of the positive and negative evidence, the Company concluded
that there was sufficient positive evidence that its deferred
tax assets will be fully utilized. Accordingly, the remaining
valuation allowance was reversed as of December 31, 2008.
As of December 31, 2009, the Company continues to believe
that it is more likely than not that the deferred tax assets
will be fully realized.
The Companys federal research and development tax credit
carryforward as of December 31, 2009 was $881. This credit
is available to offset future federal and state taxes and expire
at various times through 2024.
A reconciliation of the federal statutory income tax rate to the
Companys effective income tax rate is as follows for the
years ended December 31:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Income tax computed at federal statutory tax rate
|
|
|
34
|
%
|
|
|
34
|
%
|
|
|
34
|
%
|
State taxes net of federal benefit
|
|
|
8
|
%
|
|
|
9
|
%
|
|
|
0
|
%
|
Research and development credits
|
|
|
(1
|
)%
|
|
|
(2
|
)%
|
|
|
1
|
%
|
Permanent differences
|
|
|
8
|
%
|
|
|
8
|
%
|
|
|
(27
|
)%
|
Valuation allowance
|
|
|
0
|
%
|
|
|
(328
|
)%
|
|
|
(7
|
)%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
|
49
|
%
|
|
|
(279
|
)%
|
|
|
1
|
%
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-33
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
A reconciliation of the beginning and ending amount of
unrecognized tax benefits is as follows:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
2009
|
|
|
2008
|
|
|
2007
|
|
|
Beginning uncertain tax benefits
|
|
$
|
301
|
|
|
$
|
610
|
|
|
$
|
744
|
|
Prior year decreases
|
|
|
0
|
|
|
|
(365
|
)
|
|
|
(134
|
)
|
Prior year increases
|
|
|
18
|
|
|
|
|
|
|
|
|
|
Current year increases
|
|
|
667
|
|
|
|
56
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total
|
|
$
|
986
|
|
|
$
|
301
|
|
|
$
|
610
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Included in the balance of unrecognized tax benefits at
December 31, 2009, are $912 of tax benefits that, if
recognized, would affect the effective tax rate. Included in the
current year increases was $627 of unrecognized tax benefits
which the Company acquired through its acquisition of Anodyne,
Inc. The Company does not expect unrecognized tax benefits will
significantly change within 12 months of the reporting date.
The Company includes interest and penalties related to uncertain
tax positions as a component of its provision for taxes. For the
year ended December 31, 2009, the Companys accrued
interest and penalties recorded in its consolidated financial
statements was not significant.
The Company does not expect unrecognized tax benefits to
significantly change within 12 months of the reporting date.
For state tax purposes, the tax years 1997 through 2008 remain
open to examination by major taxing jurisdictions to which the
Company is subject, which years primarily resulted in
carryforward attributes that may still be adjusted upon
examination by the Internal Revenue Service or state tax
authorities if they have or will be used in a future period. The
Company recently concluded an Internal Revenue Service audit for
tax years 2006 through 2008. The closing of this audit resulted
in no change to the income tax benefit (provision) or previously
recorded net operating loss carryforwards.
|
|
18.
|
EMPLOYEE
BENEFIT PLAN
|
The Company sponsors a 401(k) retirement savings plan (the
401(k) Plan), under which eligible employees may
contribute, on a pre-tax basis, specified percentages of their
compensation, subject to maximum aggregate annual contributions
imposed by the Internal Revenue Code of 1986. All employee
contributions are allocated to the employees individual
account and are invested in various investment options as
directed by the employee. Employees cash contributions are
fully vested and nonforfeitable. The Company may make a
discretionary contribution in any year, subject to authorization
by the Companys Board of Directors. During the years ended
December 31, 2009, 2008, and 2007, the Companys
contributions to the Plan were $901, $673 and $235, respectively.
|
|
19.
|
COMMITMENTS
AND CONTINGENCIES
|
The Company is engaged from time to time in certain legal
disputes arising in the ordinary course of business, including
employment discrimination claims and challenges to the
Companys intellectual property. The Company believes that
it has adequate legal defenses and believes that it is remote
that the ultimate dispositions of these actions will have a
material effect on the Companys financial position,
results of operations, or cash flows. There are no accruals for
such claims recorded at December 31, 2009.
The Companys services are subject to sales and use taxes
in certain jurisdictions. The Companys contractual
agreements with its customers provide that payment of any sales
or use tax assessments are the responsibility of the customer.
Accordingly, the Company believes that sales and use tax
assessments, if applicable, will not have a material adverse
effect on the Companys financial position, results of
operations, or cash flows.
F-34
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
20.
|
SUMMARIZED
QUARTERLY UNAUDITED FINANCIAL DATA
|
As discussed in greater detail in Note 2, Restatement and
Reclassification of Previously Issued Consolidated Financial
Statements, we determined we needed to restate our previously
issued consolidated financial information for the quarterly
periods ended March 31, 2009, June 30, 2009,
September 30, 2009 and each of the quarterly periods in the
year ended December 31, 2008. The restatements resulted
from a correction to the amortization period for deferred
implementation revenue.
The following tables summarize the effects of the restatement
and presentation reclassifications on our previously issued
unaudited condensed consolidated financial statements:
Summary
of increases (decreases) in net income (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended
|
|
|
|
March 31, 2009
|
|
|
June 30, 2009
|
|
|
September 30, 2009
|
|
|
|
Three
|
|
|
Three
|
|
|
Six
|
|
|
Three
|
|
|
Nine
|
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Net income, as previously reported
|
|
$
|
2,338
|
|
|
$
|
3,029
|
|
|
$
|
5,367
|
|
|
$
|
2,112
|
|
|
$
|
7,479
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(1,334
|
)
|
|
|
(1,308
|
)
|
|
|
(2,642
|
)
|
|
|
(1,577
|
)
|
|
|
(4,219
|
)
|
Income tax provision
|
|
|
534
|
|
|
|
523
|
|
|
|
1,057
|
|
|
|
631
|
|
|
|
1,688
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, restated
|
|
$
|
1,538
|
|
|
$
|
2,244
|
|
|
$
|
3,782
|
|
|
$
|
1,166
|
|
|
$
|
4,948
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earning (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, as previously reported
|
|
$
|
0.07
|
|
|
$
|
0.09
|
|
|
$
|
0.16
|
|
|
$
|
0.06
|
|
|
$
|
0.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(0.04
|
)
|
|
|
(0.04
|
)
|
|
|
(0.08
|
)
|
|
|
(0.05
|
)
|
|
|
(0.12
|
)
|
Income tax provision
|
|
|
0.02
|
|
|
|
0.02
|
|
|
|
0.03
|
|
|
|
0.02
|
|
|
|
0.05
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, restated
|
|
$
|
0.05
|
|
|
$
|
0.07
|
|
|
$
|
0.11
|
|
|
$
|
0.03
|
|
|
$
|
0.15
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earning (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, as previously reported
|
|
$
|
0.07
|
|
|
$
|
0.09
|
|
|
$
|
0.15
|
|
|
$
|
0.06
|
|
|
$
|
0.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
$
|
(0.04
|
)
|
|
$
|
(0.04
|
)
|
|
$
|
(0.07
|
)
|
|
$
|
(0.05
|
)
|
|
$
|
(0.12
|
)
|
Income tax provision
|
|
$
|
0.01
|
|
|
|
0.01
|
|
|
$
|
0.03
|
|
|
|
0.02
|
|
|
$
|
0.04
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income (loss), restated
|
|
$
|
0.04
|
|
|
$
|
0.06
|
|
|
$
|
0.11
|
|
|
$
|
0.03
|
|
|
$
|
0.14
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
33,418
|
|
|
|
33,527
|
|
|
|
33,472
|
|
|
|
33,610
|
|
|
|
33,520
|
|
Diluted
|
|
|
34,814
|
|
|
|
34,822
|
|
|
|
34,818
|
|
|
|
34,900
|
|
|
|
34,707
|
|
F-35
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
Summary
of increases (decreases) in Net income (unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended
|
|
|
|
March 31, 2008
|
|
|
June 30, 2008
|
|
|
September 30, 2008
|
|
|
December 31, 2008
|
|
|
|
Three
|
|
|
Three
|
|
|
Six
|
|
|
Three
|
|
|
Nine
|
|
|
Three
|
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
Months
|
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Ended
|
|
|
Net income, as previously reported
|
|
$
|
1,829
|
|
|
$
|
2,779
|
|
|
$
|
4,608
|
|
|
$
|
3,700
|
|
|
$
|
8,308
|
|
|
$
|
20,563
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(884
|
)
|
|
|
(1,068
|
)
|
|
|
(1,952
|
)
|
|
|
(1,598
|
)
|
|
|
(3,550
|
)
|
|
|
(868
|
)
|
Income tax provision
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
7,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, restated
|
|
$
|
945
|
|
|
$
|
1,711
|
|
|
$
|
2,656
|
|
|
$
|
2,102
|
|
|
$
|
4,758
|
|
|
$
|
26,844
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic earning (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, as previously reported
|
|
$
|
0.06
|
|
|
$
|
0.09
|
|
|
$
|
0.14
|
|
|
$
|
0.11
|
|
|
$
|
0.26
|
|
|
$
|
0.62
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(0.03
|
)
|
|
|
(0.04
|
)
|
|
|
(0.06
|
)
|
|
|
(0.05
|
)
|
|
|
(0.11
|
)
|
|
|
(0.03
|
)
|
Income tax provision
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.22
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, restated
|
|
$
|
0.03
|
|
|
$
|
0.05
|
|
|
$
|
0.08
|
|
|
$
|
0.06
|
|
|
$
|
0.15
|
|
|
$
|
0.81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Diluted earning (loss) per common share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, as previously reported
|
|
$
|
0.05
|
|
|
$
|
0.08
|
|
|
$
|
0.13
|
|
|
$
|
0.11
|
|
|
$
|
0.24
|
|
|
$
|
0.59
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net adjustments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Implementation revenue
|
|
|
(0.02
|
)
|
|
|
(0.03
|
)
|
|
|
(0.05
|
)
|
|
|
(0.05
|
)
|
|
|
(0.10
|
)
|
|
|
(0.03
|
)
|
Income tax provision
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
0.21
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income, restated
|
|
$
|
0.03
|
|
|
$
|
0.05
|
|
|
$
|
0.08
|
|
|
$
|
0.06
|
|
|
$
|
0.14
|
|
|
$
|
0.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
32,344
|
|
|
|
32,485
|
|
|
|
32,414
|
|
|
|
32,904
|
|
|
|
32,579
|
|
|
|
33,242
|
|
Diluted
|
|
|
34,786
|
|
|
|
34,730
|
|
|
|
34,758
|
|
|
|
34,825
|
|
|
|
34,780
|
|
|
|
34,766
|
|
F-36
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
2009
Quarterly Condensed Consolidated Balance Sheets
(unaudited)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
As of March 31, 2009
|
|
|
As of June 30, 2009
|
|
|
As of September 30, 2009
|
|
|
|
As Previously
|
|
|
As
|
|
|
As Previously
|
|
|
As
|
|
|
As Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Assets
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current assets:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents
|
|
$
|
20,527
|
|
|
$
|
20,527
|
|
|
$
|
23,320
|
|
|
$
|
23,320
|
|
|
$
|
27,473
|
|
|
$
|
27,473
|
|
Short-term investments
|
|
|
69,553
|
|
|
|
69,553
|
|
|
|
72,984
|
|
|
|
72,984
|
|
|
|
77,090
|
|
|
|
77,090
|
|
Accounts receivable net
|
|
|
22,837
|
|
|
|
22,837
|
|
|
|
23,680
|
|
|
|
23,680
|
|
|
|
26,850
|
|
|
|
26,850
|
|
Deferred tax assets
|
|
|
6,441
|
|
|
|
7,904
|
|
|
|
5,844
|
|
|
|
7,307
|
|
|
|
3,901
|
|
|
|
5,364
|
|
Prepaid expenses and other current assets
|
|
|
3,805
|
|
|
|
3,805
|
|
|
|
4,517
|
|
|
|
4,517
|
|
|
|
4,959
|
|
|
|
4,959
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current assets
|
|
|
123,163
|
|
|
|
124,626
|
|
|
|
130,345
|
|
|
|
131,808
|
|
|
|
140,273
|
|
|
|
141,736
|
|
Property and equipment net
|
|
|
21,399
|
|
|
|
21,399
|
|
|
|
22,420
|
|
|
|
22,420
|
|
|
|
23,280
|
|
|
|
23,280
|
|
Restricted cash
|
|
|
1,516
|
|
|
|
1,516
|
|
|
|
1,516
|
|
|
|
1,516
|
|
|
|
1,516
|
|
|
|
1,516
|
|
Software development costs net
|
|
|
1,920
|
|
|
|
1,920
|
|
|
|
2,054
|
|
|
|
2,054
|
|
|
|
2,191
|
|
|
|
2,191
|
|
Purchased intangibles net
|
|
|
1,845
|
|
|
|
1,845
|
|
|
|
1,766
|
|
|
|
1,766
|
|
|
|
1,686
|
|
|
|
1,686
|
|
Goodwill
|
|
|
4,887
|
|
|
|
4,887
|
|
|
|
5,018
|
|
|
|
5,018
|
|
|
|
5,284
|
|
|
|
5,284
|
|
Deferred tax assets
|
|
|
8,156
|
|
|
|
14,376
|
|
|
|
8,061
|
|
|
|
14,804
|
|
|
|
8,351
|
|
|
|
15,725
|
|
Other assets
|
|
|
646
|
|
|
|
646
|
|
|
|
630
|
|
|
|
630
|
|
|
|
1,163
|
|
|
|
1,163
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total assets
|
|
$
|
163,532
|
|
|
$
|
171,215
|
|
|
$
|
171,810
|
|
|
$
|
180,016
|
|
|
$
|
183,744
|
|
|
$
|
192,581
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Liabilities and Stockholders Equity
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current liabilities:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Current portion of long-term debt and capital lease obligations
|
|
$
|
2,308
|
|
|
$
|
2,308
|
|
|
$
|
2,684
|
|
|
$
|
2,684
|
|
|
$
|
3,123
|
|
|
$
|
3,123
|
|
Accounts payable
|
|
|
1,211
|
|
|
|
1,211
|
|
|
|
642
|
|
|
|
642
|
|
|
|
1,090
|
|
|
|
1,090
|
|
Accrued compensation
|
|
|
8,471
|
|
|
|
8,471
|
|
|
|
10,065
|
|
|
|
10,065
|
|
|
|
13,808
|
|
|
|
13,808
|
|
Accrued expenses
|
|
|
5,534
|
|
|
|
5,534
|
|
|
|
5,834
|
|
|
|
5,834
|
|
|
|
7,170
|
|
|
|
7,170
|
|
Current portion of deferred revenue
|
|
|
6,829
|
|
|
|
3,166
|
|
|
|
7,104
|
|
|
|
3,435
|
|
|
|
7,633
|
|
|
|
3,861
|
|
Interest rate derivative liability
|
|
|
689
|
|
|
|
689
|
|
|
|
381
|
|
|
|
381
|
|
|
|
506
|
|
|
|
506
|
|
Current portion of deferred rent
|
|
|
1,139
|
|
|
|
1,139
|
|
|
|
1,135
|
|
|
|
1,135
|
|
|
|
1,253
|
|
|
|
1,253
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total current liabilities
|
|
|
26,181
|
|
|
|
22,518
|
|
|
|
27,845
|
|
|
|
24,176
|
|
|
|
34,583
|
|
|
|
30,811
|
|
Deferred rent, net of current portion
|
|
|
8,383
|
|
|
|
8,383
|
|
|
|
8,128
|
|
|
|
8,128
|
|
|
|
7,742
|
|
|
|
7,742
|
|
Deferred revenue, net of current portion
|
|
|
|
|
|
|
23,086
|
|
|
|
|
|
|
|
24,400
|
|
|
|
|
|
|
|
26,080
|
|
Debt and capital lease obligations, net of current portion
|
|
|
8,267
|
|
|
|
8,267
|
|
|
|
8,779
|
|
|
|
8,779
|
|
|
|
8,954
|
|
|
|
8,954
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities
|
|
|
42,831
|
|
|
|
62,254
|
|
|
|
44,752
|
|
|
|
65,483
|
|
|
|
51,279
|
|
|
|
73,587
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Preferred stock
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Common stock
|
|
|
348
|
|
|
|
348
|
|
|
|
349
|
|
|
|
349
|
|
|
|
349
|
|
|
|
349
|
|
Additional paid-in capital
|
|
|
158,748
|
|
|
|
158,748
|
|
|
|
162,221
|
|
|
|
162,221
|
|
|
|
165,777
|
|
|
|
165,777
|
|
Treasury stock
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
|
|
(1,200
|
)
|
Accumulated other comprehensive income
|
|
|
279
|
|
|
|
279
|
|
|
|
133
|
|
|
|
133
|
|
|
|
(128
|
)
|
|
|
(128
|
)
|
Accumulated deficit
|
|
|
(37,474
|
)
|
|
|
(49,214
|
)
|
|
|
(34,445
|
)
|
|
|
(46,970
|
)
|
|
|
(32,333
|
)
|
|
|
(45,804
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total stockholders equity
|
|
|
120,701
|
|
|
|
108,961
|
|
|
|
127,058
|
|
|
|
114,533
|
|
|
|
132,465
|
|
|
|
118,994
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total liabilities and stockholders equity
|
|
$
|
163,532
|
|
|
$
|
171,215
|
|
|
$
|
171,810
|
|
|
$
|
180,016
|
|
|
$
|
183,744
|
|
|
$
|
192,581
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
F-37
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2009
|
|
|
June 30, 2009
|
|
|
|
Three Month Ended
|
|
|
Three Month Ended
|
|
|
Six Month Ended
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
39,895
|
|
|
$
|
39,895
|
|
|
$
|
44,429
|
|
|
$
|
44,429
|
|
|
$
|
84,324
|
|
|
$
|
84,324
|
|
Implementation and other
|
|
|
2,204
|
|
|
|
1,133
|
|
|
|
2,290
|
|
|
|
1,219
|
|
|
|
4,494
|
|
|
|
2,352
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
42,099
|
|
|
|
41,028
|
|
|
|
46,719
|
|
|
|
45,648
|
|
|
|
88,818
|
|
|
|
86,676
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
18,298
|
|
|
|
18,561
|
|
|
|
19,160
|
|
|
|
19,397
|
|
|
|
37,458
|
|
|
|
37,958
|
|
Selling and marketing
|
|
|
6,999
|
|
|
|
6,999
|
|
|
|
8,888
|
|
|
|
8,888
|
|
|
|
15,887
|
|
|
|
15,887
|
|
Research and development
|
|
|
3,181
|
|
|
|
3,181
|
|
|
|
3,439
|
|
|
|
3,439
|
|
|
|
6,620
|
|
|
|
6,620
|
|
General and administrative
|
|
|
8,201
|
|
|
|
8,201
|
|
|
|
8,394
|
|
|
|
8,394
|
|
|
|
16,595
|
|
|
|
16,595
|
|
Depreciation and amortization
|
|
|
1,639
|
|
|
|
1,639
|
|
|
|
1,798
|
|
|
|
1,798
|
|
|
|
3,437
|
|
|
|
3,437
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
38,318
|
|
|
|
38,581
|
|
|
|
41,679
|
|
|
|
41,916
|
|
|
|
79,997
|
|
|
|
80,497
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
3,781
|
|
|
|
2,447
|
|
|
|
5,040
|
|
|
|
3,732
|
|
|
|
8,821
|
|
|
|
6,179
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
402
|
|
|
|
402
|
|
|
|
320
|
|
|
|
320
|
|
|
|
722
|
|
|
|
722
|
|
Interest expense
|
|
|
(174
|
)
|
|
|
(174
|
)
|
|
|
(283
|
)
|
|
|
(283
|
)
|
|
|
(457
|
)
|
|
|
(457
|
)
|
Gain on interest rate derivative contract
|
|
|
192
|
|
|
|
192
|
|
|
|
308
|
|
|
|
308
|
|
|
|
500
|
|
|
|
500
|
|
Other income
|
|
|
36
|
|
|
|
36
|
|
|
|
79
|
|
|
|
79
|
|
|
|
115
|
|
|
|
115
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income
|
|
|
456
|
|
|
|
456
|
|
|
|
424
|
|
|
|
424
|
|
|
|
880
|
|
|
|
880
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
4,237
|
|
|
|
2,903
|
|
|
|
5,464
|
|
|
|
4,156
|
|
|
|
9,701
|
|
|
|
7,059
|
|
Income tax provision
|
|
|
(1,899
|
)
|
|
|
(1,365
|
)
|
|
|
(2,435
|
)
|
|
|
(1,912
|
)
|
|
|
(4,334
|
)
|
|
|
(3,277
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
2,338
|
|
|
|
1,538
|
|
|
|
3,029
|
|
|
|
2,244
|
|
|
|
5,367
|
|
|
|
3,782
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.07
|
|
|
$
|
0.05
|
|
|
$
|
0.09
|
|
|
$
|
0.07
|
|
|
$
|
0.16
|
|
|
$
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.07
|
|
|
$
|
0.04
|
|
|
$
|
0.09
|
|
|
$
|
0.06
|
|
|
$
|
0.15
|
|
|
$
|
0.11
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
33,418
|
|
|
|
33,418
|
|
|
|
33,527
|
|
|
|
33,527
|
|
|
|
33,472
|
|
|
|
33,472
|
|
Diluted
|
|
|
34,814
|
|
|
|
34,814
|
|
|
|
34,822
|
|
|
|
34,822
|
|
|
|
34,818
|
|
|
|
34,818
|
|
In addition to the restatement of implementation fees and the
related tax expense, we reclassified $263, $237 and $500 of
reimbursed
out-of-pocket
expenses from direct operating costs to implementation and other
revenue for the three months ended March 31, 2009, and
June 30, 2009, and for the six months ended June 30,
2009.
F-38
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2009
|
|
|
|
|
|
|
Three Month Ended
|
|
|
Nine Month Ended
|
|
|
Three
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
Months Ended
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
December 31,
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
2009
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
45,609
|
|
|
$
|
45,609
|
|
|
$
|
129,933
|
|
|
$
|
129,933
|
|
|
$
|
53,297
|
|
Implementation and other
|
|
|
3,083
|
|
|
|
1,796
|
|
|
|
7,577
|
|
|
|
4,148
|
|
|
|
1,149
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
48,692
|
|
|
|
47,405
|
|
|
|
137,510
|
|
|
|
134,081
|
|
|
|
54,446
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
19,652
|
|
|
|
19,942
|
|
|
|
57,110
|
|
|
|
57,900
|
|
|
|
21,117
|
|
Selling and marketing
|
|
|
8,963
|
|
|
|
8,963
|
|
|
|
24,850
|
|
|
|
24,850
|
|
|
|
9,222
|
|
Research and development
|
|
|
3,748
|
|
|
|
3,748
|
|
|
|
10,368
|
|
|
|
10,368
|
|
|
|
3,980
|
|
General and administrative
|
|
|
9,732
|
|
|
|
9,732
|
|
|
|
26,327
|
|
|
|
26,327
|
|
|
|
9,784
|
|
Depreciation and amortization
|
|
|
2,098
|
|
|
|
2,098
|
|
|
|
5,535
|
|
|
|
5,535
|
|
|
|
2,232
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
44,193
|
|
|
|
44,483
|
|
|
|
124,190
|
|
|
|
124,980
|
|
|
|
46,335
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
4,499
|
|
|
|
2,922
|
|
|
|
13,320
|
|
|
|
9,101
|
|
|
|
8,111
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
216
|
|
|
|
216
|
|
|
|
938
|
|
|
|
938
|
|
|
|
78
|
|
Interest expense
|
|
|
(270
|
)
|
|
|
(270
|
)
|
|
|
(727
|
)
|
|
|
(727
|
)
|
|
|
(241
|
)
|
Gain (loss) on interest rate derivative contract
|
|
|
(125
|
)
|
|
|
(125
|
)
|
|
|
375
|
|
|
|
375
|
|
|
|
215
|
|
Other income
|
|
|
96
|
|
|
|
96
|
|
|
|
211
|
|
|
|
211
|
|
|
|
44
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other (expense) income
|
|
|
(83
|
)
|
|
|
(83
|
)
|
|
|
797
|
|
|
|
797
|
|
|
|
96
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
4,416
|
|
|
|
2,839
|
|
|
|
14,117
|
|
|
|
9,898
|
|
|
|
8,207
|
|
Income tax provision
|
|
|
(2,304
|
)
|
|
|
(1,673
|
)
|
|
|
(6,638
|
)
|
|
|
(4,950
|
)
|
|
|
(3,879
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
2,112
|
|
|
|
1,166
|
|
|
|
7,479
|
|
|
|
4,948
|
|
|
|
4,328
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.06
|
|
|
$
|
0.03
|
|
|
$
|
0.22
|
|
|
$
|
0.15
|
|
|
$
|
0.13
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.06
|
|
|
$
|
0.03
|
|
|
$
|
0.22
|
|
|
$
|
0.14
|
|
|
$
|
0.12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
33,610
|
|
|
|
33,610
|
|
|
|
33,520
|
|
|
|
33,520
|
|
|
|
33,785
|
|
Diluted
|
|
|
34,900
|
|
|
|
34,900
|
|
|
|
34,707
|
|
|
|
34,707
|
|
|
|
35,133
|
|
In addition to the restatement of implementation fees and the
related tax expense, we reclassified $290, $295 and $790 of
reimbursed
out-of-pocket
expenses from direct operating costs to implementation and other
revenue for the three months ended September 30, 2009, and
December 31, 2009, and for the nine months ended
September 30, 2009.
F-39
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
March 31, 2008
|
|
|
June 30, 2008
|
|
|
|
Three Month Ended
|
|
|
Three Month Ended
|
|
|
Six Month Ended
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
27,889
|
|
|
$
|
27,889
|
|
|
$
|
31,190
|
|
|
$
|
31,190
|
|
|
$
|
59,079
|
|
|
$
|
59,079
|
|
Implementation and other
|
|
|
1,866
|
|
|
|
1,247
|
|
|
|
1,783
|
|
|
|
995
|
|
|
|
3,649
|
|
|
|
2,242
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
29,755
|
|
|
|
29,136
|
|
|
|
32,973
|
|
|
|
32,185
|
|
|
|
62,728
|
|
|
|
61,321
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
12,787
|
|
|
|
13,052
|
|
|
|
14,076
|
|
|
|
14,356
|
|
|
|
26,863
|
|
|
|
27,408
|
|
Selling and marketing
|
|
|
4,669
|
|
|
|
4,669
|
|
|
|
5,364
|
|
|
|
5,364
|
|
|
|
10,033
|
|
|
|
10,033
|
|
Research and development
|
|
|
2,346
|
|
|
|
2,346
|
|
|
|
2,596
|
|
|
|
2,596
|
|
|
|
4,942
|
|
|
|
4,942
|
|
General and administrative
|
|
|
7,205
|
|
|
|
7,205
|
|
|
|
6,580
|
|
|
|
6,580
|
|
|
|
13,785
|
|
|
|
13,785
|
|
Depreciation and amortization
|
|
|
1,441
|
|
|
|
1,441
|
|
|
|
1,589
|
|
|
|
1,589
|
|
|
|
3,030
|
|
|
|
3,030
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
28,448
|
|
|
|
28,713
|
|
|
|
30,205
|
|
|
|
30,485
|
|
|
|
58,653
|
|
|
|
59,198
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
1,307
|
|
|
|
423
|
|
|
|
2,768
|
|
|
|
1,700
|
|
|
|
4,075
|
|
|
|
2,123
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
709
|
|
|
|
709
|
|
|
|
396
|
|
|
|
396
|
|
|
|
1,105
|
|
|
|
1,105
|
|
Interest expense
|
|
|
(23
|
)
|
|
|
(23
|
)
|
|
|
(105
|
)
|
|
|
(105
|
)
|
|
|
(128
|
)
|
|
|
(128
|
)
|
Other income
|
|
|
18
|
|
|
|
18
|
|
|
|
31
|
|
|
|
31
|
|
|
|
49
|
|
|
|
49
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income
|
|
|
704
|
|
|
|
704
|
|
|
|
322
|
|
|
|
322
|
|
|
|
1,026
|
|
|
|
1,026
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
2,011
|
|
|
|
1,127
|
|
|
|
3,090
|
|
|
|
2,022
|
|
|
|
5,101
|
|
|
|
3,149
|
|
Income tax provision
|
|
|
(182
|
)
|
|
|
(182
|
)
|
|
|
(311
|
)
|
|
|
(311
|
)
|
|
|
(493
|
)
|
|
|
(493
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
1,829
|
|
|
|
945
|
|
|
|
2,779
|
|
|
|
1,711
|
|
|
|
4,608
|
|
|
|
2,656
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.06
|
|
|
$
|
0.03
|
|
|
$
|
0.09
|
|
|
$
|
0.05
|
|
|
$
|
0.14
|
|
|
$
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.05
|
|
|
$
|
0.03
|
|
|
$
|
0.08
|
|
|
$
|
0.05
|
|
|
$
|
0.13
|
|
|
$
|
0.08
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
32,344
|
|
|
|
32,344
|
|
|
|
32,485
|
|
|
|
32,485
|
|
|
|
32,414
|
|
|
|
32,414
|
|
Diluted
|
|
|
34,786
|
|
|
|
34,786
|
|
|
|
34,730
|
|
|
|
34,730
|
|
|
|
34,758
|
|
|
|
34,758
|
|
In addition to the restatement of implementation fees and the
related tax expense, we reclassified $265, $280 and $545 of
reimbursed
out-of-pocket
expenses from direct operating costs to implementation and other
revenue for the three months ended March 31, 2008, and
June 30, 2008, and for the six months ended June 30,
2008.
F-40
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
September 30, 2008
|
|
|
December 31, 2008
|
|
|
|
Three Month Ended
|
|
|
Nine Month Ended
|
|
|
Three Month Ended
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Revenue:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Business services
|
|
$
|
33,080
|
|
|
$
|
33,080
|
|
|
$
|
92,159
|
|
|
$
|
92,159
|
|
|
$
|
39,720
|
|
|
$
|
39,720
|
|
Implementation and other
|
|
|
2,348
|
|
|
|
1,070
|
|
|
|
5,997
|
|
|
|
3,312
|
|
|
|
1,676
|
|
|
|
1,091
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total revenue
|
|
|
35,428
|
|
|
|
34,150
|
|
|
|
98,156
|
|
|
|
95,471
|
|
|
|
41,396
|
|
|
|
40,811
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Expenses:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Direct operating costs
|
|
|
14,932
|
|
|
|
15,252
|
|
|
|
41,795
|
|
|
|
42,660
|
|
|
|
17,004
|
|
|
|
17,287
|
|
Selling and marketing
|
|
|
6,275
|
|
|
|
6,275
|
|
|
|
16,308
|
|
|
|
16,308
|
|
|
|
6,519
|
|
|
|
6,519
|
|
Research and development
|
|
|
2,327
|
|
|
|
2,327
|
|
|
|
7,269
|
|
|
|
7,269
|
|
|
|
3,331
|
|
|
|
3,331
|
|
General and administrative
|
|
|
6,909
|
|
|
|
6,909
|
|
|
|
20,694
|
|
|
|
20,694
|
|
|
|
8,636
|
|
|
|
8,636
|
|
Depreciation and amortization
|
|
|
1,582
|
|
|
|
1,582
|
|
|
|
4,612
|
|
|
|
4,612
|
|
|
|
1,381
|
|
|
|
1,381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total expenses
|
|
|
32,025
|
|
|
|
32,345
|
|
|
|
90,678
|
|
|
|
91,543
|
|
|
|
36,871
|
|
|
|
37,154
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Operating income
|
|
|
3,403
|
|
|
|
1,805
|
|
|
|
7,478
|
|
|
|
3,928
|
|
|
|
4,525
|
|
|
|
3,657
|
|
Other income (expense):
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Interest income
|
|
|
412
|
|
|
|
412
|
|
|
|
1,517
|
|
|
|
1,517
|
|
|
|
425
|
|
|
|
425
|
|
Interest expense
|
|
|
(75
|
)
|
|
|
(75
|
)
|
|
|
(203
|
)
|
|
|
(203
|
)
|
|
|
(225
|
)
|
|
|
(225
|
)
|
Loss on interest rate derivative contract
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(881
|
)
|
|
|
(881
|
)
|
Other income
|
|
|
38
|
|
|
|
38
|
|
|
|
87
|
|
|
|
87
|
|
|
|
95
|
|
|
|
95
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Total other income (expense)
|
|
|
375
|
|
|
|
375
|
|
|
|
1,401
|
|
|
|
1,401
|
|
|
|
(586
|
)
|
|
|
(586
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Income before income taxes
|
|
|
3,778
|
|
|
|
2,180
|
|
|
|
8,879
|
|
|
|
5,329
|
|
|
|
3,939
|
|
|
|
3,071
|
|
Income tax (provision) benefit
|
|
|
(78
|
)
|
|
|
(78
|
)
|
|
|
(571
|
)
|
|
|
(571
|
)
|
|
|
16,624
|
|
|
|
23,773
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
|
3,700
|
|
|
|
2,102
|
|
|
|
8,308
|
|
|
|
4,758
|
|
|
|
20,563
|
|
|
|
26,844
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.11
|
|
|
$
|
0.06
|
|
|
$
|
0.26
|
|
|
$
|
0.15
|
|
|
$
|
0.62
|
|
|
$
|
0.81
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share diluted
|
|
$
|
0.11
|
|
|
$
|
0.06
|
|
|
$
|
0.24
|
|
|
$
|
0.14
|
|
|
$
|
0.59
|
|
|
$
|
0.77
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Weighted average shares used in computing net income per share:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Basic
|
|
|
32,904
|
|
|
|
32,904
|
|
|
|
32,579
|
|
|
|
32,579
|
|
|
|
33,242
|
|
|
|
33,242
|
|
Diluted
|
|
|
34,825
|
|
|
|
34,825
|
|
|
|
34,780
|
|
|
|
34,780
|
|
|
|
34,766
|
|
|
|
34,766
|
|
In addition to the restatement of implementation fees and the
related tax expense, we reclassified $320, $283 and $865 of
reimbursed
out-of-pocket
expenses from direct operating costs to implementation and other
revenue for the three months ended September 30, 2008, and
December 31, 2008, and for the nine months ended
September 30, 2008.
F-41
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
Nine Months Ended
|
|
|
|
March 31, 2009
|
|
|
June 30, 2009
|
|
|
September 30, 2009
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
2,338
|
|
|
$
|
1,538
|
|
|
$
|
5,367
|
|
|
$
|
3,782
|
|
|
$
|
7,479
|
|
|
$
|
4,948
|
|
Deferred income taxes
|
|
|
1,899
|
|
|
|
1,365
|
|
|
|
3,937
|
|
|
|
2,880
|
|
|
|
6,109
|
|
|
|
4,421
|
|
Deferred revenue
|
|
|
(116
|
)
|
|
|
1,218
|
|
|
|
159
|
|
|
|
2,801
|
|
|
|
688
|
|
|
|
4,907
|
|
Other changes in operating activities
|
|
|
379
|
|
|
|
379
|
|
|
|
2,540
|
|
|
|
2,540
|
|
|
|
7,259
|
|
|
|
7,259
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
4,500
|
|
|
|
4,500
|
|
|
|
12,003
|
|
|
|
12,003
|
|
|
|
21,535
|
|
|
|
21,535
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capitalized software development costs
|
|
|
(449
|
)
|
|
|
(449
|
)
|
|
|
(1,060
|
)
|
|
|
(1,060
|
)
|
|
|
(1,759
|
)
|
|
|
(1,759
|
)
|
Purchases of property and equipment
|
|
|
(2,142
|
)
|
|
|
(2,142
|
)
|
|
|
(5,061
|
)
|
|
|
(5,061
|
)
|
|
|
(6,616
|
)
|
|
|
(6,616
|
)
|
Proceeds from disposals and sale of property and equipment(1)
|
|
|
|
|
|
|
1,803
|
|
|
|
|
|
|
|
3,366
|
|
|
|
4,690
|
|
|
|
4,690
|
|
Purchase in long term investment
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(550
|
)
|
|
|
(550
|
)
|
Proceeds from sales and maturities of investments
|
|
|
14,500
|
|
|
|
14,500
|
|
|
|
37,000
|
|
|
|
37,000
|
|
|
|
58,000
|
|
|
|
58,000
|
|
Purchases of investments
|
|
|
(25,762
|
)
|
|
|
(25,762
|
)
|
|
|
(51,770
|
)
|
|
|
(51,770
|
)
|
|
|
(77,066
|
)
|
|
|
(77,066
|
)
|
Payments for acquisitions net of cash acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(131
|
)
|
|
|
(131
|
)
|
Increase in restricted cash
|
|
|
332
|
|
|
|
332
|
|
|
|
332
|
|
|
|
332
|
|
|
|
332
|
|
|
|
332
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) investing activities
|
|
|
(13,521
|
)
|
|
|
(11,718
|
)
|
|
|
(20,559
|
)
|
|
|
(17,193
|
)
|
|
|
(23,100
|
)
|
|
|
(23,100
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options and warrants
|
|
|
530
|
|
|
|
530
|
|
|
|
697
|
|
|
|
697
|
|
|
|
1,654
|
|
|
|
1,654
|
|
Tax benefit from stock-based awards
|
|
|
|
|
|
|
|
|
|
|
1,231
|
|
|
|
1,231
|
|
|
|
1,705
|
|
|
|
1,705
|
|
Proceeds from long-term debt(1)
|
|
|
1,803
|
|
|
|
|
|
|
|
3,366
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Payments on long term debt and capital lease obligations
|
|
|
(1,643
|
)
|
|
|
(1,643
|
)
|
|
|
(2,319
|
)
|
|
|
(2,319
|
)
|
|
|
(2,978
|
)
|
|
|
(2,978
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
690
|
|
|
|
(1,113
|
)
|
|
|
2,975
|
|
|
|
(391
|
)
|
|
|
381
|
|
|
|
381
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects of exchange rate changes on cash and cash equivalents
|
|
|
(75
|
)
|
|
|
(75
|
)
|
|
|
(32
|
)
|
|
|
(32
|
)
|
|
|
(276
|
)
|
|
|
(276
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) in cash and cash equivalents
|
|
|
(8,406
|
)
|
|
|
(8,406
|
)
|
|
|
(5,613
|
)
|
|
|
(5,613
|
)
|
|
|
(1,460
|
)
|
|
|
(1,460
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
28,933
|
|
|
|
28,933
|
|
|
|
28,933
|
|
|
|
28,933
|
|
|
|
28,933
|
|
|
|
28,933
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
20,527
|
|
|
$
|
20,527
|
|
|
$
|
23,320
|
|
|
$
|
23,320
|
|
|
$
|
27,473
|
|
|
$
|
27,473
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
To correct the presentation of draw downs of the capital lease
lines. |
F-42
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Three Months Ended
|
|
|
Six Months Ended
|
|
|
Nine Months Ended
|
|
|
|
March 31, 2008
|
|
|
June 30, 2008
|
|
|
September 30, 2008
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
As
|
|
|
|
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
Previously
|
|
|
As
|
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
Reported
|
|
|
Restated
|
|
|
CASH FLOWS FROM OPERATING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1,829
|
|
|
$
|
945
|
|
|
$
|
4,608
|
|
|
$
|
2,656
|
|
|
$
|
8,308
|
|
|
$
|
4,758
|
|
Deferred revenue
|
|
|
25
|
|
|
|
909
|
|
|
|
872
|
|
|
|
2,824
|
|
|
|
2,291
|
|
|
|
5,841
|
|
Other changes in operating activities
|
|
|
267
|
|
|
|
267
|
|
|
|
5,228
|
|
|
|
5,228
|
|
|
|
4,041
|
|
|
|
4,041
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by operating activities
|
|
|
2,121
|
|
|
|
2,121
|
|
|
|
10,708
|
|
|
|
10,708
|
|
|
|
14,640
|
|
|
|
14,640
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM INVESTING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Capitalized software development costs
|
|
|
(251
|
)
|
|
|
(251
|
)
|
|
|
(602
|
)
|
|
|
(602
|
)
|
|
|
(939
|
)
|
|
|
(939
|
)
|
Purchases of property and equipment
|
|
|
(7,668
|
)
|
|
|
(7,668
|
)
|
|
|
(9,622
|
)
|
|
|
(9,622
|
)
|
|
|
(11,483
|
)
|
|
|
(11,483
|
)
|
Proceeds from disposals of property and equipment(1)
|
|
|
|
|
|
|
400
|
|
|
|
12
|
|
|
|
1,226
|
|
|
|
12
|
|
|
|
1,637
|
|
Purchase in long-term investment
|
|
|
|
|
|
|
|
|
|
|
(250
|
)
|
|
|
(250
|
)
|
|
|
(250
|
)
|
|
|
(250
|
)
|
Proceeds from sales and maturities of investments
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
18,500
|
|
|
|
18,500
|
|
Purchases of investments
|
|
|
(26,465
|
)
|
|
|
(26,465
|
)
|
|
|
(49,154
|
)
|
|
|
(49,154
|
)
|
|
|
(57,543
|
)
|
|
|
(57,543
|
)
|
Payments for acquisitions net of cash acquired
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(6,680
|
)
|
|
|
(6,680
|
)
|
(Increase) decrease in restricted cash
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(135
|
)
|
|
|
(135
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash (used in) investing activities
|
|
|
(34,384
|
)
|
|
|
(33,984
|
)
|
|
|
(59,616
|
)
|
|
|
(58,402
|
)
|
|
|
(58,518
|
)
|
|
|
(56,893
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
CASH FLOWS FROM FINANCING ACTIVITIES:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Proceeds from exercise of stock options and warrants
|
|
|
64
|
|
|
|
64
|
|
|
|
698
|
|
|
|
698
|
|
|
|
4,071
|
|
|
|
4,071
|
|
Deferred financing fees
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(179
|
)
|
|
|
(179
|
)
|
Proceeds from long-term debt(1)
|
|
|
400
|
|
|
|
|
|
|
|
1,214
|
|
|
|
|
|
|
|
7,625
|
|
|
|
6,000
|
|
Payments on long term debt and capital lease obligations
|
|
|
(120
|
)
|
|
|
(120
|
)
|
|
|
(271
|
)
|
|
|
(271
|
)
|
|
|
(526
|
)
|
|
|
(526
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net cash provided by (used in) financing activities
|
|
|
344
|
|
|
|
(56
|
)
|
|
|
1,641
|
|
|
|
427
|
|
|
|
10,991
|
|
|
|
9,366
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Effects of exchange rate changes on cash and cash equivalents
|
|
|
(4
|
)
|
|
|
(4
|
)
|
|
|
(22
|
)
|
|
|
(22
|
)
|
|
|
(75
|
)
|
|
|
(75
|
)
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net (decrease) increase in cash and cash equivalents
|
|
|
(31,923
|
)
|
|
|
(31,923
|
)
|
|
|
(47,289
|
)
|
|
|
(47,289
|
)
|
|
|
(32,962
|
)
|
|
|
(32,962
|
)
|
Cash and cash equivalents at beginning of period
|
|
|
71,891
|
|
|
|
71,891
|
|
|
|
71,891
|
|
|
|
71,891
|
|
|
|
71,891
|
|
|
|
71,891
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Cash and cash equivalents at end of period
|
|
$
|
39,968
|
|
|
$
|
39,968
|
|
|
$
|
24,602
|
|
|
$
|
24,602
|
|
|
$
|
38,929
|
|
|
$
|
38,929
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
(1) |
|
To correct the presentation of draw downs of the capital lease
lines. |
F-43
athenahealth,
Inc.
NOTES TO
CONSOLIDATED FINANCIAL
STATEMENTS (Continued)
The following tables present selected operating results for the
quarters ended 2009 and 2008:
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2009
|
|
|
2009
|
|
|
2009
|
|
|
2009
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
|
|
|
Total revenue
|
|
$
|
41,028
|
|
|
$
|
45,648
|
|
|
$
|
47,405
|
|
|
$
|
54,446
|
|
Operating income
|
|
|
2,447
|
|
|
|
3,732
|
|
|
|
2,922
|
|
|
|
8,111
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
1,538
|
|
|
$
|
2,244
|
|
|
$
|
1,166
|
|
|
$
|
4,328
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.05
|
|
|
$
|
0.07
|
|
|
$
|
0.03
|
|
|
$
|
0.13
|
|
Net income per share diluted
|
|
$
|
0.04
|
|
|
$
|
0.06
|
|
|
$
|
0.03
|
|
|
$
|
0.12
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
For the Quarter Ended
|
|
|
|
March 31,
|
|
|
June 30,
|
|
|
September 30,
|
|
|
December 31,
|
|
|
|
2008
|
|
|
2008
|
|
|
2008
|
|
|
2008
|
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
(Restated)
|
|
|
Total revenue
|
|
$
|
29,136
|
|
|
$
|
32,185
|
|
|
$
|
34,150
|
|
|
$
|
40,811
|
|
Operating income
|
|
|
423
|
|
|
|
1,700
|
|
|
|
1,805
|
|
|
|
3,657
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income
|
|
$
|
945
|
|
|
$
|
1,711
|
|
|
$
|
2,102
|
|
|
$
|
26,844
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Net income per share basic
|
|
$
|
0.03
|
|
|
$
|
0.05
|
|
|
$
|
0.06
|
|
|
$
|
0.81
|
|
Net income per share diluted
|
|
$
|
0.03
|
|
|
$
|
0.05
|
|
|
$
|
0.06
|
|
|
$
|
0.77
|
|
F-44